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Background:  The insecticide DDT (dichlorodiphenyltrichloroethane) has been 
speculated to increase breast cancer risk due to its environmental persistence, levels of 
bioaccumulation in breast adipose tissue, and endocrine disrupting actions.  
Epidemiological studies have had inconsistent findings, however a study in MMTV-neu 
                              ,                                            -          ,   
DDE                                       T                                     -
                      ,   DDE,                                   DDT             
Objectives:  T                                               ,   DDE -regulated genes to 
determine how developmental exposure may influence mammary tumorigenesis. 
Methods:  F                     , ELV X 4 P                                      ,   
DDE,                               -         ,                  ,   DDE            
 v 
congeners       ,   DDE      ,   DDT                                           
                          ,   DDE-regulated genes were identified by microarray 
analysis and analyzed by real time RT-PCR. 
Results: L    -                    ,   DDE                                        
                                                      ,   DDE               
upregulated casein gamma (csn1s2a ), keratin 18 (krt18) and interferon-induced protein 
44 (ifi44) genes in mammary tissue. These genes were similarly, but n                 
                               T            ,   DDE                                    
                                                                                        ,   
DDE also influenced gene responses for the mixtures. However, no qualitative changes 
were observed in gland morphology.  Significant upregulation of transforming growth 
factor beta (tgfb1) and downregulation of interleukin 10 (il10                        
                                      ,   DDE            ry gland also influences 
systemic immune responses. Significant upregulation of il10     ,   DDE     
                                       ,   DDE                                -
androgenic activity.    
Conclusions: Relevant human exposure levels of  ,   DDE induce significant increases 
in expression of csn1s2a, krt18 and ifi44. This activity as well as those induced by other 
doses, ratios and hydroxyflutamide suggest  ,  DDE actions may involve anti-androgenic 
activity and influence local and systemic effects in a HER2
+  
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There have been many human epidemiology studies on the insecticide and environmental 
contaminant DDT (dicholorodiphenyltrichloroethane) that have provided inconclusive 
evidence associating its levels of exposure with increased breast cancer risk. The 
inconclusive results from these studies may be attributed to a multitude of confounding 
variables surrounding DDT, such as its endocrine disrupting actions, age of exposure, 
environmental persistence and bioaccumulation in breast adipose tissue. DDT exists in 
humans and the environment as a mixture of DDT, dichlorodiphenyldichloroethylene 
(DDE), and dichlorodiphenyldichloroethane (DDD). The DDE component has two 
isomers, para, para΄ DDE (p,p΄ DDE) and ortho, para΄ DDE (o,p΄ DDE)   T    , ΄ DDE  
isomer possesses strong anti-androgenic activity (Kelce et al., 1995)        , ΄ DDE     
very weak estrogenic activity (Ociepa-Zawal et. al., 2010). The concern with DDT 
exposure and breast cancer is that these isomers, that are hormonal mimics, are highly 
lipid-soluble and able to persist and therefore bioaccumulate in lipid-rich environments, 
such as the breast.  These congeners are also very prevalent in the environment and the 
human body due to their resistance to degradation/metabolism, which account for their 
long half-lives and ubiquitous nature. 
 
 2 
In human studies, age of exposure is usually unknown, but can occur as early as in utero 
in amniotic fluid and cord blood (Foster et al., 2000; Tan et al., 2008; Barraza-Vazquez et 
al., 2008). Thus, having a true negative control in human studies is impossible. 
 
I                             D                   ,                    , ΄ DDE         
ability to accelerate tumor formation in an MMTV-neu mouse model that mimics HER2
+
 
breast cancer. The earlier tumor onset is postulated to be associated with changes in gene 
                                                                   , ΄ DDE        
mammary gland of MMTV-neu mice.  Gaining insight into the genes that are being 
modified by these congeners may suggest directions to pursue regarding potential 
                         , ΄ DDE in vivo that result in earlier tumor onset.  The results 
from this pre-clinical study will provide important information regarding DDT-induced 
responses in vivo  I   , ΄ DDE         s the expression of similar genes in cultured 
normal human breast cells, then it may have similar actions in women, and thus, may lead 
to identification of marker genes useful as novel screening tools for breast cancer risk 
assessment with DDT exposure.  I                                       , ΄ DDE    
mammary tissue may also lead to testing of novel therapies to block these actions, such as 
to inhibit androgen action or to prevent the early onset of mammary cancer. Furthermore, 
these finding may be used to provide vital information that could aid in future policy 
decisions and risk assessment, as those involved in Superfund sites, the Stockholm 
Convention on Persistent Organic Pollutants and the World Health Organization,  that all 
continue to support the production and use of DDT for malaria vector (mosquito) control  
(van den Berg 2009). 
 3 
BACKGROUND AND SIGNIFICANCE 
 
DDT 
The organochlorine pesticide DDT gained popularity during WWII when it was used to 
combat malaria and typhoid fever. As DDT use continued to increase, it quickly began 
being used in worldwide proportions, with peak production reaching an estimated 400 
million pounds globally in the late 1960s and early 1970s. However, DDT was banned in 
the United States in 1972 after the release of the book Silent Spring by Rachel Carson. 
This publication revealed disturbing revelations about the harmful impact of DDT on the 
environment and ignited growing concerns about human health effects. 
 
Today, approximately 14 countries currently use DDT for the control of malaria and 
leishmaniasis and several other countries are preparing to reintroduce DDT (van den Berg 
2009). Although the quantity is deemed unacceptable by the Stockholm Convention on 
Persistent Organic Pollutants, 160 metric tons of DDT is still being produced each year in 
India, China, and North Korea for vector control (with India being the largest producer 
and consumer). There has been no reported use of DDT for vector control in the 
Americas (van den Berg 2009). There is still insufficient information on the safety profile 
of DDT and questions regarding global public policy remain unanswered. Moreover, 
agencies like the World Health Organization (WHO) and the United States Agency for 





Breast Cancer Biology 
Breast cancer is a multifactorial disease. It occurs when normal healthy breast cells 
undergo multiple processes and stages that cause them to change into abnormal cells that 
rapidly proliferate uncontrollably. Initiation of the disease is caused, for example, when 
genes are mutated by harmful agents/chemicals in the environment. However, not all 
chemical- induced carcinogens have genotoxic effects. Several chemicals, including 
pesticides like DDT, are non-genotoxic and therefore may be considered cancer 
promoters (Bagga et al., 2000). Promotion is characterized by an increase in the number 
of initiated cells through long-term epigenetic mechanism (Mukherjee et al., 2006). The 
final stage in carcinogenesis is progression, which is associated with 
chromosomal/karotypic changes (Ludewig et al., 2008).  
 
Breast tissue is particularly sensitive to developing cancer because estrogen stimulates 
breast cell division. Increases in breast/mammary cancer have been widely studied in 
association with environmental contaminants known to display estrogenic and/or 
endocrine disruption, such as DDT, bisphenol A, deildrin, heptachlor epoxide and 
oxychlordane (Weber and Keri 2011; Vo et al., 2008; Mukherjee et al., 2006; Cassidy et 
al., 2005).  Furthermore, these environmental contaminants and many others persist in the 
environment and human tissue because of their resistance to metabolism. Slow 
metabolism then leads to bioaccumulation in adipose tissue due to their lipid solubility. 
Bioaccumulation is the increase in concentration of the chemical with increased time and 
exposure. Therefore, girls and young women are especially susceptible from exposure to 
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carcinogens due to not having fully matured breast cells, which are more efficient at 
repairing DNA damage (Cohn et al., 2011; Snedeker and Allyger 2001). It has been 
hypothesized that lipid-soluble carcinogens in the adipose tissue in human breast may 
influence ductal epithelial cells, from which breast tumors commonly arise. Therefore, 
deposition of these chemicals in the adipose tissue of the breast has been linked to 
neoplastic transformation (Mukherjee et al., 2006). 
 
DDT Mechanisms Involved in the Pathological Process of Breast Cancer 
Postulated mechanisms involved in breast cancer have been extensively studied. Some 
include, DNA methylation associated with initiation and progression of the disease 
(Rusiecki et al., 2008), inhibition of gap junctional intercellular communication, which 
has tumor promoting potential (Kang et al., 1996), genotoxic potential (Ennaceur et al., 
2008), free-radical mediated stress (Iscan et al., 2002), apoptosis (Perez-Maldonado et al., 
2006), changes in aromatase activity (Holloway et al., 2005) and perhaps most notably, 
its endocrine disrupting potency (Li et al., 2008). 
 
p,p´ DDE is an environmental anti-androgen (Kelce et al., 1995; 1997). The role of 
androgens in breast cancer remains largely unclear. However, over 70% of human breast 
cancer biopsies from untreated women are positive for the androgen receptor (AR) (as 
reviewed by Liao and Dickson 2002), which suggests an androgen-mediated role in 
normal and malignant breast tissue. Endogenous androgens are purported to normally 
inhibit estrogen-induced mammary epithelium proliferation and, therefore, act as a 
protector of the mammary gland (Aboghe et al., 2008). Therefore, AR antagonists 
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compete with endogenous androgens for the receptor and prevent downstream activation 
of androgen-dependent gene expression (Wilson et al., 2008). However, although this is 
the most commonly accepted mechanism, there are other ways in which anti-androgens 
can interfere with androgen-signaling cascades. These alternative mechanisms include 
modifying the production or metabolism of endogenous hormones, modifying the number 
of hormone receptors, decreasing mRNA of steroidogenic enzymes and/or decreasing 
testosterone synthesis (Wilson et al., 2008). Furthermore, Yang and colleagues (2010) 
found the chaperone role of heat shock proteins to be significantly modified following  ,   
DDE  exposure, due to a decrease in expression of heat shock proteins 70 and 90. 
 
DDT and several of its isomeric forms are also environmental estrogens, meaning they 
can interact with the estrogen receptor (ER) similar to estrogen and modulate 
transcription of responsive genes to result in estrogenic responses (Jaga et al., 2000). 
Similar to anti-androgens, environmental estrogens in breast adipose tissue function by 
other mechanisms besides receptor interaction. Due to their weak affinity to estrogen 
receptors, they likely act by affecting the expression of cytochrome P450 genes encoding 
cytochromes P450 engaged in the metabolism of environmental as well as endogenous 
estrogens (Ociepa-Zawal et al., 2010).  Specifically, DDE has been found to be an 
inducer of rat hepatic cytochrome P450 2B1 and 3A1 and therefore may have an impact 
on events such as the metabolism of endogenous and exogenous substrates (Wyde et al.,  
2003). Considering  all of these possible actions, it is feasible that the androgen receptor 
antagonist  , ΄ DDE may be able to disrupt the estrogen-androgen balance regulating the 
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growth of hormone-dependent breast cancer cells (Aube et al., 2007), thus leading to 
tumorigenesis. 
 
Also, in addition to estrogen and androgen modulation of gene transcription by exerting 
their direct actions via their cognate nuclear receptor, both receptor types may have non-
classical intracellular locations such as the plasma membrane and the mitochondria, 
which add to the complexity of their functionality (Vasconsuelo et al., 2011). 
 
DDT and Endocrine Disruption 
Technical grade DDT is a mixture of three isoforms of DDT, p,p´ DDT , o,p´ DDT and 
o,o´ DDT (Nuñez et al., 2002). The main metabolite of DDT is the highly lipophilic, 
                   , ΄ DDE  P   ,     ΄ DDE                                    -
androgenic affects (Kelce et al., 1995; 1997), while its estrogenic isomer,  , ΄ DDE, is 
relatively weak (Kelce et al., 1995).  With time and exposure, these DDE isomers 
bioaccumulate in humans and the environment due to their long half-lives (Snedecker et 
al., 2001). Disruption of endocrine responses has long been associated with DDT 
congeners and metabolites in wildlife. Endocrine disruptors are any chemical that has the 
                                  ’                              ,                       
adverse effects.  These systems are usually involved in the regulation of growth, 
development, and maturation as well as many other functions. In concordance with Silent 
Spring, DDT has been shown to have an effect on reproductive systems (i.e., sexual 
development and fertility) of many wildlife vertebrates, including birds and amphibians 
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(Bernanke and Köhler 2009). These findings imply that DDT does indeed elicit hormonal 
effects and should be considered an endocrine disruptor.  
 
Hormones are also known to have a critical impact on the etiology of human cancers such 
as in the breast, uterus, ovary, prostate, testis and thyroid (Dees et al., 1997; reviewed in 
Cocco 2002). Abnormal stimulation of the breast with hormones, like estrogen, has been 
associated with uncontrolled growth and neoplasia. Androgens also play a role in breast 
development, growth and carcinogenesis (Liao et al., 2002; Suzuki et al., 2010) and these 
effects may be potentiated by compounds with hormonal influences, such as the anti-
androgenic  , ΄ DDE                  , ΄ DDE. Thus, different isomers of DDT may 
induce abnormal hormone effects in human breast tissue.  
 
DDT and Breast Cancer 
Breast cancer is the most common cancer among women in almost all developed 
countries (Shakeel et al., 2010); however, there remains inconclusive evidence regarding 
the safety of DDT and its relationship with increased breast cancer risk. There has been 
supporting evidence (Wolff et al., 1993; Charlier et al., 2003) as well as studies that 
refute (Kriger et al., 1994; Gatto et al., 2007) the association between DDT and elevated 
breast cancer risk. The ambiguous conclusions drawn from these studies may be due to 
variables associated with age or the exposure used for analysis (blood vs. adipose tissue). 
Para, pa  ΄ DDE                                                                       
because it is the most abundant and persistent of all DDT isomers. However, many of the 
                                      , ΄ DDE                   ,     -menopausal 
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women. Age of exposure to DDT is an important factor to consider due to the prepubertal 
and pubertal years were found to be critical in the development of breast cancer (Cohn et 
al., 2011), since developing mammary tissue is more sensitive to hormonal or 
carcinogenic exposures. The older women in these studies were initially exposed to DDT 
and its isomers at unknown times and therefore may have decreased or increased levels of 
 , ΄ DDE                                                                               
of testing, when they would be considered  less vulnerable to exposure. This decrease or 
increase in levels may also be the result of changes in exposure, changes in type of 
exposure (parental DDT or dietary  , ΄ DDE from environmental exposures), prior 
lactations, and metabolic processes over decades.  Thus, studies that measure exposure in 
older women may have missed this critical period (Eskenazi et al., 2009). As such, all of 
the aforementioned variables may have contributed to the lack of solid evidence linking 
DDT and breast cancer risk. 
 
 I  2  7, C                                                                   , ΄ DDT 
in young women was associated with a 5-fold increase in breast cancer risk later in life 
(odds ratio 5.52; confidence interval 1.4-19.1). This study was the first of its kind to 
investigate age of DDT exposure and its effects on breast cancer risk. This study 
i           , ΄ DDT                                                                   
women were exposed to peak levels before the age of 14. DDT came into widespread use 
in 1945 in the United States and this year was used in the study as the first possible time a 
woman could be exposed to DDT. The average age of study participants was 26 years 
and women who were 14 years or older by 1945 showed little risk. These findings may 
 10 
disagree with many of the prior studies investigating DDT and breast cancer because the 
previous studies investigated DDT levels in older women with and without breast cancer 
who were already adults in 1945. Importantly, this finding also suggest women born after 
1945, who would be less than 14 years old when exposed would have a greater risk of 
breast cancer. This also implies that these women are now reaching ages associated with 
higher incidences of breast cancer and could potentially initiate an increase in new breast 
cancer cases over the next decade. According to the Cohn et al (2007) report, women 
exposed to DDT beginning as adults would be at a low risk, which may explain the 
inconclusive results in previous epidemiology studies. Similar to the study by Cohn and 
colleagues (2007), the MMTV-neu female mice in the present study were exposed to 
DDT prior to puberty. The similarity in age of exposure between the two studies may 
ultimately lead to better designs in epidemiology studies to accurately assess DDT and its 
isomers influence on breast cancer risk in women. 
 
DDT and the Immune System 
Decreased immunosurveillance and immune dysfunction are key mechanisms underlying  
carcinogenesis. Several DDT congeners have been shown to modulate the immune 
system, which could be a means for DDT to promote carcinogenesis. For example, the 
immunosuppressive effects of DDT have been shown to decrease the function of human 
natural killer cells, which are first-line immune defense against tumor cells (Udoji et al., 
2010).  Banerjee and colleagues (1996) showed that DDT exposure produced marked 
suppression of humoral and cell-mediated responses in experimental animals. Other 
immunomodulatory effects of DDT include activation of the complement system (Dutta 
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et al., 2008) and production of tumor necrosis factor-α                                
macrophages (Nunez et al., 2002). These effects of DDT on the immune system 
contribute to inflammatory reactions, cytokine imbalance, and overall immune 
dysregulation seen following exposure (Dutta et al., 2008). Moreover, DDT affects 
interleukin secretion from lymphocytes (Beach and Whalen 2006) and relatively low 
levels of DDE have been associated with statistically significant changes in immune 
markers (Vine et al., 2001). The strong implications of DDT and its metabolites impact 
on the immune system imply these compounds may influence multiple aspects of 
immune function. 
 
DDT and Mixtures 
Another aspect of DDT exposure on breast cancer that must be considered is the effect of 
DDT as a mixture. That is, multiple congeners, like p,p´ DDT,  , ΄ DDE ,      , ΄ DDE, 
are  detected simultaneously in people worldwide exposed to organochlorine pesticides 
 V    ό        , 2  9   M              -control studies that investigate an association 
between DDT and breast cancer risk measure serum levels of a single chemical (Cohn et 
al., 2007), which is generally  , ΄ DDE, with negative or inconclusive results (Payne et 
al., 2001). Kortenkamp (2006) states that epidemiologist assessing breast cancer risk 
should take into account the recent evidence showing that pollutants, present at low 
levels, can act together to add to the internal estrogenic load. Combined effects of p,p´ 
DDT, p,p´ DDE,  , ΄ DDT     β-hexachlorocylohexane were also found to be 
synergistic and/or additive in their capacity to enhance human breast cancer cell 
proliferation (Payne et al., 2001). Additionally, it was shown that exposure of normal 
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human mammary epithelial cells exposed to environmentally relevant mixtures that 
included p,p´ DDE, o,p´ DDE and p,p´ DDD (among others), sharply up-regulated the 
mRNA expression of a number of protein kinases associated with the transformation 
process of human breast cells at concentrations close to those detected in human 
             V    ό        , 2  9   S                       1997               
combination of p,p´ DDT      , ΄ DDT                           MCF-7 human breast 
cancer cells. Mixtures are a very relevant concern that needs to be considered for 
assessing DDT and breast cancer risk. 
 
MMTV-neu MOUSE MODEL 
 The present study used the unactivated mouse mammary tumor virus (MMTV)-neu 
mouse model, which overexpresses the wild-type rat neu (erbB2) gene.  HER2, the 
human homologue of neu, is commonly elevated in 20-30% of human breast cancer cases 
(Slamon et al., 1987). This gene codes for a member of the epidermal growth factor 
receptor family of receptor tyrosine kinases.  In the transgenic mice, the neu proto-
oncogene requires spontaneous activation, similar to humans, to an oncogene to result in 
the formation of mammary adenocarcinomas that resemble human tumors (Guy et al., 
1992). Additionally, the majority of mice develop mammary tumors that frequently 
metastasize to the lungs (Taneja et. al., 2009; Hutchinson and Muller, 2000), which is 
also a common site for breast cancer metastasis. Although androgens have been shown to 
act directly on the regulatory region of the long terminal repeat (LTR) of MMTV and 
thereby possibly influence gene expression (Darbre et al., 1986; Cato et al., 1987), the 
MMTV promoter has been successfully used for studying the control of gene expression 
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by steroid hormones (Reviewed in Ringold 1985; Yamamoto 1985). The hormone 
response element (HRE) located between -202 and -59 upstream of the start of 
transcription in the LTR region is required for this induction (Cato et al.,1987), but does 
not contain an estrogen response element (ERE) and therefore, is not regulated by 
estrogens (Otten et al., 1998). The MMTV-neu mouse model was used in the present 
study because it: 1) contains the unactivated form of neu and transgenic models that 
contain the activated form of neu are not good for studying mammary carcinogenesis 
(Andrecheck et al., 2000); 2) overexpresses neu, of which the human homologue, HER2, 
is overexpressed in human breast cancer cases; 3) requires spontaneous activation like 
human cancers and produces tumors that resemble human tumors; 4) forms tumors that 
frequently metastasize to the lungs, similar to breast cancer metastasis and 5) it is the 
same one used in the tumor study, which correlates with the mouse model with 
documented influence by DDE on mammary cancer.   
 
ELVAX 40P IMPLANTS 
 In order to replicate human exposure to DDT in the breast and to remain consistent with 
the tumor study conducted by Davis and colleagues, the treatments in this study were all 
delivered locally to the mammary gland through the use of ELVAX 40P implants. These 
implants are made of an ethylene vinyl-acetate copolymer that does not cause an 
inflammatory response (Silberstein and Daniel, 1982). The implants mimic human 
exposure because they allow for the slow, sustained (approximately 100 days), local 
release of a large variety of macromolecules in vivo as well as for the assessment of 
primary (non-systemic) effects of biologically active molecules on developing tissue 
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(Silberstein and Daniel, 1982), such as the mammary gland. This material/controlled 
delivery system has been successfully used in the mammary gland previously (Haslam 
1998; Andrapp et al., 1998; Wang et al., 1990; VanderPloeg et al., 1992) and elicits no 
adverse local or systemic response over extended periods in vivo (Shastri 2002).  
 
Ethylene-vinyl acetate copolymer is synthesized by free-radical polymerization of 
ethylene gas and vinyl acetate using a peroxide catalyst. The physical properties can be 
tuned between a rigid and rubbery material by altering the ratio of the co-monomers 
(Shastri 2002). Ethylene-vinyl acetate pellets (40% by weight vinyl acetate) are the first 
biocompatible polymeric delivery system capable of continuously delivering 
macromolecules (Rhine et al., 1980). In addition,  it did not induce any inflammatory 
responses and showed no foreign cells in the region surrounding the polymer or in other 
areas of the cornea when aseptically implanted into the avascular cornea of rabbits 
(Langer and Folkman 1976). Mechanism of release does not appear to be simple 
diffusion and substances deep in the polymer may be driven to the surface by osmotic 
pressure or capillary action (Langer and Folkman 1976). Release rates were also shown 
to decrease due to increases in diffusion distance through the pores of the polymer matrix 
as time increased. However, constant release rates have been achieved with appropriate 
geometric design (Brown et al., 1983). Also, the ethylene-vinyl acetate copolymer has 





PREVISOUS STUDIES ON p,p΄ DDE AND MAMMARY CANCER 
DEVELOPMENT 
The major goals of the studies conducted by Davis and colleagues were to investigate 
tumor outcomes induced by exposure to the anti-        ,  , ΄ DDE,                  
prepubertal mammary gland of MMTV-neu mice. The purpose of the tumor study was to 
explore localized effects of the prevalent anti-          , ΄ DDE                    
      ,  , ΄ DDE                                    ,        ,                 T   
effects of a combination treatment of p,p´ DDE and o,p´ DDE in a 2:1 ratio were also 
investigated (Table 1). 
 
Table 1. Treatment Groups for the Previous Tumor Study (n=72-80)  
Treatment  Control p,p΄ DDE   o,p΄ DDE  p,p΄ DDE         
+                   
o,p΄ DDE (2:1) 




In these studies, ELVAX 40P pellets (5 µg/pellet) were bilaterally implanted into the 
axillary and inguinal mammary fat pads (20 µg total) which allowed DDE to be directly 
delivered to the mammary adipose tissue, in close proximity to the mammary epithelial 
cells, very similar to how DDT is stored in the adipose tissue of the human breast. The 
tumor study results revealed that the maximal incidence of mammary tumors was 
unaffected by localized exposure of 5 μ  p,p´ DDE via ELVAX pellets compared to the 
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control group (Fig.1). The unaffected incidence suggests DDE acts as a tumor promoter 
                               H      ,  , ΄ DDE                     =    8,  -test) 
accelerate tumor formation compared to control mice (vehicle pellet) (Fig. 2).  Age of 
tumor onset was shortened by 1.5 months, where the earliest tumor was detected in the 
 , ΄ DDE              9                                       147  S                      
percent of tumor-free animals with age also showed p,p´ DDE exposure resulted in earlier 
                 F    3   T                    ,  , ΄ DDE,                             
            , ΄ DDE  B                                                                   
from control (Fig. 1 & 2). Additionally, Cohn and colleagues (2007) observed a 
correlation between DDT levels and breast cancer in women before the age of 50.  As 
breast cancer before age 50 precedes the average age of diagnosis, the increased risk with 
higher levels of  , ΄ DDT suggests an effect on                                        , ΄ 
DDE in the MMTV-neu mice. The age of onset profoundly impacts breast cancer; early-
                              ≤ 5                                                      
than in postmenopausal years (Benz et al., 2008). Inducing an earlier onset of breast 
cancer can increase the likelihood of women developing ER-negative tumors (Benz et al., 
2008; Vetto et al., 2009), including HER2-positive breast cancer, which the mouse model 





                          
Figure 1. No significant difference in maximal tumor incidence was detected in > 9 
month old MMTV-neu female mice. The number                      , ΄ DDE 
(n=65 ,  , ΄ DDE   =59      2:1         =54                                              
control (n=57) by chi-square test, p> 0.05. 
 
                           
Figure 2.  Localized delivery of p,p´ DDE accelerated tumor formation in > 9 month 
old MMTV-neu female mice. Para,para´ DDE  significantly decreased the age of tumor 
                       1 5                                ,       , ΄ DDE       -
                   , ΄ DDE      2:1                               5 µ /  llet), latency 
effects resembled control. One-     NOV       T    ’                                 




                             
                                   
Figure 3.  p,p´ DDE consistently caused tumors to develop earlier versus control. 
The first mammary tumor was                                           , ΄ DDE       
(at 91 days of age) compared to the control animals on day 147 of age. Gehan-Breslow-
Wilcoxon test used for statistical analysis (p<0.05). 
 
                             
Also, as DDT occurs in women as a mixture, an additional group examining the 
combined effects of p,p´ DDE and o,p´ DDE in a 2:1 ratio (5 g/pellet total) was also 
investigated.  The concentration of p,p´ DDE included in the combined treatment was 
higher than o,p´ DDE due to it being the most prevalent metabolite in humans. The o,p´ 
DDE concentration was higher than found in humans, but may represent the total of 
estrogenic congeners in some women.  Surprisingly, although p,p´ DDE significantly 
accelerated tumor formation, when combined       , ´ DDE      2:1         , ΄ DDE: , ΄ 
DDE), no change in tumor latency occurred (Fig. 2). Similar to its latency, the survival 
curve of this group also resembled control, indicating that the addition of  , ΄ DDE  
           , ΄ DDE’                  celerating effects (Fig. 4). These findings imply 
that the ratio of DDE isomers may influence tumor development differently than the 
single  , ΄ DDE congener.  The incidence of mammary tumor formation was similar 
between groups, suggesting that these conge    ,  , ΄ DDE       , ΄ DDE , do not cause 
an increase in mammary tumor formation (Fig. 1).  Collectively, these findings may 
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suggest that p,p´ DDE has the ability to remove many cancer-                       ’  
life. 
 
Figure 4. Co-administration of p,p΄ DDE and o,p΄ DDE in a 2:1 ratio resembled 
control. W     , ΄ DDE                    , ΄ DDE,                                 
not observed, as the results from this combination treatment group resembled those of the 
control group. Gehan-Breslow-Wilcoxon test used for statistical analysis (p>0.05). 
 
PREVIOUS STUDY RELEVANCE 
The previous study demonstrated that p,p΄ DDE caused mammary tumors to develop 
at an earlier age in MMTV-neu female mice.  If levels and timing of exposure are 
similar in women,  , ΄ DDE  may have similar results in women.  As mice have a short 
lifespan, the 1.5 months earlier tumor onset could equate to the loss of years or decades 
of cancer-                       ’        T                 DDE                 
demonstrated when the anti-a           , ΄ DDE      -administered with the 
                   , ΄ DDE      2:1        W                    ,  , ΄ DDE          
ability to cause earlier tumor onset.  As a lower dose was tested for  , ΄ DDE, the effects 
with the 2:1 ratio may be due to dose or to the effects of the combined isomers.  Thus, the 
doses or ratios of p,p´ DDE with other DDT components within the mammary gland may 
be involved in tumor development and was tested within this study.  
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As the result in the tumor study show an effect on latency, the studies to identify markers 
    , ΄ DDE  action are needed to look for effects of  , ΄ DDE  prior to tumor onset.  
Therefore, these studies used animals exposed to the treatments for 2 months.  The 
animals examined included the pretumor study that was performed with the tumor study 
by Davis and colleagues to examine the same treatments after 2 months of exposure in 
the normal, adult mammary gland prior to tumor detection.  In addition, additional groups 
(DDT study 01 and 02) were developed to test central questions regarding the local 


















Delivery of p,p΄ DDE  to the mammary glands of MMTV-neu female mice results in 
concentrations applicable to human exposure, which induce local and systemic gene 
expression associated with cancer promotion. The p,p DDE-induced differential 
gene expression identified by microarray analysis is partially caused by the anti-
androgenic actions of p,p DDE, as well as distinct doses, ratios and immune 
properties not shared with o,p΄ DDE or p,p´ DDT  congeners that could be related to 
the cancer-promoting ability of p,p  DDE.  
 
Specific Aims  
 
1. To validate the translational relevance of the MMTV-neu mouse model by 
assessing the impact of treatment with DDT congeners on the MMTV promoter 
and the levels of DDE  in serum and mammary adipose tissue 
 
Androgens regulate MMTV transcription (Darbe et al., 1986; Cato et al., 
1987). Therefore, in order to directly correlate the decreased latency in the 
tumor study to  , ΄ DDE  treatment, the possibility of aberrant stimulation 
of the promoter needed to be excluded, as this promoter would not be 
associated with breast cancer development in women. If neu levels were 
strongly increased, its expression, and not  , ΄ DDE  actions in the 
mammary tissue, could be related to the earlier tumor formation.  
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Additionally, lipid-adjusted levels of DDE delivered by ELVAX 40P 
pellets to the mammary gland were measured in serum and mammary 
gland tissue, identical to the way it is measured in women in 
epidemiological studies, for correlating to human exposure.  
 
2. To identify candidate genes that are differentially expressed in the mammary 
gland of MMTV-neu mice after chronic exposure to p,p´ DDE 
 
The findings of Davis and colleagues showed tumors develop earlier when 
 , ΄ DDE                                                               
Normal mammary tissue prior to tumor detection was examined to identify 
genes modified by 2 months of exposure to  , ΄ DDE. Using microarray 
technology, genes that were differentially expressed in the mammary 
                             , ΄ DDE                                   
pellets) mice.  Genes (markers) selected for further testing had previously 
reported roles in cancer or were hormonally regulated or immune-related.  
 
3. To investigate the potential anti-androgenic actions of p,p΄ DDE, its dose-
dependence, and its similarity to or influence by other DDT congeners in the 
mammary tissue using the identified p,p΄ DDE -regulated genes.   
 
The genes identified in Aim 2 were further analyzed in mammary tissue in 
other treatment groups to characterize  , ΄ DDE actions.  In vitro and in 
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male rats,  , ΄ DDE  has been demonstrated to act as an anti-androgen, but 
whether it has this activity in the female mammary gland has not been 
tested.  This study will test whether  , ΄ DDE  mimics responses of a 
known anti-androgen (hydroxyflutamide). The lack of effect in the tumor 
study by the 2:1 ratio suggests either the dose of  , ΄ DDE or its 
                   , ΄ DDE               s of accelerated tumor onset. 
Therefore, varying doses of  , ΄ DDE will be tested to observe the 
resulting effects on the identified  , ΄ DDE markers.  Additionally, ratios 
                        , ΄ DDE                                        
(5 μ /pellet      , ΄ DDE                   , ΄ DDT has correlations to 
increased breast cancer risk (Cohn et al. 2007) and anti-androgenic action 
(Kelce et al., 1995), this DDT congener will also be investigated alone and 
in combination with  , ΄ DDE on the same markers.  
 
4. To investigate p,p΄ DDE effects from systemic exposure by examining its influence 
on the hormonally-responsive uterus and cytokine gene expression in splenic 
leukocytes 
 
          , ΄ DDE                                          , 
detectable levels of DDE isomers were measured in serum (see Chapter 4), 
thereby confirming systemic exposure. Cytokine gene expression was 
measured in both splenic leukocytes and lymph node positive mammary 
gland tissue to determine and compare the systemic and local effects of 
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 , ΄ DDE  U                                                       
                              , ΄ DDE  
 
Collectively, these specific aims seek to answer five key central questions: 
 
CENTRAL QUESTIONS   
 
1. What genes are differentially expressed after localized exposure to the same 
dose of  , ΄ DDE  that resulted in the earlier onset of mammary tumors? 
 
2. I                               , ΄ DDE                                  
dependent? 
 
3. Does p,p´ DDE action mimic a known anti-androgen locally within the 
mammary gland or systemically? 
 
4. D               , ΄ DDE                             , ΄ DDE               
                               , ΄ DDE-regulated markers in the mammary 
gland? 
 
5. D     , ΄ DDT,                    -androgen activity, induce similar or 




Chapter 2  
 




The first goal for Aim 1 was to confirm that the MMTV-neu mouse model is relevant for 
examining  , ΄ DDE exposure on mammary tumor development. Even though this model 
is commonly used to study breast cancer, the concerns reside in the regulation of the 
MMTV promoter by androgens and other steroid hormones (Darbe et al., 1986).  
Therefore, it is important to ensure this promoter driving expression of the neu transgene 
was not significantly regulated by p,p´ DDE and its anti-androgenic activity.  Although 
 , ΄ DDE was observed to act like an androgen in vitro (Kelce et al., 1995), its action in 
the mammary gland is unknown. It binds to the androgen receptor, and some anti-
androgens have weak androgenic activity. The MMTV sequences that direct hormonally-
regulated transcription are contained within a region of long terminal repeats (LTR) 
between nucleotides -202 and -50 relative to the start of transcription (+1) ( Gunzburgh 
and Salmons, 1992). Glucocorticoids, progestins and, most importantly for this study, 
androgens have all proven to regulate MMTV transcription (Darbre et al., 1986; Cato et 
al., 1987).  Therefore, if  , ΄ DDE abnormally stimulates the MMTV promoter and, 
consequently, rat neu transgene expression, the decreased latency may not be due to 
treatment.  In that case, the early tumor formation could be an artifact of the model.  As 
women have the HER2/neu gene regulated by its own promoter and not MMTV, then 
HER2/neu would not be similarly regulated in women to increase their risk of early 
breast cancer with  , ΄ DDE exposure.  If the transgene is not differentially stimulated 
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compared to control mice, then the  , ΄ DDE treatment versus the neu regulation by the 
MMTV promoter would be responsible for any responses detected for this treatment in 
the mammary gland; this is the desired result for using this model for analyzing tumor 
outcomes from the tumor study and for the subsequent investigations in Aims 2-4 within 
this study.  As increased expression of neu would need to precede tumor detection to 
influence tumor formation, transgene expression was examined in the normal mammary 




Total RNA Isolation 
 For gene expression investigations total RNA was isolated from lower mammary tissue 
and splenic leukocytes using the Absolutely RNA® Miniprep Kit (Stratagene, La Jolla, 
C                               ’            D                                    
adipose, RNA yields from 20 mg of tissue were consistently low. However, after 
completing a small series of tests, using approximately 30, 40, 50, 90 and 110 mg of 
mammary tissue, it was discovered that RNA yields could be increased by increasing 
tissue weight without clogging the filter or the need for additional amounts of reagents 




























1 LM 30 600 4.2 .188 .089 2.113 1:5 5.63 
2 LM 43 600 4.2 .428 .246 1.742 1:5 12.84 
3 LM 55 600 4.2 .501 .246 2.040 1:5 15.03 
4 LM 90 600 4.2 .548 .260 2.104 1:5 16.44 
5 LM 110 1000 7 1.131 .549 2.078 1:5 33.93 
LM=              ; β-ME=beta mercaptoethanol 
 
Therefore, tissue sample weights were modified and 40-90 mg of tissue was 
homogenized with 600 µl of lysis buffer (which contains guanidine thiocyanate, a strong 
                         4 2 μ     β-mercaptoethanol. The homogenate was pre-spun to 
remove particles and reduce DNA by transferring the tissue homogenate to a 2 mL 
receptacle with a fiber matrix spin cup that was provided in the kit and centrifuged at 
13,200 rpm for 5 minutes.  An equal amount of 70% ethanol was added to the filtrate, 
vortexed for 5 seconds and transferred to a fresh 2 mL receptacle with an RNA binding 
spin cup and microcentrifuged at 13,200 rpm for 60 seconds. Next, samples were washed 
     6   μ        -salt wash buffer to remove any remaining DNA and microcentrifuged 
at 13,200 rpm for 60 seconds. After the filtrate was discarded, the receptacle and RNA 
binding spin cup were centrifuged for 2 minutes in order to dry the fiber matrix. Samples 
were then treated with the DNase solution and incubated at 37°C for 20 minutes. After 
the incubation period, the samples were washed once with high-salt buffer and 
centrifuged at 13,200 for 60 seconds. The high-salt wash was followed by two 
subsequent low-salt buffer washes centrifuged at 13,200 rpm for 60 and 120 seconds, 
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respectively. To elute the highly pure RNA from the fiber matrix, the RNA binding spin 
cups were transferred to new RNase-/DNase-free tubes. Seventy five microliters of 
elution buffer warmed to 60°C was added directly to the fiber matrix and incubated at 
room temperature for two minutes, followed by centrifugation at 13,200 rpm for 60 
seconds. The elution process was repeated a second time before RNA quality/integrity 
was determined using the 260:280 nm ratio on the Beckman DU®530 Life Science 
UV/Vis spectrophotometer. High quality RNA used for subsequent real-time RT-PCR 
possessed a ratio of 1.8-2.2. 
 
cDNA Reverse Transcription (RT) Reactions 
RT reactions for real-time RT-PCR were made using the Reverse- T™ 1
st
 Strand 
S         K       B      E    , S     , UK                              ’            
In the applied two-step protocol, 500 ng of RNA was combined with random decamers 
and sterile water in thin-walled reaction tubes and heated at 70°C for 5 minutes to remove 
any secondary structures. Samples were then placed on ice. Next, 5x First Strand 
Synthesis Buffer, dNTP mix (5mM each), 100 mM DTT and Reverse- T™ RT    B     
were added to each tube and incubated at 47°C for 50 minutes for strand synthesis in the 
Eppendorf Mastercycler® ep (Brinkman Instruments, Westbury, NY). This step was 
followed by an incubation at 75°C for 10 minutes to inactivate the reverse transcriptase. 
In addition to RT reactions bei       , “N  RT”                           T     
reactions consisted of all the same components as the RT reactions with the exception of 
the Reverse- T™ RT    B    ,                                                     
RNase/DNase-free water. Total volume                     2  µ   “N  RT”               
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used as a control in order to identify possible DNA contamination. After the incubations, 
several tubes of the same sample were often pooled in order to decrease variability within 
cDNA synthesis levels, because multiple genes were examined per sample. Pooling 
produces a more accurate representation of the sample. All samples were then stored at -
20°C until ready to use for real-time RT PCR analysis of gene expression. 
 
Subsequent to the Reverse- T™ 1
st
 Strand Synthesis Kit by ABgene, RT reactions for 
                                                              S     ™  DN  
Synthesis Kit, by Quanta Biosciences (Gaithersburg, MD) due to the ABgene/BioRad 
product relationship being terminated . Although very similar to the ABgene cDNA kit 
described above, the qScript cDNA kit contained all the necessary components for cDNA 
synthesis (including random and oligo(dT), 5X optimized buffer, and dNTPs) all in one 
reaction mix, only enzyme and the RNA template needed to be added. This master mix is 
particularly beneficial considering it has both random and oligo dTs. Oligo (dT) are 
specific to the poly-A tail of the RNA and may not reach the desired region of 
amplification. However, random dTs are not specific to the poly-A tail and can produce 
cDNA from all regions of the RNA. When making RT reactions, all components were 
added to 0.2 mL thin-walled PCR tubes on ice. For a single reaction, the only component 
amounts that varied were the RNA template (250 ng) and nuclease-free water. qScript 
reaction mix remained constant at 4.0 µl as did 1.0 µl of reverse transcriptase; for a total 
RT volume of 20 µl. Once all components were added together they were place in the 
Eppendorf Mastercycler® ep (Brinkman Instruments, Westbury, NY) programmed as 
follows: 1 cycle: 22º C for five minutes, 1 cycle: 42º C for 30 minutes, 1 cycle: 85º C for 
 30 
five minutes followed by a 4º C hold. After cDNA synthesis was complete, samples were 
stored at -20°C until ready to use for real-time RT PCR analysis of gene expression. 
 
Real-Time RT-PCR 
 Real-time detection of RNA levels was performed on the iCycler (Bio-Rad, Hercules, 
CA) using SYBR Green Supermix (Quanta Biosciences, Gaithersburg, MD) detection. 
All primers (see appendix) were designed to span at least 1 intron/exon junction, in order 
to eliminate possible contamination of amplified genomic DNA. PCR protocols were as 
follows: Absolute QPCR SYBR Green Fluorescein Mix (ABgene, Rochester, NY) PCR 
protocol: enzyme activation at 95 º C for 15 minutes, followed by 50 cycles of 
denaturation for 30 seconds at 95 º C and annealing/extension at 60 º C for 30 seconds. 
Quanta B-R SYBR Green Supermix: initial activation 95 º C for 3 minutes, followed by 
50 cycles of denaturation at 95 º C for 15 seconds and annealing/extension at 60 º C for 
45 seconds. Melt curves were also performed at the end of each run to ensure the 
presence of a single product for the sample. Prior to any real-time RT-PCR being 
conducted, primer efficiencies were also conducted to ensure the primer would work. 
These efficiencies entailed assigning arbitrary concentrations of the RT using a 10-fold 
serial dilution that was then used to make a standard curve, with a perfect fit having a 
correlation coefficient of 1.00. An acceptable PCR efficiency was considered 100% ± 20. 
Additionally, gel electrophoresis was conducted on a small subset of samples tested for 
each gene used, in order to visualize that the amplified product had the appropriate base 



















































Figure 5. Example of gel electrophoresis used to confirm product size of primers. All 
genes that were investigated had their amplified product visualized to ensure proper base 
pair size. Primers were designed to be less than 300 base pairs in length. 
 
Relative Gene Expression 
 In order to analyze the data from  the real-time RT-PCR, relative gene expression was 




(Livak and Schmittgen 2001) with cyclophilin A (ppia) 
                                                 B      ,     ΔC                        
subtracting the cycle threshold (Ct) of the housekeeping gene from the Ct value of the 
gene of interest for each sample. The Ct is the number of cycles it takes for the 
fluorescent signal to cross a specific threshold value. Therefore, the more cycles needed 
to cross the threshold would be indicative of lower amounts of transcript of that gene. 
T   ΔΔC                                                ΔC                            
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            ΔC                        T                                                   
change using the equation 2
-ΔΔC 
  S                                        ΔC   
 
Statistical Analysis 
 Analyses were performed using GraphPad® Prism 5.0 software. A Mann-Whitney U test 
was used to determine the differences between two groups. This non-parametric test has 
no requirement that the two populations have a normal (Gaussian) distribution or any 
other particular distribution. One-way analysis of variance (ANOVA) was also used 
when analyzing sample variances of three or more populations that are independent of 
each other. This method is robust against variances that are not equal, meaning it works 
well unless the population variances differ by large amounts (Triola and Triola, 2006). 
            , T    ’  HSD                                         NOV             
performed in order to find what means were significantly different from one another. In 
other words, this test measures the means of every treatment to the means of every other 
treatment. Analysis by two-way ANOVA with Bonferroni post test was employed to 
determine variances between samples that are categorized two ways. Similar to a one-
way ANOVA, this method is also robust against unequal variances. The Bonferroni test 
is a multiple comparison test that identifies differences in pairs of means but makes 
adjustments to overcome for the problem of having a significance level that increases as 
the number of individual tests increases (Triola and Triola, 2006). Statistical significance 





To investigate regulation of neu expression in the MMTV-neu mice, rat neu (transgene) 
levels were measured in RNA prepared from mammary tissue of 3-month-old MMTV-
neu female mice from the Pretumor study.  Six animals from each group, including the 
control, p,p´ DDE, o,p´ DDE,          2:1         , ΄ DDE: , ΄ DDE        s, were 
examined by real-time RT-PCR using a specific primer set for rat neu transgene, which 
does not detect the endogenous mouse neu gene. None of the treatments significantly 
increased the expression of the transgene in mammary tissue (Fig.6). These findings 
demonstrate that p,p´ DDE and the other treatments used in the study did not cause 
abnormal stimulation of the promoter in normal, adult mammary tissue prior to tumor 
onset.  As  , ΄ DDE was the only treatment group that accelerated tumor development in 
the MMTV-neu mice, the lack of stimulated transgene expression by this DDT 
metabolite was an important finding for interpreting translational relevance of this tumor 






















Figure 6. Treatment groups did not modify expression of the rat neu transgene in 
mammary tissue of 3-month-old MMTV-neu female mice. Regulation of the MMTV 
promoter was not affected by the  treatments as demonstrated by there being no 
significant difference in expression of the rat neu transgene in any group compared to 
control mice. RNA levels were determined by real-time RT-PCR from random mammary 
tissue sections from mice in the Pretumor study  ΔC                            
normalized levels of the rat neu transgene to ppia                          ΔC        
indicates the gene is expressed at a higher level. Numbers displayed within each bar 
represent the fold-change compared to control using the 2
-ΔΔC 
 method. One-way 
ANOVA with Tukey's post test was used for statistical analysis (p>0.05). n=6. 
 
 
As the MMTV promoter has known regulation by several hormones, its regulation by 
other treatment groups in the Pretumor study were compared to the control and  , ΄ DDE 
groups. For example, comparing  , ΄ DDE to the known anti-androgen, 
hydroxyflutamide (OH-flut), will determine if these two anti-androgens have similar 
effects on this androgen-regulated promoter. OH-flut is the active metabolite of 
flutamide, a pharmaceutical anti-androgen used for treating prostate cancer. With oral 
delivery in men, the drug would pass through the liver and be metabolized to its active 
form. However, as little metabolism would be expected to occur in mammary tissue, OH-
flut is the preferred compound for localized delivery to the mammary glands.  OH-flut 




































androgen, even though not all anti-androgens may not stimulate or repress the exact same 
gene profile as another. In tissue culture,  , ΄ DDE was equipotent to OH-flut at 
inhibiting an androgen-regulated reporter gene (Kelce et al., 1995), so the same dose of 
both compounds was tested in the mice (5 g/pellet).  
 
The anti-androgenic activity of OH-flut was evident on the MMTV promoter, since it 
significantly down-regulated rat neu transgene expression compared to control (p=0.02, 
Mann-Whitney test). However,  , ΄ DDE was not significantly different than the control 
group.  Examination of the expression of rat neu transgene within the pretumor animals, 
revealed that the OH-flut and p,p´ DDE did not produce similar effects on rat neu gene 
expression (Fig. 7), with a difference approaching significance (p=0.06, Mann-Whitney 
test). Although the disparity between the anti-androgens was unexpected, it demonstrated 
































 Figure 7.  Anti-androgenic treatments did not uniformly impact the expression of 
the rat neu transgene after 2 months of exposure in 3-month-old MMTV-neu female 
mice.  Unlike OH-flut, the 1.6-fold neu levels compared to control mice show an up-
regulation in expression of the transgene by p,p´ DDE although not significant by one-
way ANOVA. ΔC                                                     neu transgene to 
ppia (cyclophilin A).         ΔC    lue indicates the gene is expressed at a higher level. 
Numbers displayed within each bar represent the fold-change compared to control using 
the 2
-ΔΔC 
 method.  One-way ANOVA with T    ’       test was used for statistical 
analysis (p<0.05). n=6. OH-flut= hydroxyflutamide, * denotes significance compared to 
           T    ’        
 
 
Para, para´ DDE was also compared to methyl-T (50 ng/pellet), an androgen that is not 
converted to estrogen by the enzyme aromatase. Due to the androgenic nature of methyl-
T, it might be expected to stimulate neu gene expression, however, this effect was not 
observed (Fig. 8).  The lack of significant change in transgene expression compared to 
the control mice suggests androgen regulation of the MMTV promoter by methyl-T did 






























Figure 8. The expression levels of rat neu with a non-aromatizable androgen  and 
p,p´ DDE were similar to the control group in mammary tissue of 3-month-old 
MMTV-neu females. When compared to control, p,p´ DDE (5 μ /pellet) and 
methyltestosterone (methyl-T; 50 ng/pellet) expression of the rat neu transgene resembled 
         ΔC                                                     neu transgene to ppia 
(cyclophilin A).         ΔC                                      d at a higher level. 
Numbers displayed within each bar represent the fold-change compared to control using 
the 2
-ΔΔC 
 method. One-way ANOVA with Tukey's post test was used for statistical 
analysis (p>0.05). n=6.  
                                      
Next, comparisons in rat neu expression were also made with the estrogenic treatments 
(Fig. 9). The  ,   DDE isomer with weak estrogenic activity was compared to 17β-
estradiol (E2), the most potent endogenous estrogen.  Neither o,p´ DDE nor E2 (2.5 
ng/pellet) were significantly different from control or one another.  These data support 
the findings of Otten et al., (1987) and Glover and Darbre (1989) that report MMTV 
hormone response elements (HRE) of the long terminal repeat (LTR) is not regulated by 
estrogens, because it does not contain an estrogen response element (ERE). Additionally, 
although p,p´ DDE has weak estrogenic effects (Ociepa-Zawal et al., 2010), weakly binds 
to the estrogen receptor (Kelce et al., 1995), and had similar expression levels as o,p´ 
DDE, the possibility of  p,p´ DDE having estrogenic action in the mammary glands 
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cannot be determined due to the inability of o,p´ DDE and E2 to induce a response via the 
MMTV promoter. 






























Figure 9. Estrogenic treatments did not significantly alter rat neu expression.  The 
estrogenic treatments of o,p´ DDE (5 g/pellet) and 17-estradiol (E2, 2.5 ng/pellet) did 
not significantly influence rat neu expression as expected. Additionally, p,p´ DDE 
displayed very similar expression patterns with both o,p´ DDE and E2, having fold-
changes ranging from 1.1-1.7. ΔC      ession represents the normalized levels of the neu 
transgene to ppia (cyclophilin A).         ΔC                                             
higher level. Numbers displayed within each bar represent the fold-change compared to 
control using the 2
-ΔΔC 
 method. One-     NOV ,      T    ’                          
statistical analysis (p>0.05). n=6. 
 
 
Lastly, when examining the co-administration of p,p´ DDE (3.3 µg ) and o,p´ DDE (1.7 
µg ) in a 2:1 ratio (5 µg total), a modest decrease in expression (0.3-fold) was observed, 
though this effect was not significant (Fig. 10).   These data correlate with the lack of 
regulation of the neu transgene by the individual DDE isomers in normal, adult mammary 

















Figure 10. Co-administration of p,p´ DDE and o,p´ DDE in a 2:1 ratio did not 
significantly affect neu transgene expression. Similar to the individual expression of  
p,p´ DDE (5 µg /pellet) and o,p´ DDE isomers (5 µg/pellet), the expression of the 
combination treatment of p,p´ DDE (3.3 g/pellet) and o,p´ DDE(1.7 g/pellet) in a 2:1 
ratio (total of 5 µg/pellet) [2:1 (5 µg/pellet)] was also not significantly different from 
         ΔC                                                     neu transgene to ppia 
                          ΔC            tive of the gene being poorly expressed, thus 
requiring more amplification cycles before it crosses the threshold. One-way ANOVA 
with Tukey's post test was used for statistical analysis (p>0.05). n=6. 
 
Expression of the endogenous mouse neu was also measured in the same animals by real-
time RT-PCR using a primer set that is selective for the mouse version of the endogenous 
neu gene. Investigating how the six treatment groups impacted the normal mouse neu 
gene expression by its endogenous promoter may suggest how the human HER2/neu 
gene may respond to these DDT congeners and hormones in breast tissue.  If it is 
increased strongly by p,p´ DDE, these results could suggest the potential for this 
upregulated gene to influence proliferation or tumor development in breast tissue exposed 
to this prevalent DDT metabolite. However, although 20-30% of primary human breast 






























outcome (as reviewed by Hutchinson and Muller 2000), this elevation is due to genomic 
amplification of the HER2 protooncogene (Slamon, 1987) and not simple upregulation by 
regulating factors. 
 
Mouse neu expression was measured by real-time RT-PCR using specific primers for 
mouse neu that do not recognize the rat neu transgene in six animals per group from the 
Pretumor study in the control, DDT congeners (p,p´ DDE , o,p´ DDE , 2:1 ratio) and 
hormonal controls (E2 , methyl-T  and OH-flut).  Endogenous mouse neu expression for 
all treatments was not significantly different from control (Fig. 11). Not surprisingly, 
mouse neu expression was also lower than rat neu transgene expression (Ct at least 5 
cycles later, or >30-fold, than for the transgene, see Fig. 6 & 11), because it is not under 
the control of the strong MMTV promoter. These data demonstrate that all six treatment 























Figure 11. Endogenous mouse neu expression was unaffected by DDE or hormonal 
treatments in mammary tissue of MMTV-neu mice treated for 2 months. Regulation 
of endogenous mouse neu was also not affected by treatment as demonstrated by there 
being no significant difference in expression of the gene in any treatment group 
compared to control using real-time RT-PCR  ΔC                                       
levels of endogenous neu to ppia                          ΔC                              
expressed at a higher level. Numbers displayed within each bar represent the fold-change 
compared to control using the 2
-ΔΔC 
 method. One-way ANOVA with Tukey's post test 
was used for statistical analysis (p>0.05). n=6.  OH-flut = hydroxyflutamide; Methyl-T = 

















































The MMTV-neu (c-erbB-2) mouse model was used for these studies due to it being an 
important oncogene in human breast cancer, which is amplified in 20-30% of all human 
breast cancers (Slamon et al., 1987). Its appearance in women correlates with poor 
prognosis and minor perturbations in amplified neu expression are sufficient to alter 
mammary development and induce malignant transformation (Weinstein et al., 2000). 
Furthermore, mouse mammary tumor virus (MMTV)-driven transgenic mice allow for 
the targeted expression of the neu oncogene to examine its effects on neoplastic 
transformation of mammary tissue (Taneja et al., 2009). The MMTV-neu model also 
possesses other similarities to human breast cancer, such as requiring spontaneous 
activation (Hutchinson and Muller 2000) and result in mammary tumors that frequently 
metastasize to the lungs after a long latency (Guy et al., 1992). However, although the 
MMTV-neu model had been successfully used to study breast cancer for decades, there 
are limitations of the model. For example, the oncogene utilizes an extremely strong viral 
promoter that allows for high levels of transcriptional activity. This promoter among 
others, are of necessity and not physiologic; causing elevated levels of oncogene 
expression, not regulated in a physiologic manner (Weinstein et al., 2000); therefore 
tumor development in this model does not represent an accurate recapitulation of human 
disease (McDermott and Wicha, 2010). However, the MMTV-neu mouse model has been 
proven to be a useful tool for preclinical studies on breast cancer.  One aspect of this 
model that had to be tested to ensure that the tumor-                     , ΄ DDE      
not due to an artifact of the model is the hormonal regulation of the MMTV promoter. 
 43 
The long terminal repeat (LTR) region of the MMTV promoter has a hormone response 
element (HRE) located between nucleotides -202 and -50 relative to the transcription 
initiation site (reviewed in Günzburgh and Salmons 1992). This HRE has been 
documented as being induced by androgens (Darbe et al., 1986; Cato et al., 1987; Otten 
et al., 1987; Glover et al., 1989). Since several treatment groups in the pretumor study 
contained steroid hormones or possessed hormonal activity, it is possible that the 
treatments could alter the expression of the neu transgene.  However, the group of 
concern would be  , ΄ DDE since it was the only group to significantly shorten tumor 
latency.  An increase in expression by the promoter could result in aberrant increases in 
neu expression and, possibly, earlier tumorigenesis. An increase in neu expression would 
then be considered an artifact of the model, making any potential findings by  , ΄ DDE 
less relevant as it suggests the treatment effects on tumor development could be on the 
MMTV promoter and not the mammary tissue. In women, the endogenous HER2 
promoter is not under the control of a viral promoter (MMTV), so translational relevancy 
would be reduced.  However, as expected, the androgenic  , ΄ DDE did not significantly 
modify expression of the transgene compared to the control group.  Therefore, the 
decreased latency observed in the tumor study was, in fact, due to p,p´ DDE treatment 
effects on mammary tissue and not due to the design of the mouse model. These data 
imply the MMTV-neu mouse model is an appropriate model to use for subsequent 
investigations. 
  
Comparisons between p,p´ DDE-induced effects versus OH-flut, which is an androgen 
receptor antagonist, revealed that the treatments did not have the same effect on the rat 
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neu transgene. OH-flut resulted in significantly down-regulated neu expression (0.05-
fold) compared to control (Fig. 7). As an anti-androgen, OH-flut should block the 
stimulation of the MMTV promoter via the HRE in its LRT by physiological levels of 
androgen (Glover and Darbre 1989). Therefore, its effect on rat neu expression is the 
expected response. As the strongest regulation of the neu transgene was by OH-flut (Fig. 
7), these data indicate that its dose was sufficient to inhibit the androgen-regulated 
promoter, even without the ability to bioaccumulate like  , ΄ DDE in the mammary 
gland.           , ΄ DDE     OH-flut are both anti-androgens, the lack of correlation in 
rat neu expression suggests that  , ΄ DDE is not acting like an anti-androgen on the 
MMTV promoter.  
 
Methyl-T, which is a non-aromatizable androgen, would be expected to stimulate neu 
expression by the androgen-regulated MMTV promoter.  However, the levels of neu 
transgene expression were similar to the control group; these results suggest that the dose 
of methyl-T was insufficient to regulate expression from the MMTV promoter.  Due to 
its lack of effect on the androgen-regulated MMTV promoter, no conclusions can be 
drawn about other potential androgen actions in the mammary tissue that could have been 
mediated by methyl-T.    
 
Similar to the testing of the rat neu transgene, for aberrant modulation, the endogenous 
mouse neu gene was also examined to ascertain whether or not various treatments 
induced its expression. The expression of endogenous neu was considerably lower than 
the rat transgene (Fig. 6 & 11), as expected, since the endogenous neu gene is not under 
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the control of the strong MMTV promoter.  None of the treatment groups significantly 
modified the expression of mouse neu.  These data demonstrate the endogenous mouse 
neu gene is not significantly regulated by any of the hormonal treatments tested.  This 
lack of regulation is a desired effect, which implies, if extrapolated to the human 
population, the treatments may not influence HER2-positive breast cancer development 
by modifying HER2 expression.  
 
The only treatment group to induce significant regulation of the transgene was the 
androgen receptor antagonist OH-flut, which did not cause a decrease or increase in 
latency (data not shown). Since rat neu expression does not correlate to the tumor 
outcomes, the decreased latency by p,p´ DDE would be caused by the treatment effects 
on mammary tissue. Collectively, these data suggest that the MMTV-neu mouse model is 
an acceptable model to use in the current investigations of p,p´ DDE actions in mammary 



























Lipid-adjusted DDT congener levels were measured in both serum and mammary adipose 
tissue of young (Pretumor study) and old (Tumor study) MMTV-neu female mice to 
determine how the concentrations delivered by ELVAX compare to human DDE 
concentrations and the tumor outcomes in the mice. Although these ethylene vinyl-
acetate copolymer pellets have previously been used to study hormone effects in the 
mammary gland (Haslam et al., 1988; Andrapp et al., 1998; Wang et al., 1990), it was 
important to demonstrate in our hands, that this implant material released DDE.  
However, the main purpose for these assays is to correlate levels with human exposure 
and with the tumor outcomes in the mice.  Pretumor study animals were examined which 
were treated simultaneously with the Tumor study mice.   
 
In women, p,p´ DDE is the most commonly measured congener of DDT due to its ability 
to persist and bioaccumulate (Jaga and Dharmani 2003).  Therefore, in the young mice 
treated for 2 months, levels measured in mammary glands would reflect DDE released 
over the treatment periods that would persist in the mammary fat due to its stability, slow 
metabolism, and its lipophilic properties, that all aid in  increased exposure and  
bioaccumulation with time until pellet depletion.  In the aged mice, at least 4 months after 
pellet depletion, no additional exposure would occur to add to the existing levels. Thus, 
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the levels would be expected to slowly decline in line with the half-lives of  , ΄ DDE and 
o, ΄ DDE. Therefore, both young animals from the Pretumor study after 60 days of pellet 
release and aged mice from the Tumor study over 9-months-old and > 4 months after 
pellet depletion, based on the reported 100 days for ELVAX (Silberstein and Daniel 
1982) were analyzed.   
 
Although directly delivered into the mammary fatpads, some redistribution of  , ΄ DDE 
and  ,   DDE was expected. Therefore, serum levels were measured to assess circulating 
levels. The lipid-adjusted serum levels were also compared to adipose tissue levels to 
determine local and systemic exposures.  Using lipid-adjusted  , ΄ DDE levels reduces 
the variation between adipose and serum levels in order that serum or plasma can be 
analyzed in women instead of invasive procedures to obtain breast adipose tissue.  Thus, 
to be able to compare levels in serum and adipose tissue to current epidemiology studies, 
the DDE measurements were performed as for human tissues.  These analyses of DDE 
levels in mammary adipose tissue and serum address part of Aim 1 on translational 





DDE Isomer Analysis in Serum and Mammary Adipose Tissue 
Epidemiological studies measure DDT congener concentrations in both serum and 
adipose tissue. In order to be consistent with current practices, DDE isomer 
concentrations were determined by gas chromatography-mass spectroscopy by the Centre 
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de Toxicologie, Quebec Canada, which used total serum lipids and percent lipids in the 
mammary fatpads to calculate the lipid-adjusted levels (ng/g lipid). Lipid-adjusted levels 
are what change the limits of detection among pools. Mammary gland tissue and serum 
from <3-month-old (Pretumor study) and >9-month-old (Tumor study) MMTV-neu 
females were used from previous studies conducted by Davis and colleagues.  Due to a 
minimum requirement of 1 g of mammary tissue and 2 mL of serum, samples had to be 
pooled to meet specifications. For the Tumor study, 15 animals (5 animals per pool) were 
used for both lipid-adjusted serum and mammary adipose tissue analysis. Identical 
analysis was also performed in the Pretumor study animals. However, due to the limited 
number of mice in the study and the smaller weight of mammary tissue and serum 
available per mouse, only 1 group per treatment could be analyzed, consisting of 12 





To prepare tissues for assessing DDE levels, roughly 1/3 of one inguinal mammary gland 
from 15 animals/group in the Tumor study and 12 animals/group in the Pretumor study 
were weighed and pooled for analysis by the Centre De Toxicologie, Quebec Canada. 
Due to a minimum requirement of 1 g of mammary tissue and 2 mL of serum, samples 
had to be pooled in order to meet the desired specifications. For the older mice (> 9 
months) in the tumor study, three pools were prepared for analysis, consisting of 5 
mice/pool (Table 3). The same animals in each pool were used to analyze DDE levels for 
both the serum and mammary tissue. Due to the limited number of mice in the Pretumor 
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study and the smaller weight of the mammary tissue and serum available per mouse, only 
one group of serum and mammary tissue was sent to examine concentrations in these 
younger mice (<3 months old, Table 4).  
 
Table 3. Tumor Study Pools for DDE Serum and Mammary Gland Concentrations 
Tumor Treatment Group Number of Animals Per 
Group 
Pools 
Control 5 3 (5 animals each) 
p,p´ DDE 5 3 (5 animals each) 
o,p´ DDE 5 3 (5 animals each) 
p,p´ DDE : o,p´ DDE  (2:1) 5 3 (5 animals each) 
 
 
Table 4. Pretumor Study Pools for DDE Serum and Mammary Gland 
Concentrations 
Pretumor Treatment Group Number of Animals Per 
Group 
Pools 
Control 12 1 
p,p´ DDE 12 1 
o,p´ DDE 12 1 
p,p´ DDE : o,p´ DDE  (2:1) 12 1 
      
Lipid-          , ΄ DDE       , ΄ DDE                in both serum and mammary 
gland tissue from young MMTV-neu mice treated for 2 months demonstrated detectable 
DDE levels, suggesting the predicted release of the treatments from the ELVAX 40P 
pellets into the local environment of the mammary gland (Tables 5 & 6). The levels of 
other DDT congeners not included in the treatments, p,p´ DDT, o,p´ DDT, p,p´ DDD and 






Table 5.  Lipid-adjusted DDT congener concentrations in serum of young MMTV-




























Control <14 <1.6 <7.8 <7.8 <7.8 <7.8 
p,p´ DDE  230 <1.6 <7.9 <7.9 <7.9 <7.9 
o,p´ DDE  <15 8.8 <8.2 <8.2 <8.2 <8.2 
p,p´ DDE : o,p´ DDE  
(2:1) 
150 3.4 <9.5 <9.5 <9.5 <9.5 
 
Table 6. Lipid-adjusted DDT congener concentrations in mammary tissue of young 





























Control 12 <2.4 <6 <6 <6 <3.6 
p,p´ DDE 1800 <2.2 <5.5 <5.5 <5.5 <3.3 
o,p´ DDE  11 1200 <6.2 <6.2 <6.2 <3.7 
p,p´ DDE:  o,p´ 
DDE  (2:1) 
1600 590 <5.5 <5.5 <5.5 <3.3 
 
Serum DDE isomer concentrations in young animals show o,p´ DDE and p,p´ DDE 
concentration differences of 8.8 µg/kg and 230 µg/kg, respectively, even though the same 
dose was delivered to the glands (5 g/pellet). Both isomers were also detected in the 
              ,  , ´ DDE: , ΄ DDE 2:1) (Table 5 & Fig. 12), albeit not in proportion to 
the original 2:1 ratio. Neither isomer was detected in the control group, as expected 
(Table 5). Similarly, the same trend of higher p,p´ DDE relative to o,p´ DDE was 
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observed in mammary tissue of the young mice (Table 6 & Fig. 13). However, given the 
fact that only one pool was analyzed due to tissue limitations, no statistical analysis could 
be performed to compare these concentrations.  Additionally, when lipid-adjusted p,p´ 
DDE levels were compared in serum versus mammary adipose tissue after 2 months of 
treatment, levels were consistently higher in the mammary tissue for all groups (Fig. 14). 
The higher levels were e               , ΄ DDE                                       and 
due to localized delivery to the mammary glands.  Detectable levels were also measured 
                                           , ΄ DDE         T     6     
 






































Figure 12. Lipid-adjusted p,p´ DDE  levels in serum are higher in comparison to 
o,p´ DDE  in young mice. p,p´ DDE was detected in its corresponding group and 2:1 
ratio groups at levels of 230 and 150 μg/kg, respectively. Whereas, o,p´ DDE was 
detected in its corresponding group as well as the 2:1 ratio at levels of only 8.8 and 3.4 
μg/kg, respectively. n=1 (pool consisted of 12 animals). 
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Figure 13. Lipid-adjusted levels of p,p´ DDE  in mammary tissue were detected in 
all groups and at higher levels than o,p´ DDE  in young animals. At approximately 3 
months of age p,p´ DDE  had noticeably higher concentrations than o,p´ DDE. Its 
ubiquitous nature was also demonstrated by there being detectable levels in the control 
and o,p´ DDE  groups (groups with     , ΄ DDE                                 12     

























3 mo p,p' DDE serum






Figure 14. Lipid-adjusted levels of p,p´ DDE in the mammary gland of young 
animals was consistently higher than serum concentrations in all groups. At 3 
months of age, p,p´ DDE had detectable levels in all treatment groups in mammary gland 
tissue. Conversely in serum, p,p´ DDE was either below the limits of detection (control 
and o,p´ DDE groups) or at very low concentrations (p,p´ DDE and 2:1 ratio groups). 
2:1= 3 3 μ   , ΄ DDE + 1 7 μ   , ΄ DDE  
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Similar to the measurements taken in young females, lipid-adjusted levels of DDE, DDT, 
and DDD were also measured in serum and mammary gland tissue of aged MMTV-neu 
female mice, >9 months of age from the Tumor study (Tables 7 & 8). Due to the Tumor 
study having more animals per treatment group and larger mammary glands and serum 
volumes due to their age, multiple samples with sufficient tissue and serum were 
available for measurement. For DDT congener levels in both serum and mammary 
adipose tissue, three pools were made, consisting of five animals each (Table 3). The 
average age (in months) for all three pools for the control, p,p´ DDE , o,p´ DDE, and 2:1 
ratio group were 13.0, 11.6, 12.0, and 11.6, respectively (Table 9). 
 
Table 7. Lipid-adjusted DDT congener concentrations in serum of Aged MMTV-





 , ΄DDE 
Serum 
μ /   
o,p´DDE  
Serum 
μ /   
 , ΄DDT 
Serum   
μ /   
 , ΄DDT 
Serum  
μ /   
 , ΄DDD 
Serum  
μ /   
 , ΄DDD 
Serum   
μ /   
Control <18 <2 <9.8 <9.8 <9.8 <9.8 
Control <10 <1.1 <5.6 <5.6 <5.6 <5.6 
Control <8.1 1.2 <4.5 <4.5 <4.5 <4.5 
p,p´ DDE <18 <2 <9.9 <9.9 <9.9 <9.9 
p,p´ DDE <10 <1.1 <5.5 <5.5 <5.5 <5.5 
p,p´ DDE <12 <1.3 <6.6 <6.6 <6.6 <6.6 
o,p´ DDE <10 <1.1 <5.6 <5.6 <5.6 <5.6 
o,p´ DDE <8.7 1.2 <4.9 <4.9 <4.9 <4.9 
o,p´ DDE <10 <1.1 <5.7 <5.7 <5.7 <5.7 
p,p´ DDE: o,p´ DDE 
(2:1) 
<9.5 <1.1 <5.3 <5.3 <5.3 <5.3 
p,p´ DDE: o,p´ DDE 
(2:1) 
<12 1.4 <6.6 <6.6 <6.6 <6.6 
p,p´ DDE: o,p´ DDE 
(2:1) 





Table 8. Lipid-adjusted DDT congener concentrations in mammary glands of  Aged 







Gland   
μg/kg lipid 
o,p´ DDE  
Mammary 
















Gland    
μg/kg lipid 
Control 5.7 <2.5 <6.3 <6.3 <6.3 <3.8 
Control 5.6 <2.1 <5.3 <5.3 <5.3 <3.2 
Control 3.9 <2.3 <5.7 <5.7 <5.7 <3.4 
p,p´ DDE 6.7 <2.2 <5.6 <5.6 <5.6 <3.3 
p,p´ DDE 11 <2.1 <5.2 <5.2 <5.2 <3.1 
p,p´ DDE 19 <2.2 <5.6 <5.6 <5.6 <3.4 
o,p´ DDE 4.2 <2.3 <5.7 <5.7 <5.7 <3.4 
o,p´ DDE 3.4 <2.1 <5.3 <5.3 <5.3 <3.2 












20 <2.2 <5.4 <5.4 <5.4 <3.3 
 
 
Table 9.  Average age of Tumor study animals used for DDE levels 
Tumor Study 
Treatment Group 
Pool Number                
(5 animals/pool) 
Average Age    
(months) 
Age Range        
(months) 
Control 1 12.28 9.5-14 
Control 2 12.52 9.5-14.4 
Control 3 14.22 14-14.4 
p,p´ DDE 1 12.2 9.6-14.2 
p,p´ DDE 2 10.12 9.6-10.9 
p,p´ DDE 3 12.52 10.0-14.1 
o,p´ DDE 1 11.92 9.8-13.5 
o,p´ DDE 2 11.2 9.2-14.1 
o,p´ DDE 3 12.94 11.9-14.0 
2:1 1 11.44 9.1-14.2 
2:1 2 11.64 9.2-14.0 
2:1 3 11.82 10.113.3 
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While analyzing the serum concentration differences between p,p´ DDE and o,p´ DDE in 
the older animals, it was discovered that o,p´ DDE was detectable in one of the three 
pools for all groups treated with this isomer (1.1 -1.4 µg/kg), but not in the  p,p´ DDE 
group, with detection limits ranging between 1.1 and 2 µg/kg. Para, para´ DDE was only 
detectable in one pool which was in  the 2:1 group at 12 µg/kg; this concentration was at, 
near, or below the detection limits in the other pools of all four groups. Collectively, p,p´ 
DDE had detection limits ranging from < 8.1- 18 µg/kg, indicating higher levels of p,p´ 
DDE are required for detection compared to o,p´ DDE  (Table 7). The undetectable levels 
of p,p´ DDE in the serum of older animals in comparison to some pools with detectable 
o,p´ DDE may be due to these differences in detection limits. 
 
Opposite to what was observed in the serum of older animals, p,p´ DDE levels in 
mammary adipose tissue were detected in all groups, unlike  , ΄ DDE, which was 
undetectable in all pools of every treatment group (Figure 15). These results suggest the 
                           , ΄ DDE                                                   
levels as low as 3.4 g/kg lipids and were within the detectable range (Table 8). These 
data also show that  , ΄ DDE                              ,         , ΄ DDE. Also, 
levels of  p,p´ DDE in serum and mammary glands were compared in older MMTV-neu 
female mice from the Tumor study,  >9 months of age (Fig. 16). 
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Figure 15. p,p´ DDE was the only isomer detected in mammary gland tissue after 9 
months of age in MMTV-neu female mice. Concentrations of  , ΄ DDE were below the 
limits of detection in all three pools of all treatment groups. In contrast,  , ΄ DDE levels 
were present in the control, p,p´ DDE, o,p´ DDE and 2:1 ratio groups, having average 































Figure 16. Mammary adipose tissue concentrations of p,p´ DDE in aged MMTV-neu 
animals were detected in all groups. Collectively, p,p´ DDE had a dominant presence in 
mammary gland tissue at >9 months of age compared to serum, in which it was only 












Serum  , ΄ 
DDE      
μ /   
Pretumor  
Serum  , ΄ 
DDE       
μ /   
Pretumor  
Mammary  , ΄ 
DDE  μ /   
Pretumor  
Mammary  , ΄ 
DDE   μ /   
Control ND ND 12 ND 
 , ΄ DDE 230 ND 1800 ND 
 , ΄ DDE ND 8.8 11 1200 
 , ΄ DDE  + 
 , ΄ DDE   
(2:1) 
150 3.4 1600 590 
 
Treatment  
Group         
n=3 (15/pool) 
Tumor  
Serum  , ΄ 
DDE  μ /   
Tumor  
Serum  , ΄ 
DDE   μ /   
Tumor  
Mammary  , ΄ 
DDE  μ /   
Tumor  
Mammary  , ΄ 
DDE   μ /   
Control ND ND 5.06 ND 
 , ΄ DDE ND ND 12.23 ND 
 , ΄ DDE ND ND 3.9 ND 
 , ΄ DDE  + 
 , ΄ DDE   
(2:1) 





ELVAX 40P has been successfully used for decades to study the in vivo effects of drugs 
in rodent models, especially for studying the mammary gland. (Silberstein and Daniel 
1982; Ankrapp et al., 1998; Haslam et al., 1988; Wang et al., 1990).  Until the studies in 
the Tumor, Pretumor, and current studies, DDT congeners had not been tested in this 
controlled drug delivery system within the mammary gland. This implant 
material/method is ideal for the following reasons: 1) It does not induce an inflammatory 
response (Silberstein and Daniel 1982); 2) there is no toxicity and the prognosis for 
ELVAX use in vivo is excellent (Shastri 2001); 3) it is capable of a sustained 
(approximately 100 days), gradual release of a remarkable variety of molecules 
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(Silberstein and Daniel 1982); and 4) it greatly reduces systemic effects, which, therefore, 
allows the study of direct, primary, local effects of drug treatments in the mammary 
gland.  
 
The functionality of ELVAX 40P pellets to deliver the treatments was evidenced by 
measurable DDE isomer levels in mammary adipose tissue in young mice (Pretumor 
study). Para, para DDE is the most prevalent, lipophilic and persistent congener that 
exists in the environment and humans (Cocco et al., 2000; Snedeker 2001; Eskenazai et 
al., 2009). For these reasons, it is also able to bioaccumulate in human adipose tissue 
(Jaga and Dharmani 2003). The ubiquitous nature of DDT in the environment was also 
evident in the present study as p,p´ DDE was detected in mammary adipose tissue of the 
control and o,p´ DDE  groups in young and old animals, even though these animals were 
not treated with this isomer via the ELVAX pellets and the environment was controlled. 
Turusov and colleagues (2002) stated that no living organism may be considered DDT-
free. In addition, DDT and its congeners, such as p,p´ DDE, have been detected in utero 
in amniotic fluid (Foster et al., 2000) and in cord blood samples (Tan et al., 2009) 
demonstrating exposure can occur even before birth.  The presence of this isomer in 
control mice and in women as reported  in epidemiological studies in young women 
from, for example, the United States (Cohn et al., 2007) and from developing countries 
(Shakeel et al., 2010), reinforces that there are no true negative controls when studying 




 The persistence and lipophilic properties     , ΄ DDE allow it to bioaccumulate in the 
body. The more stable isomer,  , ΄ DDE, remains detectable  in the mammary adipose 
tissue, despite the cessation of exposure due to pellet depletion, which occurred at 
approximately 100 days (Silberstein and Daniel 1982). These results support the reported 
half-life of  , ΄ DDE  in rats of 80-120 days (Muhlebach et al., 1991). However, the 
levels in the  , ΄ DDE group (6.7-19 g/kg lipids) are only slightly higher than the levels 
in control (3.9-5.7 g/kg lipids) and  ,   DDE groups (3.4-4.2 g/kg lipids) and, thus,  
may be partially due to the treatment.  In contrast,  ,   DDE levels were below detection 
limits in mammary fatpads of aged mice.  In addition, its lower serum levels in young 
mice compared to mammary adipose tissue were considerably lower due to its rapid 
metabolism, unlike the more stable  , ΄ DDE isomer.   
 
The lipid-adjusted p,p´ DDE levels obtained in this study are also consistent with ranges 
found in human epidemiological studies. For example in adipose, reported concentrations 
    : 6 66   /   Lό   -Carrillo et al., 1996) 45.5-17,387 ng/g  Lό   -Carrillo et al., 
1999), 3.5-3229 ng/g (Smeds et al., 2001), 396- 60,980 ng/g (Jaga and Dharmani 2003)  
and 0.593 - 0.642 mg/kg (Ociepa-Zawal et al., 2010). Furthermore, reported 
concentrations found in human serum/plasma were: 0.1-88 5   /   Lό   -Carrillo et al., 
1999), 0.768 (cases) and 0.817 µg/              L           , 2  1 , ≤   44 µg/g (Gatto et 
al., 2007) and 0.06- 8.0 µg/g (Eskenazi et al., 2009).  T                            , ΄ DDE  
influences mammary cancer development in levels relevant to human exposure.  
However, most of the epidemiology studies did not find a positive correlation between 
high p,p´ DDE levels and increased breast cancer risk; however, the incidence of 
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mammary cancer also was not modified in the mice.  Tumor onset was accelerated in 
mice, but this endpoint was not studied in women, which may be the reason for the lack 
of correlation between DDE levels and breast cancer risk.  
 
Breast cancer epidemiology studies used older women (at time of breast cancer 
diagnosis) to investigate the relationship between DDT levels and breast cancer risk. 
Brody and colleagues (2004) have also stated that individual differences in metabolism 
and excretion result in measures that may not represent original exposure levels, 
particularly when the assessment is many years after the exposure; such is the case in 
postmenopausal women. The levels in the present study reveal very low to non-detectable 
levels of these congeners in aged mice which did not correlate with the earlier tumor 
                    O                                        , ΄ DDE                      
shorter latency, similar to what was reported for the young women with early-onset breast 
cancer (prior to age 50) with p,p´ DDT(Cohn et al., 2007).  These findings suggest that 
age of onset versus incidence may need to be investigated in epidemiology studies 
examining DDT exposure and breast cancer risk.  
 
The 230 µg /kg lipids of p,p´ DDE in serum after a 2 month exposure was detected only 
approximately a week prior to the detection of the first palpable tumor (age 90 days). The 
timing of these events implies that  lower levels of p,p´ DDE than were detected after 2  
months of exposure may be able to promote tumorigenesis, since it takes weeks for 
tumors to develop and grow to a detectable size      , ΄ DDE                         
time (lower doses at younger ages). The lipid-adjusted level of p,p´ DDE in serum after 2 
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months of exposure is within or below the first tertile/quartile/quintile of several 
epidemiology studies                                        , ΄ DDE                    
cancer risk (Dorgan et al., 1999; Laden et al., 2001; Gatto et al., 2007; Cohn et al., 2007). 
                                 , ΄ DDE                                           nd 
breast cancer incidence) includes a level that was able to influence mammary tumor 
                       ,                                     , ΄ DDE                 
used as the reference category in future epidemiology studies.  
 
As expected and shown in younger animals, DDE concentrations in mammary adipose 
tissue were expectedly higher than serum concentrations because of the lipophilic nature 
of the compound and localized delivery to the mammary gland. Overall, the lipid-
adjusted DDE levels in serum and mammary gland suggest: 1) the ELVAX 40P pellets 
were functional, which allowed the mammary gland to be primarily exposed to DDE; 2) 
the persistence of  , ΄ DDE , as is demonstrated by measurable levels of this congener in 
the aged mice after pellet depletion, which is reported to be approximately 100 days 
(Silberstein and Daniel 2000),         , ΄ DDE; 3) the lipophilic nature of  DDE as 
supported by the higher concentrations in mammary adipose tissue and 4) the 
redistribution of the locally delivered DDE isomers by the presence of their levels in 
serum of young mice; 5) the metabolism and/or excretion of DDE as represented by their 
decreased levels in the aged versus young mice; 6                 , ΄ DDE             
with the early onset of mammary cancer are relevant to human exposure; and 7) systemic 
                                                                      , ΄ DDE      ,   
DDE were detected in the serum of young animals.  
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T                                                       , ΄ DDE       , ΄ DDE        
are present in the mammary glands and serum in mice treated for 2 months.  The MMTV-
neu                                                        , ΄ DDE,  , ΄ DDE,      , ΄ 
DDT                                                , ΄ DDE                     
subsequent studies for Aims 2-4 in the next chapters.  Accordingly, the mice treated for 
the same length of time (2 months) would be expected to have proportional exposure 
levels relating to their dose.  As serum levels and mammary adipose tissue of  , ΄ DDE 
were detected in the mice, local (Aims 2 and 3) and systemic effects (Aim 4) will be 


















                                                                                    




The next goal was to identify the effect of  , ΄ DDE exposure on mammary tissue gene 
expression through the use of microarray analysis. Microarray analysis provides an 
effective and efficient means to screen differential expression between control and treated 
groups. Each chip contained over 20,000 well characterized mouse genes that allow for 
fast and easy selection of genes with modified expression by p,p´ DDE.  The 
predetermined selection criteria used to identify the chosen genes were based upon 
whether the genes were androgen- or immune-regulated or cancer related. All genes were 
then verified by real-time RT-PCR. The significant,                                    
                                                                                        ,   
DDE action and possibly tumor outcomes.  The identification of such markers may help 
in the development of additional tumor studies that can ultimately provide a direct 
correlation to tumor outcomes. The experiments outlined in this chapter apply to Aim 2 




The first microarray was conducted to identify differential expression of genes in control, 
hydroxyflutamide (OH-flut), o,p´ DDE  and p,p´ DDE  lower mammary tissue of 
Pretumor study animals. Microarray analysis was performed by the Functional Genomics 
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C       C        C       ’  R        I        , C       , O     S         dual 
mammary gland RNA samples (RNA obtained by using the Absolutely RNA miniprep 
kit as outlined in the total RNA isolation method, p. 26) from each group were sent.  
Once received by the Functional Genomics Core, the individual RNA samples were 
pooled (3 animals per pool), to account for variability among samples. RNA quality and 
integrity were also checked before hybridization by the Functional Genomics Core. Each 
pool was run on an Affymetrix GeneChip® Mouse Genome 430 2.0 Array (Affymetrix 
Inc., Santa C    , C    T                       45,                                   3’ 
end of the gene and which represent roughly 21,000 well characterized mouse genes (Fig. 
17). It contains 8-15 probes made out of 25-mer oligonucleotides. Briefly, the RNA 
samples are converted to cDNA, which then have fluorescent nucleotides incorporated in 
it. After, the synthesized cDNA is  bound to its complement/specific probes (hybridized) 
on the genechip. The genechip is then scanned and the amount of bound target is 
measured by its fluorescent intensity. Properly designed probes and stringent 
hybridization allow for only message of a specific gene to bind, therefore the relative 
fluorescence of the probe can infer gene expression.  
 
The second microarray was performed by Vanderbilt Functional Genomics Shared 
Resources, Nashville, TN using the Affymetrix Genechip® Mouse Gene 1.0 ST 
(Affymetrix Inc., Santa Clara, CA), similar to the first array, in order to identify genes 
that were differentially expressed by p,p´ DDE . However, due to limited tissue being 
available from the pretumor study, three animals per group from the control and p,p´ 
DDE  groups were used from the present study. Unlike the genechip used in the first 
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array, this chip covers the entire length of the gene, providing whole-transcript coverage 
and a more accurate account of gene expression. Additionally, this chip has nearly 29,000 
genes, each of which are divided into roughly 27 probes made out of 25-mer 
oligonucleotides (Fig. 17). 
Gene
Gene
Affymetrix GeneChip® Mouse Genome 430 2.0




Figure 17. Schematic Representation of Genechips used for Microarrays. On the 
             43  2       ,                          3’               ,                




Chapter 2 includes the methods on total RNA isolation, cDNA reverse transcriptase 
reactions, real time RT-PCR, relative gene expression and statistical analysis that apply to 









Differential Expression of Mammary Gland Genes 
RNA was isolated from random portions of the mammary gland from six animals from 
the Pretumor study in the control and p,p´ DDE groups. The six samples were assigned to 
1 of the 2 pools consisting of three animals each (Table 11). 
 
Table 11. First Microarray Pool Designations 
Treatment Group Number of Animals Pool Designation 
 
Control 
3 Pool #1 
3 Pool #2 
 
p,p´ DDE 
3 Pool #1 
3 Pool #2 
 
 Pretumor study animals were tested in ordered to elucidate the early changes that result 
from exposure to p,p´ DDE prior to tumor formation that may have a role in the early 
tumor onset. The RNA from each animal was sent to the Functional Genomics Core at 
C        C       ’  R        I        , C       , OH ,       they confirmed the 
quality of the RNA before pooling the samples with equal amounts of RNA.  The 
microarray analysis used the Affymetrix GeneChip® Mouse Genome 430 2.0 Array 
(Affymetrix Inc., Santa Clara, CA). Initially, five genes shown to be differentially 
expressed by p,p´ DDE compared to control pools were chosen for further investigation 
based upon their correlation to cancer or androgen-regulation as shown in Table 12.  
These two characteristics were chosen due to the documented hormonal action of p,p´ 
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DDE (Kelce et al., 1995) and its ability to accelerate tumor formation, as shown by Davis 
and colleagues in the previous data. 
 
 
Table 12. First five candidate genes selected from the microarray 









hdac3 Responsible for 
transcriptional events, 
leading to events such as 
proliferation & cell survival 
Wilson et al., 
2005 
Cancer Up 1.55 
       
Serum 
Amyloid A 
saa1 Acute responses to various 
tissue insults including 
inflammation and cancer; 
Overexpression of SAA 
genes accelerates apoptosis 
of mammary epithelial cells; 
elevated 100-1000-fold as 
part of the response to 
neoplasia, trauma, infection, 
inflammation 
Kho et al., 
2008; Urieli-
Shoval et al., 
1998 
Cancer Up 4.28 
       
Tropomyosin
-2 
tpm2 Contributes to cell 
morphology and integrity of 
the actin cytoskeleton. Cell 
growth and adhesion 
properties 
Varga et al., 
2005; Li et 
al., 2006 
Cancer Down 0.60 
       
Interleukin 
18 
il18 Activates immune 
response/pro-inflammatory. 
Well known anti-tumor 
activity; also has been shown 
to have pro-cancer activity. 
Park et al., 
2009 








slco3a1 Androgen regulated. 










In order to confirm the expression patterns of the microarray, the same animals 
designated for the microarray pools were then tested individually, in addition to four 
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more animals per group using real-time RT-PCR with SYBR-Green detection. The 
results revealed that of the ten individual animals tested, none of the p,p´ DDE-treated 













             












































                                          













Figure 18. Cancer-related and androgen-regulated genes tested in the individual 
animals of the microarray pools did not show a significant difference in expression. 
Using specific primers for hdac3, slco3a1, il18, tpm2 and saa1, expression levels were 
measured by real-time RT-PCR. Expression of the 5 µg p,p´ DDE treatment group was 
not significantly di                                     ΔC                              
expressed at a higher level. Numbers displayed within each bar represent the fold change 
compared to control using the 2
-ΔΔC 
   method. The genes were not significant by the 






Table 13. Additional Candidate Genes Not Pursued from the Microarray 
Gene Name Abbreviation Function Reference Criteria 
Category 
Bcl2-like 11 Bl2l11 Involved in apoptotic 
cell death 
Hoshino et al., 
2011 
Cancer 




Id1 Involved in tumor 
growth, invasiveness, 
metastasis and 
angiogenesis; shown to 
be up-regulated in  a 
wide range of cancers 
and its expression 
correlates to disease 
stage and poor 
prognosis. 
Mern et al., 2010; 
Yap et al., 2010 
Cancer 
     
Thioredoxin 2 Tnx2 An antioxidant defense 
enzyme. ROS are 
mitogenic and capable 
of tumor promotion 




Other candidate genes initially chosen were txn2, bcl2l11 and id1 (Table 13).  However, 
bcl2l11, txn2 and id1 had opposing expression between the microarray and the individual 
animals (similar to hdac3) (data not shown).   In total, 8 genes were initially selected, but 
found unsuitable for further testing due to lack of statistical significance or not matching 
the microarray (different effect on expression). 
 
Immune-related Markers and Lymph Node Involvement in Mammary Gene 
Expression 
To attempt to identify additional candidate genes that were differentially expressed by 
p,p´ DDE, it was discovered that many immune-related genes in the microarray were 
modulated by the well-known anti-androgen OH-flut. Correspondingly, only one of the 
tested pools from the p,p´ DDE group had similar regulation as both OH-flut pools, while 
one pool did not. Upon further investigation, one pool of RNA was found to have strong 
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modulation of immune-related genes. DDT has been shown to affect macrophages and 
contribute to inflammatory reactions, cytokine imbalance, and immune dysregulation 
(Dutta et al., 2008). Moreover, Vine and colleagues (2000) concluded that relatively low 
levels of plasma DDE are associated with statistically significant changes in immune 
markers, which supported further investigation of the immune markers on the microarray.  
Therefore, the immune-regulated genes that had similar regulation in the p,p´ DDE and 
OH-flut pools were examined for differential regulation in the individual animals.  
 
Twenty immune gene markers and one non-immune related gene marker were selected 
from the OH-flut microarray according to their fold increase or decrease in expression 
values compared to control animals and that were correspondingly modified in the one 
 , ΄ DDE         Using specific primers for real-time RT-PCR with SYBR-Green 
detection, the initial genes tested were: glycosylation dependent cell adhesion molecule 
1(glycam), chemokine (C-C motif) ligand 19 (ccl19), chemokine (C-C motif) ligand 21B 
(ccl21b), selectin (sell), POU domain, class 2, associating factor 1 (pou2af1), interleukin 
7 receptor (il7r), chemokine (C-C motif) ligand 5 (ccl5), chemokine (C-C motif) ligand 7 
(ccr7), CD52 antigen (cd52), interleukin 2 receptor, gamma chain (il2rg), IL2-inducible 
T-cell kinase (itk), lymphocyte protein tyrosine kinase (lck), schlafen 2 (slfn), tumor 
necrosis factor receptor superfamily, member 11 (rankl), brain expressed gene 1 (bex1), 
T-cell receptor alpha chain (tcra),tumor necrosis factor receptor superfamily, member 
13c ( tnfrsf13c), CD8 antigen, alpha chain (cd8a), CD8 antigen, delta polypeptide ( 
cd3d), membrane-spanning 4 domains, subfamily A, member 1 (ms4a1) and  aldo-keto 
reductase family 1, member c18 (ark1c18).  Akr1c18 is not an immune-related gene, but 
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codes for a protein involved in steroid metabolism which could therefore potentially 
influence androgen-regulated genes but would have minimal effects on immune function. 
Pools of  genes from control, p,p´ DDE and OH-flut treated animals were analyzed, using 
the three individual animals used for the microarray pool that had the differential 
expression for p,p´ DDE, as well as in three additional animals not tested in the 
microarray analysis, for a total n=6. Expression of the first set of genes by p,p´ DDE and 
OH-flut  was not significantly different from control (Fig. 19).  The remaining 14 other 

























































































































































































Figure 19.  Immune-related genes were not significantly modified by p,p´ DDE or 
OH-flut treatment. (A) Immune genes glycam1, ccl19, ccl21b, sell, pou2af1, il7r did not 
induce significant changes in expression in individual pretumor microarray and non-
microarray animals. (B) p,p´ DDE  also did not induce significant effects different from 
control in akr1c18, a non-immune related gene, however, there was much less variability 
                                    ΔC                                                    
level. Numbers displayed within each bar represent the fold-change compared to control 
using the 2
-ΔΔC 
 method. Analysis by one-way ANOVA did not find significance 







I                                       ΔC                 the RNA from animals 
within each group made it difficult to obtain significance as demonstrated by scatter plots 
from the control and p,p´ DDE groups (Fig. 20). Also, it was observed that akr1c18, a 
non-immune-related gene did not display the large variation observed in the other 
immune-related genes. Due to this discovery, the pools of the microarray were recreated 
(using the same animals and RNA in equivalent amounts) and tested in the first set of 



















































































Figure 20.  Wide ΔCt variation among immune-related genes in control and p,p´ 
DDE animals in pretumor MMTV-neu  females, unlike the non-immune gene 
akr1c18. Scatter plots displayed the large variation that occurred between the three 
animals of the microarray and the three non-microarray animals in both control and p,p´ 
DDE groups. However, the distinct separation in expression values were not observed 
with akr1c18, a non-immune regulated gene. A Mann-Whitney test was used for 





































Figure 21.  Microarray p,p´ DDE pools #1 and #2 were markedly different in 
immune-regulated genes. A distinct separation pattern was discovered between the 
microarray               , ´ DDE         G         , ´ DDE      #1     ΔC         
ranging from 11.6-15.5 whereas genes in pool #2 had values ranging from 3.2-9.8. The 
non-immune-regulated gene akr1c18 did not display as large a variation and its 
expression values were opposite of the immune-related genes, with pools #1 and #2 
                 1  4     14,                       ΔC                              
expressed at a higher level. Numbers displayed within each bar represent the fold-change 
compared to control using the 2-ΔΔC         T  -way ANOVA was used for 
statistical analysis (p>0.05). n=6.   
 
A significant difference between p,p´ DDE microarray pool 1 and pool 2 was detected 
among the immune-related genes  (Table 14). In contrast, the expression of akr1c18 did 
not fit the pattern of the immune genes, as pool 2 had lower expression than pool #1.  
These data confirmed the results observed in the microarray and indicate the difference in 
expression was not due to errors in pooling the samples or labeling groups as control or 
treated.  
 
As a result of the inconsistency between the p,p´ DDE pools within the immune markers, 
the possible role of the lymph node in the mammary gland became an area of interest 
since it would contain an abundance of leukocytes that express these cytokines. 
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Therefore, if the presence of the lymph node in the mammary gland has the ability to 
alter expression of immune-related genes and not all samples used to prepare the RNA 
would contain the lymph node, it would be more difficult to select p,p´ DDE-regulated 
genes that are immune-related. The presence of the lymph node may also affect other 
unknown gene populations as well, also possibly contributing to gene selection error 
and/or skewed expression. 
 
Table 14.  Immune-related Gene Expression Differences Between Microarray Pools   




0.0019 0.0084 0.0016 0.0031 0.0066 0.0186 0.6598 








The Influence of Lymph Node Presence on Mammary Gene Expression 
To test whether or not the lymph node influenced gene expression within the mammary 
gland, a marker was sought to definitively discriminate between lymph node-positive 
(LN-positive) from lymph node-negative (LN-negative) mammary tissue. To accomplish 
this, specific mammary gland sections from two wild-type (FVB/N) mice with and 
without lymph node (as identified by visual inspection), one kidney (to serve as a 
negative control) and an individual lymph node (LN alone, to serve as a positive control) 
dissected from a mammary gland, were used to screen lymph node markers. RNA was 
isolated and then converted to cDNA by reverse transcriptase. Specific primers for 
lymphatic vessel endothelial receptor-1 (lyve-1), fms-related tyrosine kinase 4 (flt4), 
podoplanin (pdpn), prospero homeobox 1(prox-1) and neuropilin-2 (nrp2) were examined 
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using real-time RT-PCR. Genes cd3d  and ms4a1(cd20) were also employed as they are 
markers of T- and B-cells, respectively, since these leukocytes are densely populated 
within the lymph node.  Gene names and functions are listed in Table 15. Finding an 
acceptable lymph node marker was important to distinguish between the presence (LN-
positive) or absence (LN-negative) of lymph node in mammary gland tissue. Having a 
suitable lymph node marker will help to determine if the presence of the lymph node is 
responsible for the large variations in gene expression with the immune-related genes 
between the treatment groups.  
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Table 15. Potential Lymph Node Markers 







cd20 Expressed on the surface 
of premature and mature 
B-lymphocytes 
Deirickx et al., 
2011 
LN marker 
     





flt4 Found in lymphatic 
vessels 
Huang et al., 2001  





lyve-1 Lymphatic vessel 
marker 
Vigl et al., 2011; 
Ji et al., 2010 
LN marker 
     
Neuropilin-1 nrp2 A transmembrane 
receptor for the 
lymphangiogenic 
vascular endothelial 
growth factor C ( Vegf-
C), plays an important 
role in lymphatic vessel 
sprouting and lymph 
node metastasis of 
human cancers 
Xu et al., 2010; 
Yasuoka et al., 
2009 
LN marker 
     
Podoplanin pdpn Lymphatic marker; 
expressed in lymphatic 
endothelium 
Ji et al., 2010; 
Cimpean et al., 
2007; Vandenput 




prox-1 Lymphatic vessel 
marker 




As shown in the table above, seven immune-related markers were selected and screened 
in mammary tissue with (LN-positive) or without (LN-negative) lymph node, as well as 
in kidney (no lymph node). As shown in Figures 22 and 23, cd20 was identified as a 
possible immune marker as it demonstrated a higher expression in lymph node-positive 
tissue and a lower expression in lymph-node negative tissue. The other tested genes did 
not have this same pattern or had more variation among the node-negative samples and 
were not significant.  Therefore, due to the large difference in Ct values between node-
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positive and node-negative mammary tissue, the  presence of the lymph node was easier 








































































Figure  22.  Lymph node markers in lymph node-positive and lymph node-negative 
mammary gland tissue showed varying expression. Lymph node endothelial cell 
markers flt4, prox1, pdpn, nrp2, and lyve-1, as well as T- and B-cell markers cd3d and 
cd20 did not yield consistent expression. The majority of the markers did have lower 
ΔC                                 ,                                                 





















Figure 23. Lymph node marker expression varied between lymph node only and 
kidney tissue. Flt4, lyve-1, cd3d, and cd20 were more highly expressed in a lymph node 
isolated from mammary gland (lymph node only) than the negative control kidney tissue. 
Oppositely, prox1 and pdpn had lower expression in lymph node only tissue, whereas 
nrp2 appeared to have equal expression in both positive and negative control tissues. A 
      ΔC                                                           S                   
performed since single samples were examined.  
   
The presence or absence of the lymph node within the tissue may affect our gene 
expression of immune-related genes, therefore, only lymph node-negative mammary 
tissue needed to be used in all future RNA analyses. As such, designated pieces of the 
mammary gland were prepared for RNA isolation to identify samples with and without 



































                                        
Figure 24. Schematic of Mammary Gland with Designated Sections.  In order to 
avoid mammary gland tissue samples that contained the lymph node and to ensure 
consistency between samples, the mammary glands were sectioned A, B, C and D. 
Unless otherwise noted, section B was determined to be the lymph node positive region. 
 
 
To ensure mammary gland sections without lymph node had different expression of the 
three potential lymph node markers compared to section B that contained the lymph 
node, inguinal mammary glands from five wild-type (FVB/N) mice were harvested and 
visual confirmation of the lymph node was performed. Section B was designated as being 
the lymph node positive region prior to the gland being sectioned (A, B, C, and D).  Real-
time RT-PCR for the selected marker, cd20, as well as 2 other lymph node markers was 
performed to confirm the findings in Figure 22 with more samples from the designated 
mammary gland sections.   Expression of flt4 and lyve-1 in sections C and D (lymph 
node-negative) were similar, but were not significantly different from lymph node-
positive section B. In contrast, cd20 did show a significant (p<0.0001, one-way ANOVA) 
difference in expression between lymph node-positive (section B) and lymph node-









used to determine which RNA preparations were node-negative for subsequent RNA 
analyses.  




































Figure 25.  Lymph node screening revealed only cd20 expression differed between 
lymph node-positive or lymph node-negative mammary gland sections.  Real-time 
RT-PCR demonstrated expression of flt4 and lyve-1 in sections C and D were similar, but 
were not significantly different from lymph node-positive section B. In contrast, cd20 did 
show a significant (p<0.0001) difference in expression between lymph node-positive 
(section B) and lymph node-negative (sections C and D) mammary gland sections. A 
       ΔC                                                                           
amplification cycles before it can be detected. Numbers displayed within each bar 
represent the fold-change compared to control using the 2
-ΔΔC 
 method. One-way 
ANOVA was used for statistical analysis (p<0.05). n=5.   
 
All animals in the Pretumor study, including those used for the microarray analysis, had 
their mammary gland RNA screened for cd20 in order to identify which samples were 
lymph node positive and negative.  Table 16 shows the random distribution of the lymph 
node in control and p,p´ DDE animals (Pretumor study) used for the microarray, which 
probably confounded the interpretation of the data from the microarray analysis, 
especially for cytokines and other immune-related genes. When the initial six immune-
related genes had their expression measured again by real-time PCR in confirmed lymph 
node-negative mammary tissue,  , ΄ DDE treatment was not significantly different from 
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control (Fig. 26).  Therefore, no genes were identified to be differentially regulated from 
this microarray analysis.   
 
 
Table 16. Lymph Node Determination by Cd20 Screen in Microarray Pools 






A Control 14.3  X 1 
B Control 3.7 X  1 
C Control 15.2  X 1 
D Control 14.1  X 2 
E Control 4.9 X  2 
F Control 13.75  X 2 
      
A p,p´ DDE 3.05 X  1 
B p,p´ DDE 13.55  X 1 
C p,p´ DDE 13.55  X 1 
D p,p´ DDE 14  X 2 
E p,p´ DDE 4.3 X  2 








































































Figure 26.  The microarray genes examined in the p,p΄ DDE  group were not 
significantly different from control in confirmed lymph node-negative mammary 
tissue. When expression of  immune-related genes glycam1, ccl19, pou2af1,il7r, ccl21b 
and sell was re-examined by real-time RT-PCR with SYBR Green detection in lymph 
node-negative mammary gland tissue,  , ΄ DDE effects were similar to  control.  A 
       ΔC                               xpressed at a lower level and requires more 
amplification cycles before it can be detected. Numbers displayed within each bar 
represent the fold-change compared to control using the 2
-ΔΔC 
 method. A Mann-Whitney 
test was used for statistical analysis (p>0.05). n=3. 
 
 
 Preparation of Samples for Performing a New Microarray Analysis 
 
Since no candidate genes were identified, it became evident that a second microarray 
analysis needed to be prepared. Thus, for the new microarray, only lymph node-negative 
mammary tissues were used to avoid the problems with the first microarray analysis, 
including 1) the unexpectedly low number of differentially expressed genes by p,p´ DDE, 
2) immune genes not being identified because of the presence of the lymph node in some 
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samples, and  3) the inability to identify any genes differentially expressed between the 
p,p´ DDE and control groups. 
 
As a result of the tissue weight requirements needed to measure DDT congener levels and 
the RNA preparations and analyses already performed, there were insufficient amounts of 
mammary gland tissue and RNA remaining to replicate and analyze the new microarray 
analysis with the Pretumor study tissues. Therefore, in order to conduct another 
microarray analysis and to further characterize any identified genes, additional animals 
implanted with vehicle control or  , ΄ DDE (5 mg) ELVAX pellets were needed. 
Additional treatment groups for testing expression of the identified genes for Aim 3 are 
described in the next chapter.    
 
Ten prepubertal MMTV-neu females per group were bilaterally implanted with ELVAX 
40P pellets in the axillary and inguinal mammary fat pads (4 pellets/mouse) and 
euthanized after two months of treatment.  RNA was isolated from the inguinal mammary 
glands and screened for low cd20 levels to ensure the absence of  the lymph node.  
Candidate genes that were differentially regulated by p,p´ DDE were identified by 
microarray analysis by the Functional Shared Genomics Core, Vanderbilt University, 
Nashville, TN using the Affymetrix Genechip 1.0 ST. The second microarray used only 
tissues from individual animals from the DDT-01 study instead of pools from three mice. 
Three animals were tested per group to allow the genomics core to perform statistical 
analyses for differential expression. Only the control and p,p´ DDE groups were 
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examined since the goal was to identify genes that were differentially expressed by p,p´ 
DDE treatment.  
 
Candidate Gene Selection 
Candidate genes with significant differential expression by p,p´ DDE were further 
selected based on the selection criteria for genes with known associations with cancer or  
immune functions or androgen regulation as these actions have been previously related to 
DDT. Approximately 15 genes were initially selected from the microarray based upon 
these criteria and confirmed by real-time RT-PCR using SYBR-Green detection. 
Expression trends of the microarray matched that of the genes tested by real-time RT-
PCR in the individual animals used for the microarray, with the exception of rsp12. 
(Table 17).  These data indicate stronger correlations between the second microarray and 
the individual animals tested in the microarray than were observed with the first 
microarray.  The genes tested and their functions are listed in Table 18.  
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Table 17. Expression comparison between microarray analysis and real-time RT-

















aacs ↑ 2.1 ↑ 5.9
acly ↑ 2.6 ↑ 9.7
csn1s2a ↑ 6.5 ↑ 9.5
crym ↑ 2.1 ↑ 4.5
egr2 ↑ 2.4 ↑ 6.0
id4 ↓ -2.1 ↓ 0.8
ifi44 ↑ 2.5 ↑ 4.4
insig1 ↑ 2.1 ↑ 7.4
prune2 ↑ 2.0 ↑ 6.7
rsp12 ↑ 2.9 ↓ .08
sfrp5 ↓ -2.7 ↓ 0.4
slc2a5 ↑ 3.5 ↑ 55.0
sprr1a ↑ 3.9 ↑ 9.1
thbs1 ↓ -2.1 ↓ 0.8












Table 18. Candidate Genes Selected From the Second Microarray Analysis 
Gene Name Abbreviation Function Reference Criteria 
Category 
Acetoacetyl-CoA aacs Involved in 
lipogenesis 
Aguilo et al., 
2010 
Cancer 




Activated at a 
relatively early 
stage in various 
types of tumors; 
plays a role in 
tumorigenesis and 
tumor cell 
survival. Plays a 
role in the 
aggressive 
phenotype seen in 
African American 
women. 
Furuta et al., 
2010; Yancy 
et al., 2007 
Cancer 





Hilvo et al., 
2011 
Cancer 












Dillon et al., 
2007 
Cancer 
Inhibitor of  
differentiation/DNA 
binding 4 








Candia et al., 
2006; 
D   ’O    S 



























Hilvo et al., 
2011 
Cancer 








rsp12 Involved in the 
pathological 
process of BC and 
may be a useful 
biomarker 




related protein 5 
sfrp5 Inhibitor of the 
Wnt pathway. 
Often down-
regulated in BC; 
also methylated at 
high frequencies 
Suzuki et al., 
2008;Veeck 






















sprr1a Involved in 
epithelial 
differentiation. 







Haider et al., 
2006 
Cancer 









Bertin et al., 
1997; Mattila 
















thrsp Involved in lipid 
metabolism; 
highly expressed 
in clinical BC 
samples 





Of the fifteen genes identified in Table 18 with p,p´ DDE-induced differential expression, 
seven candidate genes (slc2a5, ifi44, csn1s2a, acly, thrsp, prune2 and crym) were chosen 
for analysis in the Pretumor study mammary tissues for the control,  , ΄ DDE groups as 
well as for OH-flutamide and the 2:l ratio groups. The goal of this analysis was to 
determine how the DDT-01 and Pretumor studies compare on genes identified from the 
second microarray analysis. As shown in Figure 27, no change in expression of any of the 
genes occurred in the treatment groups compared to control. The lack of significant 
regulation by p,p´ DDE  may be due to the differences between the original Pretumor 
study and the DDT-01 animals used for the two microarray analyses. These differences 
include animals and treatments were performed in different environments (Duquesne 
University and Cedars-Sinai Medical Center) and use of random regions of the mammary 



























































































































































































Figure  27.  Candidate genes from the second microarray were not differentially 
expressed in Pretumor study animals. Selected genes slc2a5, csn1s2a, acly, ifi44, 
thrsp, prune2 and crym had their gene expression tested by real-time RT-PCR with 
SYBR-Green detection. These genes in the p,p´ DDE , OH-flut, and the 2:1 ratio groups 
                                                        ΔC                              
expressed at a lower level and requires more amplification cycles before it can be 
detected. Numbers displayed within each bar represent the fold-change compared to 
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control using the 2
-ΔΔC 
 method. Mann-Whitney test was used for statistical analysis 
(p>0.05). n=6. OH-     =                 ; 2:1 = 3 3 µ /        ,   DDE + 1 7 µg/       
 ,   DDE  
 
 
Wide variability was evident among animals from the Pretumor and DDT-01 studies 
within the treatment groups, particularly between the control groups. Figure 28 displays 
the scatter plots of the seven candidate genes by real-time RT-PCR in both Pretumor and 
DDT-01studies (3 animals/group). Expression in the Pretumor study was predominately 
              ΔC             DDT-01 study, with the following ΔC           for the 
Pretumor study and DDT-01 studies, respectively, for the tested genes:  slc2a5 (5.91 and 
15.75), csn1s2a (6.38 and 9.45), acly (0.86 and 6.91), ifi44 (8.36 and 12.23), thrsp (-1.00 
and 2.21), prune2 (7.81 and 11.73), and crym  (6.98 and 8.56). Accordingly, none of the 
expression differences between the p,p´ DDE and control groups was statistically 



















































































Figure 28.  Variability between the control groups in the Pretumor and DDT-01 
studies may contribute to the lack of noticeable effect by p,p´ DDE .  Real-time RT-
PCR showed the control group of the Pretumor study had consistently higher expression 
levels among all candidate genes in comparison to the DDT-01 study controls. p,p´ DDE 
regulation among the genes was also not significantly different, with all genes exhibiting 
less variability than controls with the exception of crym           ΔC                      
gene is expressed at a lower level and requires more amplification cycles before it can be 
detected. Numbers displayed within each bar represent the fold-change compared to 
control using the 2-ΔΔC            M   -Whitney test was used for statistical analysis 





With the disparate expression results observed between the Pretumor and DDT-01 
studies, it was speculated that the amount of mammary tissue within the samples may be 
inconsistent between the two studies.  One reason for this could be that the region of 
mammary gland used in the Pretumor study for RNA preparation was not controlled.  
The Pretumor study used randomly selected pieces since the glands were broken and 
quick frozen together in one tube, during necropsy.  In contrast, the DDT-01 study used 
designated sections of the gland as shown in Figure 24. Perhaps, some sections of 
mammary gland had more fat and less mammary tissue in one study compared to a 
section that was lower in fat and higher in mammary tissue, such as the epithelium. To 
address if consistent amounts of mammary tissue were in the different samples, 
expression of an epithelial marker, cytokeratin 18 (krt18) and a differentiation marker, 
casein beta (csn2)  were compared in control and p,p´ DDE treatment groups in both 
Pretumor and DDT-01 studies by real-time RT-PCR.  Figure 29 shows no substantial 
differences in gene expression between control and p,p´ DDE groups in either study, 
indicating that the amounts of epithelial tissue between the studies was consistent. 
Therefore, the amount of mammary epithelium in the samples in the Pretumor and DDT-
01 studies may not be the cause of variation between the Ct values in the two studies.    
Consequently, the disparity in expression was likely due to other variables related to the 
study sites, such as 1) the facilities where the studies were conducted, 2) different staff 
prepared the ELVAX 40P pellets and performed the surgeries, and 3) different 
generations of breeders were used to produce the study mice.  Accordingly, for the 












































Figure  29.  Epithelial markers casein beta (csn2) and keratin 18 (krt18) show the 
mammary tissues are consistent between Pretumor and DDT-01 studies.  Mammary 
gland epithelium expression was measured by real-time RT-PCR with SYBR-Green 
detection in both Pretumor and DDT-01 studies. Results demonstrated no distinguishable 
difference in expression in either control or p,p´ DDE treatment groups. A Mann-
Whitney test was used for statistical analysis (p>0.05). n=6. 
 
The initial seven candidate genes (Fig. 28) were tested in animals from the control and 
 , ΄ DDE             the DDT-02 study in lymph node-negative mammary tissue from 
section C (Fig. 24); additional DDT-01 study animals from these groups were also tested.  
Expression of these genes was expected to be similar in the two studies since both were 
conducted at Duquesne University. The expression of the candidate genes in DDT-01 and 
DDT-02 studies were more comparable than observed with the Pretumor and DDT-01 
studies (Fig. 30 & 31).  Expression of slc2a1, csn1s2a, ifi44, prune2  and crym 
Control p,p´ DDE  
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expression in the control groups was not significantly different between DDT-01 and 
DDT-02 studies; a similar effect was observed for the  p,p´ DDE groups in both studies 
(Fig. 30 and 31).  Whereas acly and thrsp displayed significant differences between the 











































































































Figure  30.  Expression variability between DDT-01 and DDT-02 was reduced in 
comparison to DDT-01 and Pretumor studies. When the expression of the seven 
candidate genes was measured by real-time RT-PCR        DDT        ,     ΔC         
of DDT-01 and DDT-02 studies displayed less variation than those in comparison to the 
DDT- 1     P                          ΔC                                              
expressed at lower levels, therefore requiring more amplification cycles before it can be 
detected. A Mann-Whitney test was used for statistical analysis. p>0.05. Pretumor vs. 




















































































Figure 31.  Expression variability between DDT-01 and DDT-02 was reduced in 
comparison to DDT-01 and Pretumor studies. When the seven candidate genes had 
their expression measured by real-time RT-PCR        DDT        ,     ΔC            
DDT-01 and DDT-02 studies displayed less variation than those in comparison to the 
DDT- 1     P                          ΔC              icative of the transcript being 
expressed at lower levels, therefore requiring more amplification cycles before it can be 
detected. A Mann-Whitney test was used for statistical analysis. p>0.05. n=3 (Pretumor 
vs. DDT-01); DDT-01 vs. DDT-02 (n=6 and 3, respectively).  
 
 
Due to the observed decrease in variability in the Ct levels for the seven candidate genes 
observed between DDT-01 and DDT-02 study, samples from both studies were combined 
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                     , ΄ DDE                                              seven 
candidate genes were performed with the six animals from the DDT-01 study and three 
mice from the DDT-02 study (n=9). Only csn1s2a and ifi44 were significantly up-
regulated by p,p´ DDE treatment (p= 0.003 and  0.004, respectively, Mann Whitney test; 

























































































Figure 32.  p,p´ DDE significantly stimulated candidate genes csn1s2a and ifi44 in 
mammary tissue compared to control.  Identification of candidate genes by RT-PCR 
revealed csn1s2a (p=0.003) and ifi44 (p=0.004) were significantly up-regulated by p,p´ 
DDE when DDT-01 and DDT-02 studies were combined. Thrsp approached significance 
with a p value of 0.07, while all other genes also demonstrated a non-significant up-
                          G                                            ΔC                 
not requiring many amplification cycles prior to detection. The numbers within each bar 
represent the fold change compared to control using the 2- ΔΔC            M nn-






Next, to identify additional genes differentially regulated by p,p´ DDE, a second set of 
genes   were chosen from the microarray based on the predetermined criteria that were 
previously tested in the individual mice from DDT-01 study used in the second 
microarray (Table 18). The next genes analyzed were egr2, sfrp5, aacs, sprr1a, insig1, 
thbs1, id4, rps12 and csn2. Expression was measured in lymph node-negative mammary 
tissue samples from a combination of DDT-01 and DDT-02 studies by real-time RT-PCR 
(Fig. 33   H      ,  , ΄ DDE treatment did not result in a significant difference in gene 

















































































Figure 33.  Second set of candidate genes were not significantly altered by p,p´ DDE 
treatment in 3-month-old MMTV-neu mice.  When the second set of selected genes 
had their expression measured in mammary tissue by real-time RT-PCR, p,p´ DDE did 
                                                                     ΔC                     
higher amount of transcript, therefore, less amplification cycles are needed before it is 
detected. The numbers within each bar represent the fold change compared to control 
using  the 2
-ΔΔC 





Due to the                                   , ΄ DDE -induced markers from the second set 
of candidate genes, keratin 18 (krt18) expression was examined by real-time RT-PCR, to 
ensure the amount of mammary epithelial tissue in both studies was consistent. As shown 
in Figure 34, the amount of epithelial tissue was similar between the samples from the 
DDT-01 and DDT-02 studies in each group (Fig. 34A). However, krt18 was also 
significantly up-              , ΄ DDE compared to control mice (Fig. 34B). 
Consequently, in total, three genes (csn1s2a, krt18, and ifi44) were identified to be 
significantly up-              , ΄ DDE           F  . 35) compared to control animals in 
the mammary tissue from mice from the combined DDT-01 and DD-02 studies.  These 











Figure 34.  Epithelial marker krt18 is significantly modified by p,p´ DDE.  A) Krt18 
displayed uniform expression between DDT-01 and -02 studies when measured by real-
time RT-PCR. B) Gene expression of krt18 by real-time RT-PCR also revealed 
significant (*p=0.01) regulation by p,p´ DDE when study DDT-01 and -02 were 
          ΔC                             krt18 to ppia                          ΔC     
indicative of a high abundance of message, which requires less amplification before it 
crosses the cycle threshold (Ct). The numbers within each bar represent fold change 
compared to control. A two-way ANOVA (A) and Mann-Whitney test (B) were 





































































Figure 35.  p,p´ DDE increased expression of the three identified markers in 
mammary tissue.  csn1s2a, ifi44 and krt18 were identified as the final characterized 
genes of p,p´ DDE action by real-time RT-PCR.  Differentiation marker csn1s2a was 
greatly modified by p,p´ DDE exposure, having a p value of 0.002 and an up-regulation 
in expression by a 13.6 fold change. Immune-related gene ifi44 was also significantly 
(p=0.02) stimulated by p,p´ DDE, with an 1.9 fold change in expression. krt18, also a 
marker of differentiation was also significantly (p=0.01) up-regulated by p,p´ DDE, with 
a 1.4 fold change in expression by the 2
-ΔΔC 
         ΔC                                  
of gene expression compared to ppia                         ΔC                      
abundance of message and therefore requires more amplification before crossing the 
threshold cycle (Ct) of detection. Numbers within each bar represent the fold change 










Before Davis and colleagues, the direct, local effects of DDT metabolites such as  , ΄ 
DDE had not been tested in the mammary gland by a controlled drug delivery system 
(ELVAX 40P). In this study, interferon-induced protein 44 (ifi44), casein gamma 
(csn1s2a) and keratin 18 (krt18) genes were chosen to investigate           , ΄ DDE  
action. These genes were significantly regulated by  , ΄ DDE and predetermined to be 
associated with cancer (csn1s2a, krt18), immune (ifi44) or hormone regulation.  
 
Interferons are a family of proteins that are made and secreted by many different cell 
types of the immune system. They are made in order to modulate the response of the 
immune system to invading foreign substances like cancer. Ifi44 was first discovered in 
association with microtubular structures in a hepatitis C virus-infected chimpanzee and, 
more than a decade later, nothing more is known about its possible function (Hallen et al., 
2007). However, it has been considered a predictor of breast cancer outcomes and has 
been linked to aggregate patterns of gene expression that associate with lymph node 
status and recurrence (Huang et al., 2003). Here, it has been shown to be significantly up-
                                  5 μ /        , ΄ DDE . An increase in expression of 
this interferon-induced gene is suggestive of the need for additional immune response, 
perhaps due to early cancer causing events taking place. At approximately 3 months of 
age, this stimulation as well as many others may attempt to ward off tumor formation. 
However, in time, with longer exposure and higher accumulation, the response of this 
gene may not be adequate and/or may become down-regulated. Immune dysfunction 
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plays a key role in cancer development and although mechanisms are not fully 
understood, potential immune dysfunction in cancer does include defects in cytokines 
like interferons (Wang et al., 2011). In fact, interferon-stimulated gene ifi44 has been 
found to be down-regulated in lymphocytes from breast cancer patients compared to 
controls (Critchley-Thorne et al., 2009), supporting the theory of decrease expression 
with time. 
 
Cytokeratins (keratins) have been recognized for >20 years as structural markers specific 
to epithelial cells (Woelfle et al., 2004). They are regulated at the transcriptional level in 
normal mammary gland epithelia and alterations observed in breast cancer are 
characterized by partial loss of the normal regulation of cytokeratin expression (Su et al., 
1996). Their expression also varies with differentiation of the cell (Clarke et al., 2004). A 
cytokeratin, krt18, was another gene significantly up-regulated by  , ΄ DDE treatment in 
the mammary gland. It is well known that increased differentiation is associated with 
protection of the gland and this stimulation is not consistent with the tumor study 
outcome induced by  , ΄ DDE . However, although this luminal epithelial marker 
(Abdel-Fatah et al., 2008) has been associated with being down-regulated in breast 
carcinomas as compared to normal breast tissue or fibroadenoma (Linder et al., 1996; 
Woelfle et al., 2004), use of the individual cytokeratin as a diagnostic marker for breast 
cancer might lead to false-negative findings due to the observed down-regulation of this 
protein (Woelfle et al., 2004). The disparity between p,p´ DDE-induced expression of 
krt18 and the tumor study findings may  also be due to an approximate exposure time of 
two months not being long enough. The regulation of this gene may eventually change 
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over time and the expression will become repressed and concur with the previous 
findings of down regulation (Franzen et al., 1996; Woelfle et al., 2004) or possibly that of 
Willipinski-Stapelfeldt and colleagues (2005) who propose loss of cytokeratin 18 is 
indicative of an epithelial to mesenchymal transition as seen in micrometastatic cancer 
cell lines. Moreover, the increased expression of this gene could infer an attempt of the 
gland to remain morphologically normal, as krt18 is also important for normal breast 
epithelium and their proliferative epithelial processes (Böcker et al., 2009) as may be 
seen in a yet still growing gland. Another possible reason for the increased expression of 
krt18 by  , ΄ DDE could be due to the differential expression of HER-2/neu being 
associated with specific cytokeratin subtype distribution (Steinman et al., 2007). 
Considering neu was not significantly regulated by  , ΄ DDE at approximately 3 months 
of age could imply krt18 expression may be different at a later time. Conversely, 
stimulation of krt18 could be occurring due to tumor cells already present in the 
mammary gland. Trask and colleagues (1990) have shown that normal mammary 
epithelial cells produce keratins (K) K5, K6, K7, K14 and K17, whereas tumor cells 
produce mainly K8 and K18. They also demonstrate in immortalized cells, which are 
preneoplastic or partially transformed, that krt18 is increased. This finding is in better 
alignment with the tumor study and may, in fact, be what is occurring with  , ΄ DDE 
exposure. 
 
The third gene discovered to be significantly up-regulated by  , ΄ DDE was casein 
gamma. Casein genes encode the major milk proteins and are associated with mammary 
ductal differentiation. Although mainly activated with pregnancy and lactogenic stimuli, 
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residual amounts of caseins have been located on the apical surface of epithelial cells 
surrounding the ductal lumen in virgin mammary gland sections (Barash et al., 1995). As 
mentioned previously with krt18, also a marker of ductal differentiation, increased 
differentiation within the mammary gland is generally deemed as being protective. 
Stimulation of casein gamma would not correspond to the  , ΄ DDE-induced tumor 
formation observed in the tumor study. However, casein gamma, as well as all other 
caseins, have been found to be expressed in preneoplastic lesions, which are often 
developed prior to breast cancer and possess the attributes of hyperplastic normal tissue 
(Smith et al., 1984). Furthermore, when milk protein synthesis was examined in virgin 
mouse mammary tissue, which had been neoplastically transformed by a viral carcinogen 
(MMTV) and serially transplanted in gland-free fat pads of virgin mice, expression of 
casein genes accompanied the transformation (Smith et al., 1984). This finding also 
corresponds with the findings of Medina and colleagues (1987) who found tumors to 
have very high levels of casein expression. Still another possible reason casein gamma 
was up-regulated could be due to continued development of the gland. Postnatal 
development of the gland begins at puberty and is only completed upon giving birth. 
However, differentiation is initiated in virgin mice in a limited number of cells with each 
estrus cycle (Robinson et al., 1995). All animals in the study were sacrificed 
approximately at the same age in estrus to ensure the same level of hormonal influence. 
Therefore, the stimulation of both differentiation markers could also be attributed to 
organogenesis of the gland, thereby affecting development. 
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At this time, the exact roles of ifi44, krt18 and casein gamma remain unclear in regards to 
their involvement in breast tumorigenesis. Though immune effects are more definitively 
associated with cancer formation, the role of mammary ductal differentiation is not as 
clear. It is possible that the expression of these genes are more of a reflection of earlier 
events that have already taken place, thus making their regulation more of a consequence 




























T                            , ΄ DDE                                               , 
casein gamma (csn1s2a) and cytokeratin 18 (krt18), are associated with mammary 
epithelial growth and differentiation.  Keratin 18 and casein gamma are markers of 
luminal mammary epithelial cells (Steinman et al., 2007; Bocker et al., 2009; Barash et 
al., 1995).  T                          ,   DDE action was interferon-induced protein 44 
(ifi44). Immune dysfunction plays a key role in cancer development and although 
mechanisms are not fully understood, potential immune dysfunction in cancer does 
include defects in cytokines like interferons (Wang et al., 2011). As mammary gland 
development, growth, and differentiation are regulated by androgens, estrogens, and 
progesterone (Chambo-Dilho et al., 2005; Liao et al., 2002; Conneely et al., 2001; Jaga et 
al., 2000), the expression of the genes for these hormone receptors were studied in 
               RN                    , ΄ DDE-treated MMTV-neu mice.  In addition, 
to visualize the ductal tree of the mammary glands from the DDT-01 study mice for 
effects on mammary gland morphology that could correlate to the increased gene 
               , ΄ DDE ,                                                          
enhanced epithelial tissue and/or differentiation.    
 
 In the Tumor study, Davis and colleagues demonstrated that a dose of 5 µg/pellet of p,p´ 
DDE induces an earlier latency in MMTV-neu female mice (Fig. 2). However, how  , ΄ 
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DDE influenced the mammary gland is unclear and requires further investigation. To 
investigate the potential actions of  , ΄ DDE in the mammary glands in Central Questions 
2-5, DDT-01 and DDT-02 studies were conducted to generate tissues for analyzing Aim 
3.  For example, the anti-androgenic action of  , ΄ DDE (Kelce et al., 1995) was 
investigated by comparing it to the well-known anti-androgen, hydroxyflutamide (OH-
flut).  If gene expression similarities are observed for the identified  , ΄ DDE -induced 
genes from Chapter 4, these potential findings could imply  , ΄ DDE has anti-androgenic 
properties in the mouse mammary gland.    
 
The dose of 5 µg/pellet of  , ΄ DDE  accelerated mammary tumor onset; however, when 
a reduced dose of p,p´ DDE (3.3 µg/pellet) was co-administered in a 2:1 ratio with o,p´ 
DDE (1.7 µg /pellet; 5 µg/pellet total), the earlier latency did not occur as it did with 5 
µg/pellet p,p´ DDE alone (Fig. 2).  The comparable latency between the 2:1 ratio and 
control groups implied that the reduced dose of p,p´ DDE and/or the ratio of p,p´ DDE 
with its estrogenic isomer may be the reason for the inability of the 2:1 ratio group to 
accelerate tumor development. To investigate dose effects on gene expression, additional 
groups treated with                   , ΄ DDE                ;                         
identified in Chapter 4 were tested in mammary tissue RNA from these groups.  To 
                 , ΄ DDE           , ΄ DDE actions in the 2:1 ratio, groups treated 
with 2:1, 5:1, and 10:1 ratios of  p,p´ DDE:o,p´ DDE, with varying levels of o,p´ DDE 
and the 5 μ /pellet  , ΄ DDE dose held constant, were generated to remove the potential 
                , ΄ DDE     
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High levels of p,p´ DDT in young women were  associated with increased breast cancer 
risk before age 50 (Cohn et al., 2007).  These results suggest similar effects as observed 
      , ΄ DDE                -onset mammary cancer in MMTV-neu mice; these 
potenti                                                                , ΄ DDE -induced 
genes.  Therefore, additional animals were treated and tested for gene expression changes 
between the p,p´ DDE, p,p´ DDT, and control groups.  In addition, since p,p´ DDT is co-
               , ΄ DDE              /                                        , ΄ DDE 
ratio resulted in unexpected effects, a combination of p,p´ DDE and p,p´ DDT (1:1 ratio, 
2.5 g each) was also generated for examining expression of the three identified markers.  
Accordingly, additional groups of MMTV-neu mice were treated for investigating gene 
expression in order to address Central Questions 2, 3, 4, and 5 for local effects in the 




Whole Mount Fixation and Staining 
 
Mammary gland whole mounts allow for visualization of the entire gland structure, 
which can then be qualitatively or quantitatively assessed. Carmine alum stain was 
prepared by first adding 1 g of Carmine powder and 2.5 g of aluminum potassium sulfate 
to 250 mL of dH2O in an Erlenmeyer flask. The combining of these reagents was 
followed by the addition of another 250 mL of dH2O. The mixture was allowed to boil on 
a hotplate for 20 minutes and then the final volume adjusted to 500 mL. After the volume 
was adjusted, the solution was filtered twice using a mild vacuum and stored at 4°C with 
a pinch of thymol used as a preservative. 
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 After mammary glands that were fixed overnight in 4% p-formaldehyde and stored in 
70% ethanol were carefully trimmed away from the skin they were placed flat in a round 
tissue capsule (labeled with pencil) in order to maintain integrity and shape. On the first 
day of staining, mammary tissues were washed in a large beaker with a stir bar containing 
70% EtOH for 15 minutes, followed by a 5 minute rinse in dH2O. Tissue capsules were 
then placed in the Carmine Alum stain overnight at 4° C. On the second day, tissues were 
removed from the stain and washed in a large beaker of rapidly stirring 70% EtOH for 15 
minutes. Next, tissues were washed in 95% EtOH followed by a 100% EtOH wash, both 
for 15 minutes. The last wash was prolonged if needed until all stain had been removed. 
Once all stain was removed, tissue capsules were transferred into toluene and spun for 
30-40 minutes in order to remove the fat. Once the tissues appeared translucent, they 
were removed from the toluene and the glands transferred into scintillation vials filled 
with methyl salicylate for storage. Whole mounts were viewed using a Nikon 
stereoscopic microscope with an Olympus DP70 microscope digital camera. Whole 
mount digital images were captured using DP controller software using a blue filter 
background for optimal viewing quality.  
 
Chapter 2 includes the methods on total RNA isolation, cDNA reverse transcriptase 
reactions, real time RT-PCR, relative gene expression and statistical analysis that apply to 










Hormone Responsiveness in the Mammary Gland with Localized p,p´ DDE Exposure 
To examine whether local exposure to the anti-androgen p,p´ DDE  had any effects on the 
hormone receptors that regulate hormone responsiveness in the mammary gland, 
expression of the genes for estrogen receptor alpha (esr1), G protein-coupled receptor 30 
(gpr30), androgen receptor (ar), aryl hydrocarbon receptor (ahr) and progesterone 
receptor (pgr), were analyzed by real-time RT-PCR in animals from the DDT-01 study.  
In addition, the subtypes of the progesterone receptor (PR) were examined using primer 
sets that differentiate between the two receptor subtypes coded for the prg (progesterone 
receptor) gene, progesterone receptor-A (PRA) and progesterone receptor-B (PRB).   
Furthermore, to investigate whether a gene involved in mammary proliferation and 
cancer development and which is also influenced by neu (Taneja et al., 2009) was 
affected as a function of p,p´ DDE action, cyclin D1 (ccnd1)  expression was also 
evaluated (Fig. 36). The 5 µg /pellet dose of p,p´ DDE did not significantly modulate the 
expression of any of the tested markers. However, the relative expression differences 
      , ΄ DDE                                          1-fold for the control mice, 1.6-
fold for esr1, 1.3-fold for gpr30, 1.2-fold for ar, 1.6-fold for ahr, 1.7-fold for prg 
(includes both subtypes, PRA and PRB) , 2.5-fold for the message for PRA, 2.5-fold for 
the message for PRB, and 1.7-fold for ccnd1.   
 116 
























































































Figure 36.  p,p´ DDE does not induce significant changes in hormone receptor gene 
expression in mammary tissue. Expression of hormone markers esr1, ar, gpr30, ahr, 
pgr (all PR messages), subtypes PR-A and PR-B, as well as a gene involved in mammary 
proliferation, ccnd1, were measured by real-time RT-PCR with SYBR-Green detection. 
N                                                           5 μ /                    
p,p´ DDE, however fold-changes of all genes are slightly higher that the control group. 
ΔC                 ed level of the gene of interest compared to ppia (cyclophilin A). A 
       ΔC                                                            T                  
each bar represent the fold change compared to control using the 2
-ΔΔC 
 method. The 
Mann-Whitney test was used for statistical analysis, all genes had p values >0.05. n=6. 
 
Treatment Effects on Mammary Gland Morphology  
Since two of the p,p´ DDE-regulated genes (csn1s2a and krt18) are markers of ductal 
differentiation, digital images of mammary gland whole mounts were examined (Fig. 37). 
These images allowed the observation of potential morphological changes that may have 
occurred within the gland with treatment. Whole mounts from the nine treatment groups 
in the DDT-01 study were prepared and stained to allow visualization of the ductal tree 
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within the inguinal mammary glands. Possible effects of steroid hormone treatment on 
mammary gland morphology may include changes in mammary gland arborization, 
terminal end bud number, length and alveolar density (Fielden et al., 2002). Development 
of the mammary gland occurs in two major phases, hormone-independent and hormone-
dependent. The latter occurs at puberty and results in ductal elongation and side 
branching, as a consequence of estrogen and progesterone, r             B           
O’M       2 1    T        ,     -                       ,   DDE                      
potential to also impact glandular development. Qualitatively, within each group, 
variations were observed such as the amount of fat pad occupied by the gland, secondary 
and tertiary branching and differences in growth patterns in relation to the ELVAX 40P 
pellet.  For example, arrest of ductal growth beyond the pellet was observed with the 
highest concentration of p,p´ DDE, leaving the remainder of the mammary fat pad empty 
(Fig. 37E). However, this effect also occurred in some animals in other groups and may 
be due to the surgical procedure (such as scarring) or other unknown effects. 
Additionally, it was observed that some glands grew over the pellet (Fig. 37G), while 
others appeared to avoid it (Fig. 37I).  Possible surgery effects could only potentially 
damage the adipose tissue and not the ducts themselves since pellet implantation occurred 
within the mammary fatpad prior to glandular development. Despite these observations, 
no consistent changes were apparent in the ductal structures among the groups to report 
them as a treatment effects; thus, quantitative analysis was not performed. Considering 
some of these genes were significantly stimulated by p,p´ DDE, the lack of noticeable 
morphological differences between the groups may suggest that the age of almost 3 
months, when the animal is a mature adult and mammary gland development is 
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essentially complete, was too late to detect gross changes in gland morphology. These 
                                                             , ΄ DDE                   
morphology is warranted except that glands should be examined at earlier time points 










Figure  37.  No apparent morphological changes were observed in the mammary 
glands. Qualitatively, no structural changes were observed in any treatment group; A) 
Control; B) 5 µg p,p´ DDE; C) 0.5 µg p,p´ DDE ; D) 2.0 µg p,p´ DDE; E) 10 µg p,p´ 
DDE; F) 2.5 o,p´ DDE ; G) 2:1 ratio; H) 5:1 ratio; I) 10:1 ratio.  However, at the highest 
             , 1  μ   , ´ DDE,                                           E   W     
mounts were viewed using a Nikon stereoscopic microscope with an Olympus DP70 
microscope digital camera. Digital images were captured using DP controller software 
using a blue filter background for optimal viewing quality. Pictures above are 
representative images of all pictures in the group. Control n=4; 5 µg  ,   DDE  =4;   5 
µg  ,   DDE  =5; 2   µg  ,   DDE n=2; 10 µg  ,   DDE  =2; 2 5 µg  ,   DDE n=6; 10:1 










DDT-01 and -02 Studies Treatment Groups in MMTV-neu Mice 
To test the actions of p,p´ DDE, DDT-01 study was conducted  to investigate the effects 
caused by p,p´ DDE alone, at varying doses, and in combination with its estrogenic 
isomer, o,p´ DDE on the identified markers in Chapter 4.  New treatment groups were 
created (Table 19) in addition to  ,   DDE and o,   DDE alone at 5 µg/pellet, varying 
ratios of  ,   DDE : ,   DDE  (2:1, 5:1, 10:1) were tested. However, in these ratios,  ,   
DDE  was held constant at 5 µg/pellet and only the  ,   DDE  concentration was 
modified.  Gene expressions of the identified markers were also evaluated in varying 
doses of  ,   DDE  in order to gain a better understanding of its action. 
 
Table 19.  DDT-01 Study Treatment Groups 
DDT-01 Study (Ratios) 
Treatment 
n=10 
Control p,p´ DDE o,p´ DDE p,p´ DDE     
+      
o,p´ DDE 
(2:1) 
 , ΄ DDE     
+      
o,p´ DDE 
(5:1) 
 , ΄ DDE     
+      
o,p´ DDE 
(10:1) 




0 5 μ  0 μ             
+                
2 5 μ  
 
 
5 μ             
+                
2 5 μ   
5 μ              
+                
1   μ  
5 μ             
+                
  5 μ  
 
DDT-01 Study (Doses) 
Treatment            
n=10 
p,p´ DDE p,p´ DDE p,p´ DDE OH-flut OH-flut 
Dose (per 
pellet) 




The DDT-02 study was conducted in order to gain a better understanding of the 
similarities and/or differences between p,p´ DDE and p,p´ DDT action. Identical 
treatment methods to deliver the treatment, time of exposure, age, and animal model were 
used for study DDT-02 treatment groups (Table 20). However, due to the information 
gained from the previous two studies (Pretumor and DDT-01), the lymph node was 
visually identified at necropsy and the mammary gland sectioned according to Figure 24. 
 

























p,p´ DDT     
 
0 5 μ  2 5 μ   
 
5 μ  
 
 
2 5 μ  
2 5 μ   
   +             
2 5 μ  
  
OH-flut       5 µg  2.5 µg  
 
 
Gene Expression in Mammary Tissue of DDT-01 and -02 Studies 
Using mammary tissue obtained from the two studies, real-time RT-PCR analysis of gene 
expression was performed on the three identified markers (krt18, ifi44 and csn1s2a) in 
Chapter 4. The three genes were chosen to be significantly modified by  , ΄ DDE 
exposure using animals in the control and  , ΄ DDE groups from both DDT-01 and -02 
studies.  Therefore, these genes can be tested in the different treatment groups in both 
studies to address all aspects of Aim 3.  First, to examine the potential anti-androgenic 
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actions of  , ΄ DDE in mammary tissue in vivo after chronic exposure (2 months), the 5 
µg/pellet dose of  , ΄ DDE was compared to the same dose of the known androgen 
antagonist, hydroxyflutamide (OH-flut).  Next, to test the impact of additional doses of 
 ,   DDE  besides 5 µg/pellet, gene expression induced by a tenth (0.5), half  (2.5), and 
double (10) the 5 µg dose were also tested.   T                                    ,   DDE  
when co-administered with its estrogenic isomer,  ,  DDE , ratios of  , ΄ DDE with  ,   
DDE were investigated, and lastly, comparisons of  , ΄ DDE  to p,p´ DDT were also 
studied in order to identify similarities and differences in action between the two isomers. 
These studies will address Central Questions 2-5 for local effects of  , ΄ DDE actions in 
the mammary gland, including as an androgen antagonist, dose effects, similarities and 
differences to p,p´ DDT, and effects of mixtures with the two DDT congeners,  ,   DDE 
and p,p΄ DDT.   
 
Anti-androgenic Action of p,p´ DDE 
The role of androgens within the breast has not been clearly defined, however, the 
consensus among most reports show androgens to be antiproliferative and to counteract 
estradiol stimulation of the mammary epithelial cells (Zhou et al., 2000; Leung et al., 
2002; Suzuki et al., 2010). Additionally, 70-90% of primary breast tumors express the 
androgen receptor.  Based on the results in the MMTV-neu mice, it has been verified that 
p,p´ DDE influences mammary carcinogenesis, but whether these effects are related to its 
reported anti-androgenic properties is unknown and there are very few studies that have 
investigated the modulation of gene expression by androgens in mouse mammary tissue 
(Aboghe et al., 2008).  Androgen receptor antagonists compete with endogenous 
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androgens acting on the androgen receptor to prevent down-stream activation of 
androgen-dependent gene expression (Wilson et al., 2008). However, without a set of 
known genes regulated by androgens or anti-androgens in the mammary gland, the 
potential anti-                       , ΄ DDE                                           
ways. Therefore, in this study, the expression of the identified p,p´ DDE-induced genes 
was compared to OH-flut to determine if both treatments result in similar effects.     
 
In order to investigate the anti-androgenic actions of p,p´ DDE, the modulation of the 
three candidate genes (csn1s2a, ifi44, krt18      , ΄ DDE     compared to mice treated 
with the androgen receptor antagonist, OH-flut   I                           , ΄ DDE     
behaving as an anti-androgen in the mammary gland, then the effect of 5 g/pellet  , ΄ 
DDE on csn1s2a, ifi44, and krt18 should mimic those of 5 g/pellet OH-flut.  Even 
though significance was not reached, the pattern of regulation between OH-flut and  , ΄ 
DDE was similar (Fig. 38). For csn1s2a, both  , ΄ DDE and OH-flut increased 
expression, having fold changes of 13.6 and 5.0, respectively. However, among both 
groups compared to control, only  , ΄ DDE treatment was significant (p <0.003, one-way 
ANOVA). Epithelial marker krt18 resulted in a non-                           5μ /       
doses of p,p´ DDE and OH-flut, having similar fold changes of 1.4 and 1.3, respectively. 
However,  , ΄ DDE expression was significant when compared to control (p <0.02, 
Mann Whitney test), OH-flut approached significance (p=0.065, Mann Whitney test), and 
the two anti-androgens were not significantly different when compared to each other. 
Lastly, immune-related marker ifi44 was not significantly modulated by p,p´ DDE or 
OH-flut (Fig. 38), but both induced an increase in expression, with fold changes of 1.9 
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and 1.4, respectively. Taken together, the common direction in expression of p,p´ DDE 
and OH-flut suggest both have a similar effect on the genes, possibly as anti-androgens, 





































































































Figure 38.  p,p´ DDE treatment showed similar trends in expression in csn1s2a, 
krt18, and ifi44 when compared to OH-flut at an equivalent dose. Real-time RT-PCR 
demonstrated both anti-androgens evoked a common response in gene expression at the 
same concentration per pellet. csn1s2a expression was significant (p < 0.003, one-way 
 NOV                                      , ´ DDE  **    T    ’    st), but not for  
hydroxyflutamide (OH-flut) compared to control.  The  , ΄ DDE and OH-flut groups 
                                                    T    ’      ,                         
similar increase in expression .  The gene krt18 was also stimulated, though not 
significantly by either  , ΄ DDE    OH-flut (p> 0.05, 1 way-ANOVA; no groups 
               T    ’         E                                                ifi44 as 
both anti-androgen treatments induced non-significant increases in expression compared 
to control (p> 0.05, one-      NOV ;                          T    ’         T   
                                                                   ΔC         
normalized expression of the target gene compared to the housekeeper gene, ppia 
(cyclop                  ΔC                                                     O  -way 
ANOVA was used for statistical analysis (p<0.05 ,      T    ’                  C       
and p,p´ DDE groups, n=13; OH-flut group, n=6. ** indicates level of significance by 




Dose Effects of p,p´ DDE 
P         ,                    , ΄ DDE  treatment (5 µg/pellet, 4 pellets/mouse, 20 µg 
total dose) decreased tumor latency.  In this investigation, the effects of p,p´ DDE  dose 
were examined on csn1s2a, ifi44, and krt18 gene expression. To test dose affects, varying 
          , ΄ DDE    5, 2 5, 5  ,     1  μ /pellet) were delivered to the mammary glands 
as previously described. The results from this study will help to determine which doses of 
 , ΄ DDE        ly and minimally modulate the three identified genes within the 
mammary gland.  
 
 To evaluate the dose effects of p,p´ DDE, the results                        , ΄ DDE    
gene expression of csn1s2a, krt18, and ifi44 were measured in the mammary tissue by 
real-time RT-PCR. In Figure 39, the 5 µg/pellet dose of p,p´ DDE elicited the strongest 
stimulation of all three genes in comparison to both the higher (10 µg ) and lower (0.5 
µg, 2.5 µg ) doses.   Unexpectedly,                     , ΄ DDE         significantly 
down-regulated gene expression (krt18) or was without effect (csn1s2a and ifi44) (Fig. 
39                             ,  , ΄ DDE                       csn1s2a, krt18, and ifi44 
gene expression when compared to control, but was significantly attenuated when 
                                           5 μ /pellet  , ΄ DDE (krt18 and ifi44). 
Results also demonstrate the 2.5 µg                   , ΄ DDE                    
different than the 5 µg concentration for both krt18 and ifi44. Collectively, these data 
                       , ΄ DDE                                            csn1s2a, ifi44, 
       18          5 μ /pellet  , ΄ DDE                       , which is the dose that 
























































































































































                       
Figure  39.  The 5 µg/pellet dose of p,p´ DDE evoked the strongest stimulation in 
expression for all the genes.  Investigation of the potential doses of p,p´ DDE that 
modulated expression of marker genes by real-time RT-PCR revealed 5 µg/pellet 
increased expression of csn1s2a, krt18, and ifi44              , ΄ DDE                 
                              5 µ /                ,   DDE                               
(p<0.02, one-way ANOVA) in expression in csn1s2a. Doses below 5 µg/pellet in krt18 
were significantly repressed compared to the c               5 µ /            ,           
                                                                                 
              2 5 µ   ,   DDE                                    5 µ /        ,   DDE  
Significance p<0.0001, one-way ANOVA, with significance between the groups noted 
                             T    ’                     ,                                
for ifi44 (p=0.002, one-way ANOVA) occurred.  Specifically, the 2.5 and 10µg/pellet 
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doses compared to the stimulated 5 µg/pellet       T                   , ΄ DDE    ifi44 
also induced non-significant stimulation; similar to what occurred in csn1s2a  ΔC         
normalized gene expression compared to the housekeeper gene ppia (cyclophilin A). A 
       ΔC                            low abundance. Numbers within each bar represent 
the fold change compared to control. One-way ANOVA used for statistical analysis 
(*p<0.05),      T    ’               . **p<0.01 and ***p<0.001 = level of significance 
                 T    ’      ,  =6-13. Significant comparisons are only between the 




p,p´ DDE and o,p´ DDE Mixtures 
T            , ΄ DDE       resulted in earlier tumor development     5 μ   The 2:1 ratio 
    , ΄ DDE: , ΄ DDE  did not induce the early tumor latency; however, in the Tumor 
     ,              , ΄ DDE                     3 3 μ  in each pellet         5 μ   
Therefore, it is unknown                            , ΄ DDE  and/or the inclusion of 
 , ΄ DDE   ere responsible for the lack of effect on tumor latency for the 2:1 ratio, 
unlike  , ΄ DDE   5 μ /pellet) alone. The dose was previously tested (Fig. 39), so the 
goal of these experiments were to test the ratios of  , ΄ DDE with  , ΄ DDE. To test 
whether or not mixtures of p,p´ DDE and  , ΄ DDE influenced gene expression by 
removing the potential dose effects of  , ΄ DDE,         doses of  , ΄ DDE were tested 
in the ratios with the concentration of  , ΄ DDE held constant at the 5 g/pellet dose that 
accelerated tumor onset   S           ,                            , ΄ DDE: , ΄ DDE  2:1, 
5:1, 10:1) were tested; the 2:1 ratio included 2.5 g  ,   DDE for at total of 7 5 μ  , the 
5:1 ratio included 1.0 g  ,   DDE for at total of 6   μ , and the 10:1 ratio included 0.5 
g  , ΄ DDE for at total of 5 5 μ  in each pellet. I   , ΄ DDE modifies  , ΄ DDE action, 
then the expression of csn1s2a, ifi44, and krt18 genes would not resemble the 5 μ /       
dose of  , ΄ DDE alone in groups with higher doses of  , ΄ DDE   If the dose of  , ΄ 
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DDE was the most important, it could be hypothesized little variation in expression of 
these genes would be evident for all three ratios compared to the 5 g  , ΄ DDE group.  
 
As shown in Figure 40, the 2:1 ratio resulted in similar stimulated expression levels for 
all three genes compared to  , ΄ DDE alone (5 g); but, expression was reduced by  ,   
DDE alone again in all three genes compared to control, although only significantly for 
krt18.  For csn1s2a, the 5 µg/pellet concentration of  ,   DDE  induce expression that 
was significantly different than its estrogenic isomer,  ,   DDE. This trend was also 
demonstrated in krt18, where the 2:1 ratio was also significantly different than its 
individual components, as was the case for csn1s2a as well. The gene ifi44 was not 
significantly affected. These results suggest that the dose and not the combination with 
 , ΄ DDE  affect expression of these three genes in mammary tissue.  However, the 5:1 
and 10:1 ratios do not result in similar expression patterns compared to the  , ΄ DDE 
group alone.  Since there are no groups tested with the lower doses of  ,   DDE alone 
(0.5 and 1µg), these findings are difficult to interpret, but may suggest some influence of 
















































































































                                 
Figure 40. Ratios of p,p´ DDE to o,p´ DDE influence expression of  csn1s2a and 
krt18 in the mammary gland of  MMTV-neu mice. Investigation into varying ratios of 
p,p´ DDE to o,p´ DDE reveal by real-time RT-PCR that both csn1s2a and krt18 
expression was significantly altered. For csn1s2a, the groups for the individual isomers 
and the  ratios are significant (p=0.0013, one-way ANOVA). The 5 µg  ,   DDE group 
was significantly stimulated compared to control and gene expression induced by the 2:1 
ratio                                                            T    ’         S        , 
krt18, repression caused by the  ,  DDE group was significantly different from the 2:1 
ratio, the 5 µg group and control. Additionally, the 5:1 and 10:1 ratios were significantly 
                        2:1                          T    ’         O                        
krt18 is p<0.0001,one-way ANOVA . Expression of ifi44 was unaffected (p>0.05,one-
way ANOVA). ΔC                                                   ppia (cyclophilin 
A). Numbers within each bar represent fold change compared to control. One-way 
 NOV      T    ’                     for statistical analysis (p<0.05). *p<0.05, 
**p<0.01, ***p<0.001 = le                       T    ’      , n=6-13. Significant 




 p,p´ DDT, Alone and Combined with p,p´ DDE  
Davis and colleagues have previously shown p,p´ DDE is capable of causing early 
mammary tumor formation. Cohn and colleagues (2007) reported more women exposed 
to higher levels of p,p´ DDT before age 14 developed breast cancer before age 50. Their 
study was the first to investigate DDT and breast cancer risk in terms of the significance 
of age at exposure. In addition, p,p´ DDT is reported to have anti-androgenic activity, 
though weaker than  , ΄ DDE (Kelce et al., 1995).  Furthermore, p,p´ DDT is the primary 
constituent of commercial grade DDT (Cohn et al., 2  7 ;          ,                         
                                    ,   DDE   
 
T                              , ΄ DDE     p,p´ DDT similarly modulate csn1s2a, ifi44, 
and krt18,                                              , ΄ DDE   2 5 μ      5 μ      
p,p´ DDT  2 5 μ     5 μ                        1:1                    2 5 μ  p,p´ DDT:2.5 
μ   , ΄ DDE, total 5 μ  in each pellet) (Fig. 41). The 5 μ           , ´ DDT     
included to match the dose of p,p´ DDE demonstrated to cause early tumor formation in 
the mammary gland by Davis and colleagues. In addition, every animal study has some 
variation and the goal was to compare expression of the identified markers to this dose of 
 , ΄ DDE, this treatment as well as the control (vehicle pellets) were included in both 
studies.  A 1:1 ratio of p,p´ DDE and p,p´ DDT was also tested since neither of these 
congeners exist alone in the environment or in vivo and, therefore, may influence each 
other. Since both congeners have previously been linked to breast cancer (Wolff et al. 
1993; Charlier 2003; Cohn et al., 2007)      , ΄ DDE accelerated mammary cancer in 
MMTV-neu mice, comparison of these congeners alone and together on expression of the 
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p,p´ DDE-induced markers may suggest if existing mixtures act similarly or not in 
women exposed to DDT.   
 
Expression of the csn1s2a gene induced by 5 and 2.5 µg     ,   DDE  and p,p´ DDT or a 
1:1 ratio (2.5 µg  ,   DDE: 2 5 µg p,p´ DDT)  was minimally affected across most 
groups; with only 5µg  ,   DDE  being significantly different than 2.5 µg of p,p´ DDT 
(p=0.0031, one-way ANOVA).  However,       , ΄ DDE (5 µg) and p,p´ DDT (5 µg) 
were compared to each other individually , their difference in expression approached 
significance (p= 0.05, Mann-Whitney test). The 2.5 µg/pellet concentration of p,p´ DDT 
was significantly differen           1:1           , ΄ DDE :  , ΄ DDT (p =0.0043, Mann-
Whitney test) , containing the same concentration of both congeners  2 5 μ /pellet), 
producing fold changes of 0.1 and 4.1, respectively.  
 
Interestingly, gene expression of krt18 among the diffe      ,   DDE     p,p´ DDT 
treatment groups was very similar, despite the 5 µg/pellet concentrations of p,p´ DDE and 
p,p´ DDT approaching significance (p= 0.065, Mann-Whitney test) and having fold 
changes of 1.4 and 1.0, respectively. They were also both significantly different from 
their half (2.5 µg) concentrations. At the half concentration (2.5 µg/pellet),  ,   DDE  and 
 ,   DDT expression was identical. Not only were both significantly different from 
control, but they were also not significantly different from one another and had identical 
fold changes of 0.2. Furthermore, 2.5 µg/           ,   DDE     p,p´ DDT were also both 
significantly different from 5 µg/           ,   DDE     p,p´ DDT. Also, both 2.5 
µg/                          ,   DDE      ,   DDT                                       
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1:1      ,                                             W     ,   DDE      ,   DDT were 
placed in a 1:1 combination (2.5 µg each), they no longer elicited expression as they did 
alone, as demonstrated by the 0.2-fold change of the individual isomers compared to the 
co-administration concentration 1.2-fold change. 
 
The expression of ifi44 was similar to krt18 with the exception of the 5 µg/       
                  ,   DDE,                                     an the 5 µg concentration 
of p,p´ DDT, having fold changes of 1.9 and 0.6, respectively. Additionally, 5 µg  ,   
DDE-induced expression was significantly different from both 2.5 µg concentrations. 
Furthermore, also comparable to krt18, the 2.5 µg/pellet concentration of  ,   DDT was 
significantly different from the 1:1 ratio although it contained the same concentration of 
 ,   DDT. 
 
Overall, these trends suggest p,p´ DDE and p,p´ DDT have both similar and dissimilar 
actions amongst themselves and between each other.  Furthermore, when they are 
combined, they induce an opposite response to what is induced by each individually. 
These results revealed that the presence of one isomer influences the other. 
 133 

































































































































































                                      
Figure 41.  p,p´ DDE and p,p´ DDT induce similar and dissimilar expression in 
genes regulated by p,p´ DDE. Using specific primers for csn1s2a, ifi44 and krt18, 
induced expression by p,p´ DDE, p,p´ DDT and a 1:1 combination of both was measured 
by real-time RT-PCR. For csn1s2a, among all groups (p=0.0031, one-way ANOVA), 
only the 2.5 µg/pellet of p,p´ DDT was significantly different from the 5 µg/pellet dose of 
p,p´ DDE    T    ’      ,        ,                                              
comparisons being investigated . Ifi44 expression was also significantly modified 
(p<0.0001, 1-way ANOVA). p,p´ DDE and  p,p´ DDT were significantly different at the 
5 µg/             T    ’       . Additionally, both half doses of 2.5 µg/pellet were also 
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significantly repressed compared to the stimulation induced by 5 µg/                ,   
DDE  T    ’         L     , ifi44 expression at the 2.5 µg concentration of p,p´ DDT was 
significantly different from the 1:1 ratio group consisting of the same concentration test. 
expression of krt18 was also significantly modulated by the treatment groups (p<0.0001, 
one-way ANOVA). Both 5 µ /                 ,   DDE     p,p´ DDT were significantly 
different from their half concentrations (2.5 µg), which were also significantly repressed 
                     T    ’                      ,     2 5 µg/pellet concentrations      
                   ,   DDE     p,p´ DDT but induced significant stimulation when co-
                                         T    ’          ΔC                      y or 
weakly the gene is expressed.       ΔC                                                    
normalize level of the gene compared to the housekeeper gene ppia (cyclophilin A). The 
numbers within each bar represent the fold change compared to control. One-way 
ANOVA and T    ’  tests were used for statistical analysis (p<0.05). n=13 (control and 
5 μ   , ΄ DDE ;  =6   5 μ   , ´ DDT, 2 5 μ   , ΄ DDE and p,p´ DDT and 1:1 
ratio).* <   5, ** <   1, *** <    1 =                          T    ’        Significant 

































An effect of p,p´ DDE, besides its reported androgen receptor binding and inhibition of 
androgen-regulated genes, may be to modify hormone responsiveness of the mammary 
gland.  One way to modify its responsiveness would be to alter expression levels of the 
hormone receptors involved in modulating responses important in proliferation, 
differentiation, and neoplastic formation. Therefore, gene expression for the androgen 
receptor (ar), estrogen receptors (esr1 and gpr30), progesterone receptor (pgr) and its 
subtypes PRA and PRB,  cyclin D1 (ccnd1) and the aryl hydrocarbon receptor (ahr) were 
investigated. The gene for esr2 (estrogen receptor beta) was not tested because it was not 
detected in other studies. Previous studies show  , ΄ DDE      s to the androgen 
receptor, binds poorly to the estrogen receptor (Kelce et al., 1995), has relatively low 
binding affinity for GPR30 (Thomas and Dong 2006), acts as a progesterone receptor 
antagonist (Li et al., 2008), and binds to the aryl hydrocarbon receptor (Long et al., 2006 
). In this study,  , ΄ DDE did not significantly modify the expression of any of these 
genes.  
 
The lack of changes in expression of these genes by  , ΄ DDE does not mean these 
receptor levels are or are not modified. Since investigations in this study were on their 
transcript levels, the measured expression of these genes may not reflect their protein 
levels or activity.  Therefore, no obvious changes in receptor gene expression suggest 
hormone levels are unchanged.  The presence of these receptors in mammary tissue 
suggests the receptors are available for binding to  , ΄ DDE or to induce responses from 
other hormones.  But, if the mRNA levels reflect the receptor levels, the gland would not 
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be more or less responsive to these hormones or DDT congeners.  However, other p,p´ 
DDE-induced changes could occur to affect hormone responsiveness in the mammary 
gland, such as by modifying androgen, estrogen, and progesterone synthesis or 
metabolism.  
 
Although DDT has been shown to increase cyclin D1 protein synthesis in MCF-7 breast 
cancer cells (Dees et al., 1997), p,p´ DDE treatment in <3-month-old female MMTV-neu  
mice did not significantly alter cyclin D1 (ccnd1) gene expression. These results are in 
agreement with Silva and colleagues (2010) who found that p,p´ DDE is a fairly weak 
transcriptional inducer of CCND1 in breast cancer cells.   
 
DDT has been reported to be a morphogen, increasing cell proliferation and promoting 
the maturation of the undifferentiated terminal end buds to more differentiated lobular 
terminal ductal structures (Brown and Lamartinier 1995).  The gene expression effects in 
this study suggest this effect may have occurred in the MMTV-neu mice. However, gross 
observation of the glands did not reveal any morphological changes despite both 
differentiation genes, csn1s2a and krt18, being significantly up-r             , ΄ DDE    
The lack of consistent change in morphology is likely due to variations within groups that 
obscure potential treatment effects; therefore, additional studies will be required to 





Anti-androgenic Effects       ΄      
In the mammary tissue, OH-flut stimulated the expression of three genes             , ΄ 
DDE, but its expression was not significantly different from control or  , ΄ DDE for 
csn1s2a, krt18, and ifi44.  Although these data suggest some similar actions by these two 
treatments, the lack of significance does not confirm that  , ΄ DDE is acting as an anti-
androgen. As the genes tested in the mammary tissue have not been reported to be 
regulated by androgens in this tissue, it may be expected that OH-flut would not 
significantly influence their expression. Androgen-stimulated genes may need to be 
identified to accurately test whether  , ΄ DDE (and OH-flut) have anti-androgenic action 
in vivo on gene expression in mammary tissue; then, the anti-androgenic actions can be 
confirmed by repressing its expression in the presence of endogenous androgens.  
Expression of neu via the MMTV promoter would be the closest test for this anti-
androgen action.  However, due to regulation of the MMTV promoter by progesterone 
                                                                                    , ΄ 
DDE  to the progesterone receptor,  , ΄ DDE may not be able to reduce its expression.  
The ability of OH-flut to reduce neu transgene expression suggests it may be a better 
progesterone receptor antagonist than p,p´ DDE.    
 
Dose dependence 
D                , ΄ DDE                                      , ΄ DDE          O      
four  , ΄ DDE  doses, 0.5, 2.5, 5, and 10 μ /      ,     5 μ                              
stimulation for all three genes. There was also a noticeable biphasic trend involving the 
2.5, 5,     1  μ         I                 ,                                                  
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suggestive of repression by 2.5 and 10 µg  ,   DDE,           5 μ       resulted in up-
regulation, which was significant versus control mice (Fig. 39). Due to this particular 
pattern of response, the concept of hormesis may be applicable. Hormesis is defined as a 
dose-response relationship in which there is a biological activation at low doses, but an 
inhibition at high doses, or vice versa, resulting in a U, J or inverted U-shaped dose 
response (Calabrese 2002). Although no studies exist linking a hormetic effect of  , ΄ 
DDE to gene regulation in the mammary gland, Fukushima and colleagues (2005)  have 
explored non-genotoxic carcinogens, like DDT, to examine possible mechanisms of 
hormesis and have demonstrated a hormetic effect in the liver of rats. Hepatocarcinogenic 
hormesis-like effects of DDT have been witnessed previously (Sukata et al., 2002) and 
most recently in rat hypothalamus (Shutoh et al., 2009).  
 
T                    5 μ       stimulated the  , ΄ DDE -induced genes. For krt18, the 
three other doses were significantly different than     5 μ       (Fig. 39). For ifi44, the 
2.5 and 10 g doses were significantly different that the 5 g dose that accelerated 
mammary tumor development.  Collectively, these results demonstrate that expression of 
 , ΄ DDE-induced genes csn1s2a, ifi44, and krt18 depends on the          , ΄ DDE  in 
the ELVAX pellets.  The lower dose of  , ΄ DDE (2.5 g) resulted in no effect for 
csn1s2a (1.0-fold) or significantly lowered expression in krt18 and ifi44 compared to 5 
   , ΄ DDE   T ese results suggest that if a similar effect to what occurred with these 
genes also affected genes or responses involved in mammary tumor development, the 
reason for the lack of effect on tumor latency by the 2:1 ratio in the Tumor study may be 
related to                    , ΄ DDE   3 3 g in the 2:1 ratio).  Future studies will be 
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required to determine if these three genes tested in the mammary tissue in this study are 




p,p΄ DDE in Combination with o,p΄ DDE   
Comm             DDT                        , ΄ DDT      , ΄ DDT  N             
congeners exist alone in nature and the entire population of the world presents with 
                                                               OC   V    ό        , 
2009), suc     DDT  F          ,   DDT                                  , ΄ DDE , 
p,p´ DDD, and  , ΄ DDD                                                    
                  V    ό        , 2  9      é                 2 11                          
effects of an OC mixture containing 15 compounds, with  , ΄ DDE  as a major 
compound, on CAMA-1 cells appeared mainly due to the anti-                      , ΄ 
DDE. Additionally, Sprague-Dawely rat neonates exposed to a mixture of p,p´ DDE, p,p´ 
DDT,  and polychlorinated biphenyls (PCB) stimulated the development of MNU-
induced mammary tumors (Desaulniers et al., 2001). Finally, technical grade DDT (a 
mixture) has been shown to inhibit the functional activation of murine macrophages in 
response to infection (Nuñez et al., 2002). These findings imply that mixtures of DDT 
and its metabolites are, indeed, capable of exerting effects on many systems including 
affecting human mammary epithelial and breast cancer cell lines and the murine immune 
system to promote tumor formation, proliferation, and other cancer-related events. 
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In the Tumor study conducted by Davis and colleagues, the 2:1 ratio group, consisting of  
3.3 μ   , ΄ DDE     1 7 μ   , ΄ DDE  5 μ        ,                    In this 
combination, since the 3.3 g of  , ΄ DDE did not cause the early latency it induced 
alone (5g), one possible explanation could be the influence     , ΄ DDE.  Another 
possible reason is the lower dose, which was tested above (Fig. 39).  It is also possible 
                       , ΄ DDE       he inclusion of its estrogenic isomer have a role in 
                                       , ΄ DDE                            , ΄ DDE 2:1 
ratio). In the current study, the influence of  , ΄ DDE     , ΄ DDE  was investigated by 
varying the concentrations of o,p΄ DDE                                      , ΄ DDE 
                5 μ                                             and differentially induce 
expression of the three identified genes. The results revealed that both csn1s2a and krt18 
were significantly up-regulated by the 2:1 ratio group compared to control and had a 
similar effect on  , ΄ DDE (Fig. 40). The effect on these genes with the revised 2:1 ratio 
(5 g + 2.5 g ; 7.5 g total) mimicked the 5 g  , ΄ DDE      , unlike the 2:1 ratio in 
the Tumor study (3.3 g + 1.7 g; 5 g total) which mimicked the control group and not 
 , ΄ DDE                    S              csn1s2a and krt18 by  ,   DDE was not 
observed with the 2:1 ratio.  A similar effect was observed for ifi44, although significant 
diffe                       S                                 , ΄ DDE           , ΄ DDE, 
                           ,                     ,  , ΄ DDE                         
                                                                         , ΄ DDE   
In contrast to the 2:1 ratio, the gene levels for the 5:1 and 10:1 ratios did not follow the 
pattern of expression of the 5 g  , ΄ DDE    However it is difficult to determine the true 
impact of these two ratios without knowing the effect of 1 μ        5 μ      , ΄ DDE  
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alone. Therefore, further work will be required to understand the effects of these ratios 
            , ΄ DDE                  
                                                                                                                                                                                                                
p,p´ DDE in Combination with p,p´ DDT 
The p,p´ DDT congener has also most recently been associated with a 5-fold increased 
risk of breast cancer (Cohn et al., 2007). Their study was the first to examine the 
significance of age at exposure and breast cancer risk. With higher serum levels of p,p´ 
DDT, the women in this study (average age of 26) developed breast cancer before the age 
of 50, which suggests accelerated tumor formation similar to what was observed in the 
Tumor study conducted by Davis and colleagues. Cohn and colleagues hypothesize that it 
                            , ΄ DDT                                                         
development rather than chronic exposure to its metabolite, p,p´ DDE. The preclinical 
studies conducted by Davis and colleagues as well as the current study mimic important 
aspects of the human study conducted by Cohn and colleagues. First, all the animals were 
exposed initially to p,p΄ DDE              ,                                           
mice at weaning (3 weeks of age). Second, the mice were exposed prior to puberty, when 
the gland is most vulnerable (Macmahon et al., 1970).  Third, this study also investigated 
the effect of p,p´ DDT                            , ΄ DDE  due its similar effects on early-
onset breast cancer (Cohn et al., 2007) compared with the early-onset mammary cancer 
      , ΄ DDE         T              MMTV-neu mice.   
 
The 1:1 ratio of  , ΄ DDE to p,p´ DDT up-regulated expression of csn1s2a (4.1-fold), 
ifi44 (1.4-fold), and krt18 (1.2-fold). The components of the ratio, 2 5 μ  of  , ΄ DDE 
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and p,p´ DDT, did not correlate with the 1:1 ratio for these same genes. However, the 
expression of the genes in the 1:1 ratio group was most similar to the 5 μ   , ΄ DDE  
treatment which also increased expression of csn1s2a (13.6-fold), ifi44 (1.9-fold), and 
krt18 (1.4-fold).  Moreover, 5 μ   , ΄ DDE and p,p´ DDT were not similar as 5 μ  p,p´ 
DDT was close to control or repressed for the three genes. Therefore, the 1:1 ratio 
appeared to have influences from both p,p´ DDT and  , ΄ DDE since the lower doses had 
                       H      ,                                                , ΄ 
DDE,  but at the 5 μ  dose; this result suggests that the two congeners add up to act like 
the 5 μ      , ΄ DDE          5 μ  p,p´ DDT, even though the 2 isomers do not have the 
same effect on the genes. 
 
The divergent expression between the individual  , ´ DDT      , ΄ DDE        5 μ     e 
may be related to their differences in metabolism. Both congeners are highly lipophilic 
and p,p´ DDE is more stable in the breast tissue for long durations of time; whereas, p,p´ 
DDT  is more readily metabolized to  , ΄ DDE (Tebourbi et al., 2006).  Humans and 
animals perform this conversion particularly during periods of active exposure (Morgan 
and Roan 1975). Because the ELVAX 40P pellets were actively releasing p,p´ DDT over 
a 2             ,                    , ΄ DDT     , ΄ DDE             time is likely. 
Thus, the 5 μ  p,p´ DDT mice may contain a reduced level of  p,p´ DDT as well as 
                   , ΄ DDE                         T                             , ´ 
DDT may explain why the 1:1 ratio resembles the 5 μ   , ΄ DDE                    , ´ 
DDT                          ’           T                                            
correlate to the levels of p,p´ DDT and  , ΄ DDE in the animals in the 5 μ , 2.5 μ  , and 
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1:1 ratio treated groups, the levels of both congeners need to be measured to determine if 
























Effects of Systemic    ΄     Exposure 
 
INTRODUCTION 
The studies of Davis and colleagues (Pretumor and Tumor studies) as well DDT-01 and 
DDT-02 studies are the first to investigate p,p´ DDE action in the mammary gland. 
Moreover, detectable levels of both DDE isomers have been measured in serum (Table 
10), even though the delivery was localized to mammary glands. Therefore, systemic 
effects in addition to local effects tested in the previous chapters may also influence 
mammary gland responses and tumor development.  Thus, two known actions of DDT 
congeners were examined, relating to potential influences on the immune system and on 
the hormonally-responsive uterus.   
 
DDT exposure has been reported to affect the immune system, such as decreasing human 
natural killer cell lytic function by as much as 55% (Udoji et al., 2010) and modulating 
other humoral and cellular responses in rats (Banerjee et al., 1996).  Furthermore, p,p´ 
DDE is known to modulate immunoglobulin G and antinuclear antibodies in humans  
(Cooper et al., 2004) and it decreased cell viability and proliferation while also increasing 
apoptosis of leukocytes in Chinook salmon, leading to immune suppression (Misumi et 
al., 2005). The basic structure and functional characteristics of fish and mammalian 
immune systems are quite similar (Misumi et al., 2005). Since immune dysfunction can 
influence cancer development, including defects in cytokines (Critchley-Thorne et al., 
2009), pro- and anti-tumor cytokines were measured in the circulating cells of the 
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immune system collected from the spleen as a concentrated source of these leukocytes.  
Four cytokine genes were investigated in leukocytes of MMTV mice treated for 2 months 
in the DDT-02 study, interleukin 10 (il10), interleukin 12 (il12), interleukin 18 (il18), and 
                           β1  tgfb1).    
 
As  , ΄ DDE has anti-androgenic actions in vitro and in vivo in male rats (Kelce et al., 
1995), the presence of circulating levels may influence hormonally-responsive tissues 
outside the mammary gland, such as the uterus.  If the serum levels of  , ΄ DDE 
stimulate or repress uterine wet, these data would suggest that exposure to this endocrine 
disruptor may modify the systemic hormone environment. The uterine wet weight was 
investigated in all three animal studies, Pretumor, DDT-01, and DDT-02 studies after two 
months of exposure.   
 
These endpoints were examined in mice treated with hydroxyflutamide (OH-flut) in 
comparison to  , ΄ DDE to see if this isomer mimics the actions of the pharmaceutical 
anti-androgen. In addition, as p,p´ DDT has anti-androgenic actions (Kelce et al., 1995) 
and has been associated with increased breast cancer risk in an epidemiology study (Cohn 
et al., 2007), its effects alone and in combination with  , ΄ DDE were also investigated.  
Effects on uterine wet weight from varying doses of  , ΄ DDE and in ratios with the 
estrogenic isomer, o, ΄ DDE, were also examined in animals from DDT-01 studies.  






Chapter 2 includes the methods on total RNA isolation, cDNA reverse transcriptase 
reactions, real time RT-PCR, relative gene expression and statistical analysis that apply to 




Cytokine Expression in Splenic Leukocytes  
To test whether local administration of  , ΄ DDE to the mammary gland has systemic 
effects on immune functions, gene expression of anti- and pro-tumor cytokines 
interleukin 10 (il10), interleukin 12 (il12), interleukin 18 (il18), and transforming growth 
       β1  tgfb1) were measured in isolated splenic leukocytes by real-time RT-PCR (Fig. 
42).  The expressions of il12 (anti-tumor) and il18 (pro-inflammatory) genes were 
minimally altered by p,p´ DDE  as their levels were similar to the control group (Fig. 42). 
However, the il10 gene, which codes for the cytokine that inhibits cell functions such as 
T-helper cell activity (Kundu et al., 1996), was significantly decreased by treatment with 
5 µg/pellet p,p´ DDE (p=0.008, Mann Whitney). The gene for tgfb1, which codes for the 
growth factor that is considered to have both pro-and anti-tumor activities (Cox et al., 
2007), was significantly up-regulated by 5 µg/pellet p,p´ DDE treatment (p=0.01, Mann 
Whitney). These data demonstrate that local administration of p,p´ DDE to the mammary 
gland produced systemic effects within the leukocytes and modulated genes involved in 
immune function.  
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Figure  42.  Expression of cytokines il10 and tgfb1 were significantly modified by 
p,p´ DDE in splenic leukocytes. Local exposure of p,p´ DDE in the mammary gland of 
MMTV-neu females treated for 2 months elevated significant changes in expression of 
genes for the cytokines il10 (p<0.009) and tgfb1 (p<0.013) in splenic leukocytes. Genes 
for the cytokines il12 and il18                                 ΔC         normalized level 
of gene expression compared to the housekeeper ppia                        ΔC     
indicative of a higher abundance of message. Numbers within each bar represent fold 
change compared to control. The Mann-Whitney test was used for statistical analysis 












Cytokine Expression in Lymph Node-positive Mammary Gland  
As the expression of the cytokines in leukocytes could influence mammary tissue as these 
cells circulate throughout the body, their expressions in lymph node-positive mammary 
glands were examined.  The lymph node would be expected to contain high levels of 
leukocytes, but these immune cells may also be affected by the higher  , ΄ DDE levels in 
the mammary gland versus serum. Therefore, the same four cytokines were also 
examined by real-time RT-PCR in lymph node-positive mammary glands of six animals 
(Fig. 43). The p,p´ DDE treatment did not induce significant changes in expression of the 
genes for cytokines il10, il12, il18 or tgfb1 in the mammary gland; however, tgfb1 
expression approached significance (p =0.065). These data suggest that this cytokine may 























































Figure  43.  p,p´ DDE does not elicit significant changes in expression of genes for 
cytokines il10, il12, il18 or tgfb1 in lymph node-positive mammary gland of MMTV-
neu  mice. Using specific primers for il10, il12, il18 and tgfb1, expression was measured 
by real-time RT-PCR with SYBR-Green detection in lymph node-positive mammary 
glands. None of the cytokines were significantly altered by p,p´ DDE treatment, although 
fold changes were indicative of slight increases in expression in all genes. Additionally, 
tgfb1 expression was nearly significant, having a p value of 0.065  ΔC                    
level of the target gene compared to ppia                           ΔC                  
gene is expressed at a lower level. The numbers within each bar represent the fold change 
compared to control using the 2
-ΔΔC 
 method. A Mann-Whitney test was used for 
statistical analysis (p>0.05). n=6.  
 
 
To compare RNA expression levels in the two tissues (splenic leukocytes and lymph 
node-positive mammary glands), tissue and treatment effects were examined by a two-
way ANOVA. All four immune-related genes examined showed significantly higher 
expression in splenic leukocytes to lymph node-positive mammary glands (Fig. 44).   
This effect is likely due to the multiple cell and tissue types in the mammary gland 
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containing the lymph node which would contribute to the RNA in these samples. Thus, 
the amount of RNA from the leukocytes alone (and not blood or lymphatic vessels, 
mammary tissue, fat, etc.) would be reduced.              ,  , ΄ DDE  treatment effects 
were significant for all genes.  These data indicate that with the exception of il12, there 
were both significant treatment and tissue effects induced by  ,   DDE in theses 
















































Figure  44.  Tissue and treatment effects observed in expression of cytokine genes 
il10, il12, il18 and tgfb1 in splenic leukocytes and lymph node-positive mammary 
glands. Isolated splenic leukocytes (SL) and lymph node-positive mammary glands [LM 
(LN+)] from 6 MMTV-neu animals from the DDT-02 study were prepared into RNA for 
analysis of the cytokine genes by real-time RT-PCR. il10 expression demonstrated an 
overall significant interaction (p=0.0015), with tissue and treatment effects also being 
significant, having p values of 0.0013 and 0.0250, respectively.  Extremely significant 
tissue effects were see with il12 expression (p<0.0001) and il18 and tgfb1 had significant 
tissue and treatment effects without significant interaction. IL18 expression in tissue and 
between treatments had p values of 0.0126 and 0.0475, respectively.  tgfb1 also had 
marked differences in expression when comparing tissue and treatments, have p values of 
Source of Variation p value 
Interaction 0.0015 
SL vs. LM 0.0013 
Control vs. p,p´ DDE  0.0250 
Source of Variation p value 
SL vs. LM <0.0001 
Control vs. p,p´ DDE  0.0015 
Source of Variation p value 
SL vs. LM 0.0126 
Control vs. p,p´ DDE  0.0475 
Source of Variation p value 


















































<     1         15,               ΔC                                                    
when compared to a housekeep such as ppia                        ΔC                
is highly expressed. Two-way ANOVA with Bonferroni post test used for statistical 
analysis (p<0.05). n=6. SL=splenic leukocytes; LM (LN+) = lower mammary, lymph 
node positive.  Expression levels in relative to the control animals (fold difference) are 
noted in Fig. 42 and 43.  
 
 
Cytokine Expression in Leukocytes from Other Treatment Groups 
Cytokine expression in splenic leukocytes was also measured by real-time RT-PCR in the 
additional groups of the DDT-02 study (5 µg/pellet p,p´ DDT  and OH-flut, 2.5 µg/pellet 
p,p´ DDE and p,p´ DDT, and 1:1 ratio) in order to obtain a better understanding of their 
levels in relation to  p,p´ DDE (Fig. 45). Also, cytokine RNA levels were              , ΄ 
DDT-exposed animals to determine if similar patterns of gene expression occurred 
             , ΄ DDE      -androgenic influences on systemic immune effects were 
also tested using 5 µg/pellet of OH-flut.  Similar trends in gene expression for p,p´ DDE 
compared to OH-flut may suggest an anti-androgenic effect by circulating levels of this 
DDT metabolite. Dose effects of p,p΄ DDE                       , ΄ DDE  n  , ΄ DDE’  
action on immune-related genes in splenic leukocytes were also addressed. Cytokine il18 
was not pursued further than the initial tests in control and 5 µg/pellet p,p´ DDE in 
splenic leukocytes and lymph node positive mammary glands because it was shown to 
not be significantly regulated by p,p´ DDE (Fig. 42 & 43).            , ΄ DDE         
significantly modulate the expression of il12 in leukocytes, il12 was explored further 
because of              ’  role as the inverse counterpart to IL10; that is, the ratio of 
these two cytokines (protein) may play a role in mammary tumorigenesis as well as many 
other cancers (Jacobs et al., 1998;Takeuchi et al., 2002; Lopez et al., 2005).  
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tgfb1 expression was significantly up-regulated in mice exposed to 5 µg/pellet p,p´ DDE  
compared not only to the control group, but all other groups as well (p=0.0004, one-way 
ANOVA) (Fig. 45). Additionally, all of the other treatment groups were similar to the 
control group in expression for this cytokine.  Therefore,  , ΄ DDE had a unique response 
that was unlike its lower dose (2.5 µg/pellet); the anti-androgen, OH-flut; the p,p´ DDT 
congener; or the 1:1 ratio of p,p´ DDE:p,p´ DDT.  
 
il10 expression in splenic leukocytes was significantly regulated by all treatments 
(p<0.0001, one-way ANOVA) (Fig. 45) and  gene expression by 5 µg/pellet p,p´ DDE 
was similar to the expression induced by 5 µg/pellet OH-flut. This similarity, may be 
suggestive of a common systemic hormonal influence. For example, both anti-androgens 
(5 µg) significantly downregulated il10 expression compared to control, having fold 
changes of 0.2 and 0.1, respectively. Furthermore, expression induced by  ,   DDE and 
OH-flut was similarly significantly different from 2.5 µg/pellet  ,   DDE and 5 µg/pellet 
 ,   DDT, and their expression was not different from one another. However, il10 
expression by OH-flut was significantly different from two treatment groups, the 1:1 ratio 
and 2.5 µg/pellet  ,   DDT, both of which were not significantly different from 5 
µg/pellet  ,   DDE.  The differential effects on il10 expression of p,p´ DDE and p,p´ 
DDT  are suggestive that these congeners may have different modes of action in 
leukocytes on this cytokine gene and it also demonstrates that dose is an important factor 
as well.  
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Unlike the other two cytokines, expression of il12 in isolated splenic leukocytes was not 
substantially altered in any treatment group compared to control mice. However, because 
IL12 serves as an inverse counterpart to IL10 (Jacobs et al., 1998; Takeuchi et al., 2002; 
Lopez et al., 2005),  ,   DDE- and  ,   DDT-induced changes in il10 mRNA levels 
without changes in il12 mRNA levels could still change the ratio of IL10:IL12 cyotkine 


























































































































































































Figure 45.  Expression of the il10 gene is repressed by both p,p΄ DDE and OH-flut in 
isolated splenic leukocytes.  Real-time RT-PCR with SYBR-Green detection in study 
DDT-02 study animals: Tgfb1 expression was significantly altered by 5 µg/pellet p,p´ 
DDE, which was also significantly different from all other treatments, demonstrating its 
unique action. p,p´ DDE and OH-flut evoked significant repression in il10, having fold-
changes of 0.2 and 0.1, respectively. Their expression was also similarly and significantly 
different from expression induced by 2.5 µg  ,   DDE and 5 µg  ,   DDT. Additionally, 
5 µg/pellet p,p´ DDT was significantly different from OH-flut, possibly suggestive of 
distinct hormonal differences. il12 was not substantially altered in any treatment group. 
ΔC                                     et gene compared to the housekeeper, ppia 
                         ΔC                                                       -way 
 NOV       T    ’                                                <   5   ).*p<0.05, 
**p<0.01, ***p<0.001 = level of significanc     T    ’        (n=4 for 2.5 µg p,p´ 
DDT); (n=6 for control, 5 µg p,p´ DDE, 5 µg p,p´ DDT, 5 µg OH-flut  , 2.5 µg p,p´ DDE 
and 1:1). Significant comparisons are only between the closet hatch mark and the next 
when in a continuous horizontal line. 
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Effects of p,p´ DDE Exposure on Uterine Wet Weight 
 As the uterus is highly responsive to hormone effects, uterine wet weights (normalized to 
body weight) were measured in all three animal studies for mice in estrus at necropsy 
(Fig. 46). There were no significant differences in uterine weight with any treatment 
compared to the control group within each study for the DDT-01, DDT-02 or Pretumor 
studies. However, in the Pretumor study, the OH-flut treatment group was significantly 
                   17β-estradiol (E2) group for uterine weight, demonstrating their unique 
effects on this tissue during the estrus phase of the cycle. As no estrogenic treatments 
were included in the DDT-02 study, no significant effects were observed for OH-flut in 
that study.   
 
To ensure that the body weights were similar for the normalized uterine weights and for 
examining treatment effects on the mice, the animal weight was measured at necropsy 2 
months after implant surgery.  The significant difference between the 17-estradiol and 
OH-flut groups in the Pretumor study observed for uterine weight was also evident in 
body weight. Other than OH-flut, little variation in body weight was evident between the 
control group and the treatments within each study.  These results suggest the animals in 
all studies were healthy and did not have any major adverse effects with DDT congener 





















































































































































































































































































































































































































































Figure 46.  Body weights and uterine weights of < 3-month-old MMTV-neu mice in 
Pretumor, DDT-01 and DDT-02 studies were unaffected by treatment. At 
termination of the study, body weights and uterine wet weights were taken at necropsy. 
Uterine weights, only for mice in estrus at necropsy, are shown in the right panels. No 
significant difference in either weight was observed compared to control, in all studies; 
suggesting there were no adverse treatment effects and the animals remained healthy. 
However, in pretumor animals, T    ’              body weights in the OH-flut group 
were significantly different from both the estrogenic treatments of 5 µg/pellet o,p´ DDE 
and 2.5 ng E2. Similarly, uterine weights in the pretumor animals of the OH-flut group 
were also significantly different from the 2.5 ng E2 group.  Uterine weight p value 
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equaled 0.04. One-way ANOVA was used for statistical analysis (p>0.05). n=19-20 


















































Decreased immune surveillance and overall immune dysfunction play a vital role in 
cancer development, promotion and progression and may also have a role in the 
accelerated mammary tumor onset by p,p´ DDE.  DDT and its metabolites have been 
reported to modulate immune responses in humans (Cooper et al., 2004), by negatively 
affecting human natural killer cells (Udoji et al., 2010), and producing modest increases 
in white blood cells, lymphocytes and immunoglobulin A levels, indicative of  DDT 
having the ability to evoke immune response (Vine et al., 2001). Furthermore, Dutta and 
colleagues (2008) have reported that DDT is able to activate the complement system, 
induce the significant production of tumor necrosis factor-α                     
macrophages and contribute to inflammatory reactions, cytokine imbalance and immune 
dysregulation. Due to the ability of DDT to influence the immune system, isolated 
leukocytes from the spleen provided an ideal tissue to examine host defense mechanisms 
                , ΄ DDE   S                                                          
immune syst                 , ΄ DDE    C               M            , 2  5   B     
structure and functional characters of fish and mammalian immune systems are quite 
similar and their findings also revealed immune suppression, by direct action of DDE on 
leukocytes.  Message levels of the cytokines with both pro- and anti-tumor properties 
were also examined in lymph node-positive mammary glands for local immune responses 
in the gland.  The following cytokines were investigated:  interleukin 10 (il10), 
interleukin 12 (il12), interleukin 18 (il18),                                β1  tgfb1), 
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whose functions are to regulate differentiation, growth, and activity of different immune 
cells, thereby influencing the immune response, both locally and systemically. 
 
Interleukin 10 is a potent anti-inflammatory cytokine, capable of down regulating 
antigen-specific immune responses by inhibiting cytokine production (Heckel et al., 
2011) and T-cell response (Woo et al., 2007). TGF1 has been described as both a tumor 
suppressor and a tumor promoter (Cox et al., 2007), with conflicting results regarding its 
association with breast cancer. Its signaling has been reported to elicit a preventative or 
tumor suppressive effect during earlier stages of tumorigenesis, but later in tumor 
development, when carcinoma cells become refractory to TGF-mediated growth 
inhibition, response to TGF1 signaling elicits predominately tumor progressing effects 
(Connolly and Akhurst 2011). It has also been shown to prevent T-cell proliferation and 
is associated with increased invasiveness and metastasis (Heckel et al., 2011). Interleukin 
12 is a major inducer of Th1 T-cell differentiation and cytokine production, including the 
induction of interferon gamma production by T-cell response (Heckel et al., 2011). 
Lastly, interleukin 18 is a pro-inflammatory, systemic cytokine produced by activated 
macrophages, epithelial cells and cancer cells and has well known anti-tumor activity 
(Park et al., 2009). It also promotes the differentiation of T-cells and enhances the 
cytotoxic activities of natural killer cells. (Khalili-Azad et al., 2009). (See Chapter 4 for 
more background on the functions of these cytokines.) 
 
The significant changes in expression of il10 and tgfb1     , ΄ DDE                     
cytokines may have a role in the early onset of mammary cancer in the MMTV-neu mice.  
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However, it is unknown if the protein levels of these cytokines correlate with their 
messages and, accordingly, their function.   
  
E            , ΄ DDE      -androgenic action was observed with il10 expression in 
splenic leukocytes. The 5 μ  dose of  , ΄ DDE                                             
gene (0.2-fold) as did the equivalent dose of OH-flut (0.1-fold). An attenuation of il10 
expression could potentially mean there is a need for increased immune involvement 
following p,p´ DDE and/or anti-androgenic exposure. Additionally, both these treatments 
were significantly different from the 2.5 µg dose of  ,   DDE and the 5 µg dose of  ,   
DDT. This similarity in expression supports that  , ΄ DDE is acting as an anti-androgen.  
The exact roles and mechanisms of androgens in mammary carcinogenesis remain 
undefined (Liao et al., 2002; Suzuki et al., 2010); however, one well accepted notion is 
that androgens counteract or inhibit estrogen-induced mammary epithelial and breast cell 
proliferation (Zhou et al., 2000; Dimitrakakis et al., 2003; Hofling et al., 2007). With this 
activity, it is conceivable that blocking androgen action with an anti-androgen, such as 
 , ΄ DDE     OH-flut, could result in increased proliferation and, thus, tumorigenesis by 
interfering with hormonal actions that  influence mammary tumor development 
(Desaulniers et al., 2001). Therefore, the anti-                       , ΄ DDE   e one 
means for its cancer-promoting activity.  
 
In t                ,  , ΄ DDE                                                        
the cytokines. Also, p,p´ DDT                1:1             , ΄ DDE        node-positive 
mammary glands did not significantly alter the expression of tgfb1, Il10, or il12, although 
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organochlorine pesticides, including  , ΄ DDT, have been shown to affect interleukin 
secretion from lymphocytes (Beach and Whalen 2006).  The lack of significant 
expression in the mammary gland could be due to several effects. First, it may be 
suggestive of a homeostatic immune environment. Expression similar to control may 
have been caused by the immunologic balance being properly maintained within the 
microenvironment of the gland. Another reason could be that there may have been no 
significant changes in immune expression with the chosen markers due to hormonal 
action within the gland, as hormones influence immune function.  The differing levels of 
 , ΄ DDE                                                                              
leukocytes within the lymph node in the mammary glands compared to those observed in 
the leukocytes.  Also, in the mammary gland, other tissues may express some cytokines, 
like TGF1, to contribute to the levels detected from the leukocytes.  Additionally, a 
different percentage of some types of leukocytes may be present in the lymph node 
compared to the spleen, and some subtypes may express the cytokines at different levels.     
 
A significant increase in tgfb1 expression was detected in isolated splenic leukocytes. 
The tgfb1 gene codes for a cytokine that is involved in many different processes, 
including cell differentiation and proliferation, inflammation, wound healing, cellular 
adhesion, and host immunity (reviewed in Teicher 2001). It has been described as both a 
tumor suppressor and a tumor promoter, with conflicting results regarding its association 
with breast cancer (Cox et al., 2007). Th                           5 μ /        , ΄ DDE 
significantly increased expression of tgfb1 in splenic leukocytes. These increased 
transcript levels could influence  , ΄ DDE  mammary tumor formation, considering the 
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findings of Nicolini and colleagues (2006) who state that cytokines such as TGF1 
stimulate breast cancer proliferation and/or invasion. However, there is also the 
possibility TGF1                                                     , ΄ DDE,  thereby 
regulating events, such as  immune suppression and angiogenesis and, therefore, inducing 
effects that are more protective in the gland. The significant 1.4 fold increase in 
expression is possibly indicative of an induced response to suppress tumor formation as a 
           , ΄ DDE            
 
Conversely, il10 expression was significantly repressed in leukocytes isolated from the 
spleen. However, similar to tgfb1, this cytokine also has both immunosuppressive 
(potentially cancer promoting) and anti-angiogenic (potentially cancer inhibiting) 
properties (Howell et al., 2006). With this in mind, it is difficult to determine exactly 
what role il10 has wit   , ΄ DDE           C                                        
mammary gland, it is possible the function of this cytokine is being modulated by the 
stromal environment, as adipose derived stem cells of breast cancer patients has been 
reported to influence both il10 and tgfb1 expression (Razmkhah et al., 2011).  A decrease 
in il10 expression,                             , ΄ DDE         , could be interpreted as a 
needed anti-tumor event, causing a reduction in the inhibition of cytokine production. 
Woo and colleagues (2007) also found an overexpression of il10 to be correlated with a 
down-regulation in T cell response. These findings are suggestive of il10 repression 
possibly being associated with increased T cell response and tumor formation protection. 
In contrast, il10 has been found to have anti-tumor activity and be a potent anti-metastatic 
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agent in a murine mouse model of breast cancer (Kundu et al., 1996); these findings are 
               , ΄ DDE  acting to reverse these effects.  
 
Additionally, expression of both anti-tumor cytokines il12 and il18 were unaffected by 
 , ΄ DDE                                   T                      latory activity 
taking place is uncertain, despite the significant increase and decrease in expression 
observed with tgfb1 and il10, respectively. No changes in expression imply these two 
                                             , ΄ DDE   H      ,     levels of the 
cytokines need to be measured to determine how the transcript concentrations compare to 
the translated proteins and secreted cytokines.    
 
T                 , ΄ DDE                                                               
exposure to the mammary gland. The lack of significant changes in expression in the 
mammary gland compared to the isolated splenic leukocytes may be the result of 
concentration differences in the tissues. Since the leukocytes were isolated from the 
spleen, cytokine expression is presumably more robust because of the dense population 
of leukocytes, whereas expression in the mammary gland was diluted by the multiple 
tissue and cell types in the gland. Although the mammary gland tissue was lymph node-
positive, the leukocytes were not isolated and, therefore, dispersed amongst all the other 
tissue types of the gland, decreasing their concentration and weakening their expression, 
which is observed by the higher Ct values in the RNAs from the mammary gland versus 
splenic leukocytes. Therefore, treatment effects may be obscured by lower transcript 
levels for the cytokines compared to the increased message levels for the housekeeping 
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gene (present in all cell types in the mammary gland) used for normalizing the 
expression.   
 
Body and Uterine Weights 
For the uterine weight, no changes were detected between the control group and any of 
the treatment groups in three animal studies in the MMTV-neu mice.  If there was higher 
estrogen stimulation as result of one treatment in the intact mice, the uterus might be 
found to have an increased weight (uterotropic effect).  However, as progesterone reduces 
estrogen stimulation in the uterus, a lower uterine weight might be detected for animals 
that enhance its activity or response. The significant differences in uterine weight in the 
Pretumor study between the anti-androgen, OH-flut, and the estrogenic treatments, 5 g 
 , ΄ DDE     17-estradiol, suggests that anti-androgens and estrogens would have 
                                    N                                   , ΄ DDE      
OH-                  ,                                , ΄ DDE      anti-androgenic 
effects in the uterus. Therefore, the lack of difference in uterine weight compared to the 
control groups suggests the DDE isomers and p,p´ DDT do not sufficiently modify the 
hormonal environment in intact mice with endogenous estrogens, progesterone, and 
androgens. However,  ,   DDT concentrations were not measured in serum, therefore it 
cannot be determined if this isomer has a systemic presence after local mammary gland 
administration.  The absence of a systemic effect     , ΄ DDE  on uterine weight may be 
expected  consideri    , ΄ DDE                                                       
than in mammary adipose tissue.  The lack of effect by the DDT congeners is in 
agreement with Desaulniers and colleagues (2005), who also reported a lack of 
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uterotropic effects in Sprague-Dawley rats after exposure to p,p´ DDT, p,p´ DDE, and 
PCBs.    
 
Another systemic exposure endpoint examined was body weight. There has been some 
speculation about the role of endocrine disruptors, which                        ’  
adipose tissue biology, endocrine hormone systems, or central hypothalamic-pituitary-
adrenal axis, thereby altering homeostatic mechanisms important to weight control (Grün 
et al., 2009). In the present study, no change in body weights in both DDT-01 and DDT-
02 studies occurred in response to treatment. Dirinick and colleagues (2010) found no 
association between p, ΄ DDE                           niform body weight among 
animals in all treatment groups in both studies also signifies that  , ΄ DDE               
any adverse effects and that the animals were relatively healthy.  
 
Collectively, these results demonstrate that local             2           , ΄ DDE  has 
systemic effects, by modifying cytokine expression in leukocytes isolated from the 
spleen. Therefore, gene expression and tumor development in the mammary gland may 
be influenced by systemic effects on tissues outside the mammary gland that can impact 
responses within the gland.  In addition, the animals remain relatively healthy with no 
apparent influences on body weights and on the hormonal environment, as observed with 
no significant changes in uterine weight.   
 
This document has not been reviewed or approved by Dr. Vicki Davis, who oversaw the 




Abdel-Fatah TMA, Powe DG, Hodi Z, Reis-Filho JS, Lee HS, Ellis IO. (2008)  
Morphological and molecular evolutionary pathways of low nuclear grade 
invasive breast cancers and their putative precursor lesions: further evidence to 
support the concept of low nuclear grade breast neoplasia family. Am J Surg 
Pathol, 32, 513-523. 
 
Aboghe DH, Bolduc C, Yoshioka M, St-Amand J. (2008) Effects of dihydrotestosterone  
on gene expression in mammary gland. Journal of Steroid Biochemistry & 
Molecular Biology, 111, 225-231. 
 
Aguilo F, Camarero N, Relat J, Marrero P, Haro D. (2010) Transcriptional regulation of 
 the human acetoacetyl-CoA synthetase gene. Biochem. J. 427, 255-264. 
 
Andrecheck ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ. (2000)  
Amplification of the neu/erbB-2 oncogene in a mouse model of mammary 
tumorigenesis. PNAS, 97 (7), 3444-3449. 
 
Ankrapp DP, Bennett JM, Haslam SZ. (1998) Role of epidermal growth factor in the 
acquisition of ovarian steroid hormone responsiveness in the normal mouse 
mammary gland. Journal of Cellular Physiology, 174, 251-260. 
 
Archibeque-Engle SL, Tessari JD, Winn DT, Keefe TJ, Nett TM, Zheng T. Comparison  
of organochlorine pesticide and polychlorinated biphenyl residues in the human 
breast adipose tissue and serum. J Toxicol Environ Health, 52, (4), 285-293. 
 
Aubé M, Larochell C, Ayotte P. (2011) Differential effects of a complex organochlorine  
mixture on the proliferation of breast cancer cell lines. Environmental Research, 
111, 337-347. 
 
Bagga D, Anders KH, Wang HJ, Roberts E, Glaspy JA. (2000) Organochlorine pesticide  
content of breast adipose tissue from women with breast cancer and control 
subjects. Journal of the National Cancer Institute, 92 (9), 750-753. 
 
Banerjee BD, Ray A, Pasha ST. (1996) A comparative evaluation of immunotoxicity of  
DDT and its metabolites in rats. Indian Journal of Experimental Biology, 34, 517-
522. 
 
Barraza-Vazquez A, Borja-Aburto V, Bassol-Mayagoitia S, Monrroy A, Recio-Vega R. (2008) 
Dicholordiphenyldichloroethylene concentrations in umbilical cord of newborns and 
determinant maternal factors.  Journal of Applied Toxicology; 28: 27-34. 
 
Barash I, Faerman A, Puzis R, Peterson D, Shani M. (1995) Synthesis and secretion of  
caseins by the mouse mammary gland: production and characterization of new 
polyclonal antibodies. Molecular and Cellular Biochemistry, 144, 175-180. 
 168 
 
Beach TM, Whalen MM. (2006) Effects of organochlorine pesticides on interleukin  
secretion from lymphocytes. Human & Experimental Toxicology, 25, 651-659.  
 
Benz CC, Yau C. (2008) Ageing, oxidative stress and cancer: paradigms in parallax.  
Nature Reviews Cancer, 8(11), 875-879.  
 
Bernanke J, Köhler HR. (2009) The impact of environmental chemicals on wildlife  
vertebrates. Rev Environ Contam Toxicol, 198, 1-47. 
 
Bertin N, Clezardin P, Jubiak R, Frappart L.(1997) Thrombospondin-1 and -2 messenger  
RNA expression in normal, benign and neoplastic human breast tissues: 
correlation with prognostic factors, tumor angiogenesis and fibroblastic 
desmoplasia. Cancer Research, 57, 396-399. 
 
Böcker W, Hungermann D, Decker T. (2009) Anatomy of the breast. Pathologe, 30 (1),  
6-12. 
 
Bordon A, Bosco N, Du Rourne C, Bartholdy B, Khler H, Matthias G, Rolink AG, 
Matthias P. (2008) Enforced expression of the transcriptional coactivator OBF1 
impairs B cell differentiation at the earliest stage of development. PLoS ONE, 3, 
e407. doi:10.1371/journal.pone.0004007. 
 
B       C, O’M      B   2 1   H                                    Cold Spring 
Harb Perspect Biol, 2:a003178 
 
Brody JG, Aschengrau A, McKelvey W, Rudel RA, Swartz CH, Kennedy T. (2004) 
Breast cancer risk and historical exposure to pesticides from wide-area 
applications assessed with GIS. Environmental Health Perspectives, 112 (8), 889-
897. 
 
Brown LR, Wei CL, Langer R. (1983) In vivo and in vitro release of macromolecules  
from polymeric drug delivery systems. Journal of Pharmaceutical Sciences, 
72(10), 1181-1185.  
 
Brown NM, Lamartiniere CA. (1995) Xenoestrogens alter mammary gland  
differentiation and cell proliferation in the rat. Eviron Health Perspect, 103 (7-8), 
708-713. 
 
Calabrese EJ. (2002) Hormesis: changing view of the dose-response, a personal account  
of the history and current status. Mutat Res, 511,181-189. 
 
 
Candia P, Akram M, Benezra R, Broga E. (2006) Id4 messenger RNA and estrogen 
receptor expression: inverse correlation in human normal breast epithelium and 
carcinoma. Human Pathology, 37, 1032-1041. 
 169 
 
Cassidy RA, Natarajan S, Vaughan GM. (2005) The link between the insecticide 
hepatachlor epoxide, estradiol, and breast cancer. Breast Cancer Res Treat, 90(1), 
55-64. 
 
Cato ACB, Henderson D, Ponta H. (1987) The hormone response element of the mouse  
mammary tumor virus DNA mediates the progestin and androgen induction of 
transcript in the proviral long terminal repeat region. The EMBO Journal, 6 (2), 
363-368. 
 
Chambo-Filho A, Camargos AF, Pereira FEL. (2005) Morphological changes induced by 
testosterone in the mammary glands of female wistar rats. Brazilian Journal of 
Medical and Biological Research, 38, 553-558. 
 
Charlier C, Albert A, Herman P, Hamoir E, Gaspard U, Meurisse M, Plomteux G. (2003)  
Breast cancer and serum organochlorine residue. Occup Environ Med, 60, 348-
351. 
 
Cebrain A, Pharoah PD, Ahmed S, Smith PL, Luccarini C, Luben R, Redman K, Munday 
H, Easton DF, Dunning AM, Ponder BA. (2006) Tagging single-nucleotide 
polymorphisms in antioxidant defense enzymes and susceptibility to breast 
cancer. Cancer Res, 66(2), 1225-1233. 
 
Chen CL, Chu JS, Su WC, Huang SC, Lee WY. (2010) Hypoxia and metabolic    
phenotypes during breast carcinogenesis: expression of HIF-1α, GLUT-1, and 
CAIX. Virchows Arch, 457, 53-61. 
 
Chen SC, Vassileva G, Kinsley D, Holzmann S, Manfra D, Wiekowski MT, Romani N,  
Lira SA. (2002) Ectopic expression of the murine chemokines CCL21a and 
CCL21b induces the formation of lymph node-like structures in pancreas, but not 
skin, of transgenic mice. The journal of Immunology, 168, 1001-1008. 
 
Cimpean AM, Raica M, Izvernariu DA, Tatucu D. (2007) Lymphatic vessels identified 
with podoplanin. Comparison of immunostaining with three different detection 
systems. Romanian Journal of Morphology and Embryology, 48,139-143. 
 
Clarke CL, Sandle J, Parry SC, Reis-F     JS, O’H    MJ, L       SR   2  4   
Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell 
phenotype. Journal of Pathology, 204, 147-152. 
 
Cocco P. (2002) On the rumors about the silent spring. Review of the scientific evidence  
linking occupational and environmental pesticide exposure to endocrine 





Cohn, BA. (2011) Developmental and environmental origins of breast cancer: DDT as a  
case study. Reproductive Toxicology, 31 (3), 302-311. 
 
Cohn, BA, Wolff MS, Cirillo PM, Sholtz RI. (2007) DDT and breast cancer in young  
women: new data on the significance of age at exposure. Environ Health Perspect 
115 (10), 1406-1414. 
 
Connolly EC, Akhurst RJ. (2011) The complexities of TGF-β                       
 and squamous cell carcinogenesis. Curr Pharm Biotechnol, [Epub ahead of print] 
 
 
Cooper GS, Martin SA, Longnecker MP, Sandler DP, Germolec DR. (2004) Associations  
between plasma DDE levels and immunologic measures in African-American 
farmers in North Carolina. Environmental Health Perspectives, 112 (12), 1080-
1084. 
 
Cox DG, Penney K, Guo Q, Hankinson SE, Hunter DJ. (2007) TGFB1 and TGFBR1  
                                            N    ’  H      S      BMC Cancer, 
11 (7), 175.  
 
Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, 
Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP. (2009) 
Impaired interferon signaling is a common immune defect in human cancer. 
PNAS, 106 (22), 9010-9015. 
 
Darbre P, Page M, King RJ. (1986) Androgen regulation by the long terminal repeat of 
 mouse mammary tumor virus. Molecular and Cellular Biology, 6, 2847-2854. 
 
Davis VL, Jayo MJ, Ho A, Kotlarczyk MP, Hardy ML, Foster WG, Hughes CL. (2008) 
Black cohosh increases metastatic mammary cancer in transgenic mice expressing 
c-erbB2. Cancer Research, 68 (20), 8377-8383. 
 
  
De Candia P, Muzaffar A, Benezra R, Brogi E. (2006) Id4 messenger RNA and estrogen 
receptor expression: inverse correlation in human normal breast epithelium and 
carcinoma. Human Pathology, 37, 1032-1041. 
 
Dees C, Askari M, Foster JS, Ahamed S, Wimalasena J. (1997) DDT mimics estradiol  
stimulation of breast cancer cell to enter the cell cycle. Molecular Carcinogenesis, 
17, 107-114. 
 
Dell-Orso S, Ganci F, Blandino G, Fontemaggi G. (2010) ID4: a new player in the cancer 





Deng SS, Xing TY, Zhou HY, Xiong RH, Lu YG, Wen B, Liu SQ, Yang HJ. (2006) 
Comparative proteome analysis of breast cancer and adjacent normal breast 
tissues in human. Genomics Proteomics Bioinformatic, 4(3), 165-172. 
 
Denkert C, Liobl S, Noske A, Roller M, Muller M, Komor M, Dudczies J, Darb-Esfahani 
S, Kronenwett, R, Hausch C, von Torne C, Weichert W, Engels K, Solbach C, 
Schrader I, Dietel M, von Minckwitz G. (2010) Tumor-associated lymphocytes as 
an independent predictor of response to neoadjuvant chemotherapy in breast 
cancer. J Clin Oncol, 28, 105-113. 
 
Desaulniers D, Leingartner K, Russo J, Perkins G, Chittim BG, Archer MC, Wade M,  
Yang J. (2001) Modulatory effects of neonatal exposure to TCDD, or a mixture of 
PCBs, p,p´ DDT ,  , ΄ DDE ,       ylnitrosourea-induced mammary tumors 
development in the rat. Environ Health Perspect, 109 (7), 739-747. 
 
Desaulniers D., Cooke G, Leingartner K, Soumano K, Cole J, Yang J, Wade M,  
Yagminas A. (2005) Effects of postnatal exposure to a mixture of polychlorinated 
biphenyls, p,p´ DDT      , ΄ DDE ,                                 S      - 
dawley rats. International Journal of Toxicology, 24, 111-127. 
 
Dierickx D, Delannoy A, Saja K, Verhoef G, Provan D. (2011) Anti-CD20 monoclonal 
antibodies and their use in adult autoimmune hematological disorders. Am. J. 
Hematol., 86, 278-291. 
 
Dillon RL, Brown ST, Ling C, Shioda T, Muller WJ. (2007) An EGR2/CITED1  
transcription factor complex and the 14-3-3 tumor suppressor are involved in 
regulating erbB2 expression in a transgenic-mouse model of human breast cancer. 
Molecular & Cellular Biology, 27 (4), 8648-8657. 
 
Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C.  
(2003) A physiologic role for testosterone in limiting estrogenic stimulation of the 
breast. Menopause, 10 (4), 292-298. 
 
Dirinck E, Jorens PG, Covaci A, Geens T, Roosens L, Neels H, Mertens I, Van Gaal L.  
(2010) Obesity and  persistent organic pollutants: possible obesogenic effect of 
organochlorine pesticides and polychlorinated biphenyls. Obesity, 19 (4), 709-
714. 
 
Dorgan JF, Brock JW, Rothman N, Needham LL, Miller R, Stephenson GE, Schussler N 
Taylor PR. (1999) Serum organochlorine pesticide and PCBs and breast cancer 
risk: results from a prospective analysis (USA). Cancer Causes and Control, 10, 
1-11. 
 
Dutta R, Mondal AM, Arora V, Nag TC, Das N. (2008) Immunomodulatory effect of  
DDT (bis[4-chlorophenyl]-1,1,1-trichloroethane) on complement system and 
macrophages. Toxicology, 252, 78-85. 
 172 
 
Einbond LS, Su T, Wu HA, Friedman R, Wang X, Jiang B, Hagan T, Kennelly E,  
Kronenberg F, Weinstein IB. (2007) Gene expression analysis of the mechanisms 
whereby black cohosh inhibits human breast cancer cell growth. Anticancer 
Research, 27, 697-712. 
 
Eskenazi B, Chevrier J, Rosas LG, Anderson HA, Bornman MS, Bouwman H, Chen A,  
Chon BA, de Jager C, Henshel DS, Leipzig F, Leipzig JS, Lorenz EC, Snedeker 
SM, Stapleton D. (2009) The pine river statement: human health consequences of 
DDT use. Environmental Health Perspectives, 117 (9), 1359-1367. 
 
Fielden MR, Fong CJ, Haslam SZ, Zacharewski TR. (2002) Normal mammary gland  
morphology in pubertal female mice in utero and lactational exposure to genistein 
at levels comparable to human dietary exposure. Toxicology Letters, 133, 181-
191. 
 
Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM. (2009) Involvement of a novel chemokine 
decoy receptor CCX-CKR in breast cancer growth, metastasis and patient 
survival. Clin Cancer Res, 15, 2962-2970. 
 
Foster W, Chan S, Platt L, Hughes C. (2000) Detection of endocrine disrupting chemicals in  
samples of second trimester human amniotic fluid. Journal of Clinical Endocrinology 
and Metabolism 85: 2954-2957 
 
Franzén B, Linder S, Alaiya AA, Eriksson E, Uruy K, Hirano T, Okuzawa K, Auer G.  
(1996) Analysis of polypeptide expression in benign and malignant human breast 
lesions: down-regulation of cytokeratins. British Journal of Cancer, 73, 1632-
1638. 
 
Fukushima S, Kinoshita A, Puatanachokchai R, Kushida M, WanibuchiA, Morimura K.  
(2005) Hormesis and dose-response-mediated mechanisms in 
carcinogenesis:evidence for a threshold in carcinogenicity of non-genotoxic 
carcinogens. Carcinogenesis, 26 (11), 1835-1845. 
 
Furuta J, Okuda H, Koayashi A, Watabe K. (2010) Metabolic genes in cancer; their roles  
in tumor progression and clinical implications. Biochemic et Biophsyica Acta, 
1805, 141-152. 
 
Gatto NM, Longnecker MP, Press MF, Sullivan-Halley J, McKean-Cowdin R, Bernstein  
L. (2007) Serum organochlorines and breast cancer: a case-control study among 
African American women. Cancer Causes Control, 18, 29-39. 
 
Glover JF, Darbe PD. (1989) Multihormonal regulation of MMTV-LTR in transfected T- 
47-D human breast cancer cells. Journal of Steroid Biochemistry, 32 (3), 357-363. 
 
Grün R, Blumberg B. (2009) Endocrine disrupters as obesogens. Molecular and Cellular 
Endocrinology, 304, 19-29. 
 173 
 
Günzburg WH, Salmons B. (1992) Factors controlling the expression of mouse 
 mammary tumor virus. Biochem. J., 283, 625-632. 
 
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. (1992)  
Expression of the neu protooncogene in mammary epithelium of transgenic mice 
induces metastatic disease. Proc. Natl. Acad., 89, 10578-10582. 
 
Hallen LC, Burki Y, Ebeling M, Broger C, Siegrist F, Oroszlan-Szovik K, Bohrmann B,  
Certa U, Foser S. (2007) Antiproliferative activity of the human IFN-α-Inducible 
Protein IFI44. Journal of Interferon & Cytokine Research, 27, 675-680. 
 
Haslam SZ. (1988) Local versus systemically mediated effects of estrogen on normal 
mammary epithelial cell deoxyribonucleic acid synthesis. Endocrinology, 122 
(3), 860-867. 
 
Heckel MC, Wolfson A, Slachta CA, Schwarting R, Salgame P, Katsetos CD, Platsoucas 
CD. (2011) Human breast tumor cells express IL-10 and IL-12p40 transcripts and 
proteins, but do not produce IL-12p70. Cellular Immunology, 266, 143-153. 
 
Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T,  
Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, 
Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyotylaninen T, 
Kallioniemi O, lljin, Oresic M. (2011) Novel theranostic opportunities offered by 
characterization of altered membrane lipid metabolism in breast cancer 
progression. Cancer Res,71 (9), 3236-3245. 
 
Hofling M, Hirschberg AL, Skoog L, Tani E, Hägerström T, Schoultz BV. (2007) 
Testosterone inhibits estrogen/progesterone-induced breast cell proliferation in 
postmenopausal women. Menopause, 14 (2), 183-190. 
 
Holloway AC, Stys KA, Foster WG. (2005) DDE-induced changes in aromatase activity  
in endometrial stromal cells in culture. Endocrine, 27 (1), 45-50. 
 
Howell WM, Rose-Zerilli MJ. (2006) Interleukin-10 polymorphisms, cancer  
susceptibility and prognosis. Familial Cancer, 5, 143-149. 
 
Hoshino Y, Katsuno Y, Ehata S, Miyazono K. (2011) Autocrine TGF-β                 
cancer cells from apoptosis through reduction of BH3-only protein, Bim. J 
Biochem, 149 (1), 55-65. 
 
Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES,  
Liao M, Chen CM, West M, Nevins JR, Huang AT. (2003) Gene expression 




Huang HY, Ho CC, Huang PH, Hsu SM. (2001) Co-expression of VEGF-C and its  
receptors VEGFR-2 and VEGFR-3 in endothelial cell of lymphangioma. 
Implications in autocrine or paracrine regulation of lymphangioma. Lab Invest, 
81(12), 1729-1734. 
 
Hutchinson JN, Muller WJ. (2000) Transgenic mouse models of human breast cancer.  
Oncogene, 19, 6130-6137. 
 
Iscan M, Coban T, Cok I, Bulbul D, Eke BC, Burgas S. (2002) The organochlorine  
pesticide residues and antioxidant enzyme activities in human breast tumors: is 
there any association? Breast Cancer Res Treat., 72(2), 173-182. 
 
Iwasaki M, Inoue M, Sasazuki S, Kurahashi N, Itoh H, Usuda M, Tsugane S. (2008) 
Plasma organochlorine levels and subsequent risk of breast cancer among 
Japanese women: a nested case-control study. Science of the Total Environment, 
402, 176-183. 
 
Jacobs N, Giannini SL, Doyen J, Baptista A, Moutschen M, Boniver J, Delvenne P.  
(1998) Inverse modulation of IL-10 and IL-12 in the blood of women with 
preneoplastic lesions of the uterine cervix. Clin Exp Immunol., 111(1), 219-224. 
 
Jacobs SR, Michalek RD, Rathmell JC. (2010) IL-7 is essential for the homeostatic 
 control of T cell metabolism in vivo. J Immunol., 184, 3461-3469. 
 
Jaga K, Dharmani C. (2003) Global surveillance of DDT and DDE levels in human 
tissue. International Journal of Occupational Medicine and Environmental 
Health, 16 (1), 7-20. 
 
Ji RC, Eshita Y, Xing L, Miura M. (2010) Multiple expressions of lymphatic markers and  
morphological evolution of newly formed lymphatics in lymphangioma and 
lymph node lymphaniogenesis. Microvascular Research, 80:195-201. 
 
Jurgen V, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R, Dahl E. (2008)  
Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in 
human breast cancer is associated with unfavorable prognosis. Carcinogenesis, 29 
(5), 991-998. 
 
Kang KS, Wilson MR, Hayshi T, Change CC, Trosko JE. (1996) Inhibition of gap  
junctional intercellular communication in  normal human breast epithelial cells 
after treatment with pesticides, PCBs, and PBBs alone or in mixtures. Environ 







Kelce WR, Stone CR, Laws SC, Gray LE, Kemppalnen JA, Wilson EM. (1995)  
Persistent DDT metabolite  , ΄ DDE is a potent androgen receptor antagonist. 
Nature, 375,581-585. 
 
Kelce WR, Lambright CR, Gray LE, Roberts K. (1997) Vinclozolin and  , ΄ DDE  alter  
androgen-dependent gene expression: in vivo confirmation of an androgen 
receptor-mediated mechanism. Toxicology and Applied Pharmacology, 142, 192-
200. 
 
Khalili-Azad T, Razmkhah M, Ghiam AF, Doroudchi M, Talei AR, Mojtahedi A,  
Ghaderi A. (2009) Association of interleukin-18 gene promoter polymorphisms 
with breast cancer. Neoplasma, 56, doi:10.4149/neo_2009_01_22. 
 
Kho Y, Kim S, Yoon BS, Moon JH, Kim B, Kwak S, Woo J, Oh S, Hong K, Kim S, Kim 
H, You S, Choi Y. (2008) Induction of serum amyloid A genes is associated with 
growth and apoptosis of HC11 mammary epithelial cells. Biosci. Biotechnol. 
Biochem, 72(1), 70-81. 
 
Kortenkamp A. (2006) Breast cancer, oestrogens and environmental pollutants: a re- 
evaluation from a mixture perspective. International Journal of Andrology, 29, 
193-196. 
 
Kriger N, Wolff MS, Hiatt RA, Rivera M, Bogelman J, Orentreich N. (1994) Breast 
cancer and serum organochlorines: a prospective study among white, black and 
asian women. Journal of the National Cancer Institute, 86 (8), 589-599. 
 
Kundu N, Beaty TL, Jackson MJ, Fulton AM. (1996) Antimetastatic and antitumor  
activities in interleukin 10 in a murine model of breast cancer. Journal of the 
National Cancer Institute, 88, 536-541. 
 
Laden F, Hankinson SE, Wolff MS, Colditz GA, Willett WC, Speizer FE, Hunter DJ. 
(2001) Plasma organochlorine levels and the risk of breast cancer and extended 
follow-                ’               Int. J. Cancer, 91, 568-574. 
 
Langer R, Folkman J. (1976) Polymers of the sustained release of proteins and other  
macromolecules. Nature, 263 (5580), 797-800. 
 
Laubli H, Borsig L. (2010) Selectins as mediators of lung metastasis. Cancer  
Microenvironment 3:97-105. 
 
Leung PS, Wong TP, Chung YW, Chan HC. Androgen dependent expression of AT1  






Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, Zeng R, Wu J, Lu JS, Di GH, Ou 
ZL, Xia QC Shen ZZ, Shao ZM. (2006) Identification of breast cancer 
metastasis-associated proteins in an isogenic tumor metastasis model using two-
dimensional gel electrophoresis and liquid chromatography-ion trap-mass 
spectrometry. Proteomics, 6 (11), 3352-3368. 
 
Li J, Li N, Ma M, Giesy JP, Wang Z. (2008) In vitro profiling of the endocrine disrupting 
 potency of organochlorine pesticides. Toxicol Lett, 183 (1-3), 65-71. 
 
Li J, Takaishi K, Cook W, McCorkle SK, Unger RH. (2003) Insig-1 “      ”              
in adipocytes and inhibits differentiation of preadipocytes. PNAS, 100 (16), 9476-
9481. 
 
Liao D, Dickson R. (2002) Roles of androgens in the development, growth, and  
carcinogenesis of the mammary gland. Journal of Steroid Biochemistry & 
Molecular Biology, 80, 175-189. 
 
Livak KJ, Schmittgen TD. (2001) Analysis of relative gene expression data using real- 
time quantitative PCR and the 2
-ΔΔC 
 method. Methods, 25, 402-408. 
 
Long M, Andersen BS, Lindh CH, Hagmar L, Giwercman A, Manicardi GC, Bizzaro D,  
Spano M, Toft G, Pedersen HS, Zvyezday V, Bonde JP, Bonefeld-Jorgensen EC. 
(2006) Dioxin-like activities in serum across European and Inuit populations. 
Environmental Health: A Global Access Science Source, 25 (5), 14. 
doi:10.1186/1476-069X-5-14. 
 
Lopez MV, Adris SK, Bravo AL, Chernajovsky Y, Podhajcer OL. (2005) IL-12 and IL- 
10 expression synergize to induce the immune-mediated eradication of 
established colon and mammary tumors and lung metastasis. Journal of 
Immunology, 175(9) 5885-5894. 
 
Lό   -Carrillo L, Torres-Sá      L, Lό   -Cervantes M, Blair A, Cebrián ME, Uribe M. 
(1999) The adipose tissue to serum dichlorodiphenyldichloroethane (DDE) ratio: 
some methodological considerations. Environmental Research Section A, 81, 142-
145. 
 
Lowery JT, Byers T, Kittelson J, Hokanson JE, Mouchawar J, Lewin J, Merrick D, Hines  
L, Singh M. (2011) Differential expression of prognostic biomarkers between 
interval and screen-detected breast cancers: does age or family history matter? 
Breast Cancer Res Treat, doi: 10.1007/s10549-011-1448-8. 
 
Ludewig G, Lehmann L, Esch H, Robertson LW. (2008) Metabolic activation of PCBs to 





MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras  
VG, Yuasa S. (1970) Age at first birth and breast cancer risk. Bull World Health 
Organ, 43(2), 209-221. 
 
Malinowska K, Cavarretta IT, Susani M, Wrulich OA, Uberall F, Kenner L, Lulig Z.  
(2009) Identification of mu-cyrstallin as an androgen-regulated gene in human 
prostate cancer. Prostate, 69(10), 1109-1118. 
 
Marshall D, Hardman MJ, Neild KM, Byrne C. (2001) Differentially expressed late  
constituents of the epidermal cornified envelope. Proc Natl Acad Sci USA, 98(23), 
13031-13036. 
 
Mattila MM, Tarkkonen KM, Seppanen JA, Ruohola JK, Valve EM, Harkonen PL.  
(2006) Androgen and fibroblast growth factor 8 (FGF8) downregulation on 
thrombospondin1 (TSP1) in mouse breast cancer cells. Mol Cell Endocrinol, 
253(1-2), 36-43. 
 
McDermott SP, Wicha MS. (2010) Breast tumors: of mice and women. Breast Cancer  
Research, 12 (3), 108. doi: 10.1186/bcr2569. 
 
Medina D, Schwartz M, Taha M, Oborn CJ, Smith GH. (1987) Expression of  
differentiation-specific proteins in preneoplastic mammary tissues in BALB/c 
mice. Cancer Research, 47, 4686-4693. 
 
Mern DS, Hoppe-Seyler K, Hoppe-Seyler F, Hasskarl J, Burwinkel B. (2010) Targeting  
Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell 
cycle arrest and apoptosis in breast cancer cells. Breast Cancer Res Treat, 124, 
623-633. 
 
Misumi I, Vella AT, Leong JC, Nakanishi T, Schreck CB. (2005)  , ΄ DDE  depresses  
the immune competence of Chinook salmon (Oncorhynchus tshawytscha) 
leukocytes. Fish & Shellfish Immunology, 19, 97-114. 
 
Morgan D, Roan CC. (1975) The metabolism of DDT in man. Essays in Toxicology  
(Hayes WJ, ed). New York: Academic Press, 39-97. 
 
Muhlebach S, Moor MJ, Wyss PA, Bickel MH. (1991) Kinetics of distribution and  
elimination of DDE in rats. Xenobiotica, 21 (1), 111-120. 
 
Mukherjee S, Koner BC, Ray S, Ray A. (2006) Environmental contaminants in  







Nandi S, Guzman RC, Yang J. (1995) Hormones and mammary carcinogenesis in mice,  
rats and humans: a unifying hypothesis. Proc. Natl. Acad. Sci., 92, 3650-3657. 
  
Nicolini A, Carpi A, Rossi G. (2006) Cytokines in breast cancer. Cytokine & Growth  
Factor Reviews, 17, 325-337. 
 
Nielsen PJ, Georgiev O, Lorenz B, Schaffner W. (1996) B lymphyocytes are impaired in 
mice lacking the transcriptional co-activator Bob1/OCA-B/OBF1. Eru J   
Immunol., 26 (12), 3214-3218. 
 
Nuñez GM, Estrada I, Calderon-Aranda ES. (2002) DDT inhibits the functional 
activation of murine macrophages and decreases resistance to infection by 
mycobacterium microti. Toxicology, 174 (3), 201-210. 
 
Ociepa-Zawal M, Rubis B, Wawrzynczak D, Washowiak R, Trzeciak W. (2010) 
Accumulation of Environmental Estrogens in Adipose Tissue of Breast Cancer 
Patients. Journal of Environmental Science and Health Part A, 45, 305-312. 
 
Oresic M. (2011) Novel theranostic opportunities offered by characterization of  
altered membrane lipid metabolism in breast cancer progression. Cancer 
Research, 71(9), 3236-3245. 
 
Otten AD, Sanders MM, McKnight GS. (1988) The MMTV LTR promoter is induced by  
progesterone and dihydrotestosterone but not by estrogen. Molecular 
Endocrinology, 2 (2), 143-147. 
 
Park S, Yoon SY, Kim K-E, Lee HR, Hur DY, Song H, Kim D, Bang SI, Cho D-H.  
(2009) Interleukin-18 induces transferring expression in breast cancer cell line 
MCF-7. Cancer Letters, 286,189-195. 
 
Payne J, Scholze M, Kortenkamp A. (2001) Mixtures of four organochlorines enhance  
human breast cancer cell proliferation. Environ Health Perspect, 109 (4), 391-
397. 
 
Peng, Y, Gellert LL, Zou X, Wang J, Singh J, Xu R, Chiriboga L, Daniels G, Pan R,  
Zhang DY, Garabedian MJ, Schneider RJ, Wang Z, Lee P. (2010) Androgen 
receptor  coactivation p44/Mep50 in breast cancer growth and invasion.  J. Cell. 
Mol. Med,14, 2780-2789. 
 
Perez-Maldonado IN, Athanasiadou M, Yanez L, Gonzalez-Amaro R, Bergman A, Diaz- 
Barriga F. (2006) DDE-induced apoptosis in children exposed to the DDT 
metabolite. Sci Total Environ, 370 (2-2), 343-351. 
 
Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi A, Medina D. (2007) Hormone- 
induced protection of mammary tumorigenesis in genetically engineered mouse 
models. Breast Cancer Research, 9 (1), doi:10.1186/bcr1645 
 179 
 
Rasmussen LK, Johnsen LB, Petersen TE, Sorensen ES. (2002) Human GlyCAM-1  
mRNA is expressed in the mammary gland as slicing variants and encodes 
various aberrant truncated proteins. Immunology Letters, 83, 73-75. 
 
Razmkhah M, Jaberipour M, Erfani N, Habibagahi M, Talei A, Ghaderi A. (2011)  
Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-
4, IL-10, TGF-β1                                                      T      : 
do they protect breast cancer cells from the immune response? Cellular 
Immunology, 266, 116-122. 
 
Rhine WD, Hsieh DS, Langer R. (1980) Polymers for sustained macromolecule release:  
procedures to fabricate reproducible delivery systems and control release kinetics. 
Journal of Pharmaceutical Sciences, 69 (3), 265-270. 
 
Ringold GM. (1985) Steroid hormone regulation of gene expression. Annu. Rev.  
Pharmacol.Toxicol., 25, 529-566. 
 
Robinson GW, McKnight RA, Smith GH, Hennighausen L. (1995) Mammary epithelial  
cells undergo secretory differentiation in cycling virgins but require pregnancy for 
the establishment of terminal differentiation. Development, 121, 2079-2090. 
 
Romieu I, Hernandez-Avila M, Lazcano-Ponce E, Weber JP, Dewailly E. (2000) Breast 
cancer, lactation  history and serum organochlorines. American Journal of 
Epidemiology, 152 (4), 363-370. 
 
Rusiecki JA, Baccarelli A, Bollativ V, Tarantini L, Moore LE, Bonefeld-Jorgensen EC.  
(2008) Global DNA hypomethylation is associated with high serum-persistent 
organic pollutants in Greenlandic Inuit. Environ Health Perspect, 116 (11) 1547-
1552. 
 
Schmidt M, Veolker HU, Kapp M, Krockenberger M, Deitl J, Kammerer U. (2010)  
Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT-
1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol, 136, 219- 
225. 
 
Shastri PV. (2009) Toxicology of polymers of implant contraceptives for women.  
Contraception, 65, 9-13. 
 
Shakeel MK, George PS, Jose J, Jose J, Mathew A. (2010) Pesticides and breast cancer 
risk: a comparison between developed and developing countries. Asian Pacific J 
Cancer Prev, 10, 173-180. 
 
Shekhar PVM, Werdell J, Basrur VS. (1997) Environmental estrogen stimulation of  
growth and estrogen receptor function in preneoplastic and cancerous human 
breast cell lines. J Natl Cancer Inst, (89 (23), 1774-1782. 
 180 
 
Shutoh Y, Takeda M, Ohtsuka R, Haishima A, Yamaguchi S, Fujie H, Komatsu Y, Maita 
K, Harada T. (2009) Low dose effects of dichlorodiphenyltrichloroethane (DDT) 
on gene transcription and DNA methylation in the hypothalamus of young male 
rats: implication of hormesis-like effects. J Toxicol Sci, 34 (5), 469-482. 
 
Silberstein G, Daniel C. (1982) Elvax 40P Implants: sustained, local release of bioactive 
molecules influencing mammary ductal development. Developmental Biology, 9, 
272-278. 
 
Silva E, Kabil A, Kortenkamp A. (2010) Cross-talk between non-genomic and genomic  
signaling pathways – distinct effect profiles of environmental estrogens. 
Toxicology and Applied Pharmacology, 245, 160-170. 
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987) Human 
breast cancer: correlation of relapse and survival with amplification of the HER 
2/neu oncogene. Science, 235, 177-182.  
Smeds A, Saukko P. (2001) Identification and quantification of polychlorinated biphenyls  
and some endocrine disrupting pesticides in human adipose tissue from Finland. 
Chemosphere, 44, 1463-1471. 
Smith GH, Vonderhaar BK, Graham DE, Medina D. (1984) Expression of pregnancy-
specific genes in preneoplastic mouse mammary tissue from virgin mice. Cancer 
Research, 44, 3425-3437. 
Snedeker SM. (2001) Pesticides and breast cancer risk: a review of DDT, DDE and 
Dieldrin. Environmental Health Perspectives, 109 (supplement 1), 35-47. 
Snedeker SM, Allyger E. (Revised 2001) Pesticides and breast cancer risk, an evaluation 
of DDT and DDE. Cornell University Program on Breast Cancer and 
Environmental Risk Factors in New York State (BCERF). Fact Sheet #2. 
Steinman S, Wang J, Bourne P, Yang Q, Tang P. (2007) Expression of cytokeratin  
markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ 
(DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. 
Annals of Clinical & Laboratory Science, 37 (2), 127-134. 
 
Su L, Morgan PR, Lane EB. (1996) Expression of cytokeratin messenger RNA versus 
protein in the normal mammary gland and in breast cancer. Hum Pathol, 27 (8), 
800-806. 
 
Sukata T, Uwagawa S, Ozaki K, Ogawa M, Nishikawa T, Iwai S, Kinoshita A,  
Wanibushi H, Imaoka S, Funae Y, Okuno Y, Fukushima S. (2002) Detailed low-
dose study of 1,1-bis(p-chlorophenyl)-2,2,2-trichloroethane carcinogenesis 
suggests the possibility of a hormetic effect. Int J Cancer, 99 (1), 112-118. 
 181 
 
Suzuki H, Toyota M, Caraway H, Gabrielson E, Ohmura T, Jujikane T, Nishikawa N,  
Sogabe Y, Nojima M, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, 
Tokino T. (2008) Frequent epigenetic inactivation of Wnt antagonist genes in 
breast cancer. British Journal of Cancer, 98, 1147-1156. 
 
Suzuki T, Miki Y, Takagi K, Hirakawa H, Moriya T, Ohuchi N, Sasano H. (2010)  
Androgens in human breast carcinoma. Med. Mol. Morphol., 43, 75-81. 
 
Takeuchi E, Yanagawa H, Suzuki Y, Shinkawa K, Ohmoto Y, Bando H, Sone S. (2002)  
IL-12-induced production of IL-10 and interferon-gamma by mononuclear cells in 
lung cancer-associated malignant pleural effusions. Lung Cancer, 35(2), 171-177. 
 
Tan J, Loganath A, Chong Y, Obbard J. (2009) Exposure to persistent organic pollutants  
in utero and related maternal characteristic on birth outcomes: A multivariate data 
analysis approach. Chemosphere, 74, 428-433. 
 
Taneja P, Frazier D, Kendig R, Maglic D, Sugiyama T, Kai F, Taneja NK, Inoue K. 
(2009) MMTV mouse models and the diagnostic values of MMTV-like 
sequences in human breast cancer. Expert Rev. Mol. Diagn 9 (5), 423-440. 
 
Tebourbi O, Driss MR, Sakly M, Rhouma KB. (2006) Metabolism of DDT in different  
tissues of young rats. J Envion Sci Health B, 41 (2) 167-176. 
 
Teicher B. (2001) Malignant cells, directors of the malignant process: role of  
transforming growth factor beta. Cancer and Metastasis Reviews, 20, 133-143. 
 
Thomas P, Dong J. (2006) Binding and activation of the seven-transmembrane estrogen 
receptor GPR30 by environmental estrogens: a potential novel mechanism of 
endocrine disruption. J Steroid Biochem Mol Biol, 102 (1-5), 175-179. 
 
Trask DK, Band M, Zajchowski DA, Yaswen P, Suh T, Sager R. (1990) Keratins as  
markers that distinguish normal and tumor-derived mammary epithelial cells. 
Proc. Natl. Acad. Sci., 87, 2319-2323. 
 
Triola MM, Triola MF. (2006) Biostatistics for the biological and health sciences.  
Boston: Person Publishers. 
 
Turusov V, Rakitsky V, Tomatis L. (2002) Dichlorodiphenyltrichloroethane (DDT):  
ubiquity, persistence and risks. Environ Health Perspect, 110, 125-128. 
 
Udoji F, Martin T, Etherton R, Whalen MM. (2010) Immunosuppressive effects of  
triclosan, nonylphenol, and DDT on human natural killer cells in vitro. Journal of 




Urieli-Shoval Sm Cohen P, Shlomit E, Matzer Y. (1998) Widespread expression of  
serum amyloid A in histologically normal human tissue: predominate localization 
of the epithelium. The Journal of Histochemistry & Cytochemistry, 46 (12), 1377-
1384. 
 
Valencia CA, Cotton SW, Liu R. (2007) Cleavage of BNIP-2 and BNIP-XL by caspases.  
Biochemical and Biophysical Research Communications, 364, 495-501. 
 
V    ό  PF, P       JJ, L       OP, Z       ML,        M, B     LD. (2009) 
Differential effects exerted on human mammary epithelial cell by 
environmentally relevant organochlorine pesticides either individually or in 
combination. Chemico-Biological Interactions, 180,485-491. 
 
Van den Berg H. (2009) Global status of DDT and its alternatives for use in vector  
control to prevent disease. Environmental Health Perspectives, 117 (11), 1656-
1663. 
 
Vandenput I, Vanhove T, Calster BV, Gorp TV, Moerman P, Vervist G, Vergote I,  
Amant F. (2010) The use of lymph vessel markers to predict endometrial cancer 
outcome. Int J Gynecol Cancer, 20, 363-367. 
 
VanderPloeg LC, Wolfrom DM, Rao AR, Braselton WE, Welsch CW. (1992) Caffeine,  
theophylline, theobromine and developmental growth of the mouse mammary 
gland. J Environ Pathol Toxicol Oncol, 11 (3), 177-189. 
 
Varga AE, Stourman NV, Zheng Q, Safina AF, Quan L, Li X, Sossey-Alaoui K, Bakin  
AV. (2005) Silencing of the tropmyosin-1 gene by DNA methylation alters tumor 
suppressor function of TGF-beta. Oncogene, 24(32), 5043-5052. 
 
Vasconsuelo A, Pronsato L, Ronda AC, Boland R, Milanesi L. (2011) Role of 17B- 
estradiol and testosterone in apoptosis. Steroids, 76(12), 1223-1231. 
 
Veeck J, Geisler C, Noetzel E, Alkaya S, Hartman A, Knuchel R, Dahl E. (2008) 
Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in 
human breast cancer is associated with unfavorable prognosis. Carcinogenesis, 
29(5), 991-998. 
 
Vetto JT, Shiuh WL, Naik A. (2009) Breast cancer in premenopausal women. Current  
Problems in Surgery, 46(12), 944-1004. 
 
Vigl B, Aebischer D, Nitschke M, Lolyeva M, Rothlin T, Antsiferova O, Halin C. (2011)  
Tissue inflammation modulated gene expression of lymphatic endothelial cell and 





Villaamil M, Gallego A, Rubira V, Campelo G, Ayers V, Pulido G, Bolos V, Cainzos S,  
Aparico A. (2011) Fructose transporter GLUT5 expression in clear renal cell 
carcinoma. Oncol Rep., 25 (2), 315-323. 
 
Vine MF, Stein L, Weigle K, Schroeder J, Degnan D, Tse CJ, Backer L. (2001) Plasma  
1,1-discholor-2,2-bis(p-chlorophenyl)ethylene (DDE) levels and immune 
response. American Journal of Epidemiology, 153 (1), 53-63. 
 
Vo TT, Gladen BC, Cooper GS. (2008) Dichlorodiphenyldichloroethane and  
polychlorinated biphenyls: interindividual changes, correlations and predictors in 
healthy women from the southeastern United States. Cancer Epidemiol 
Biomarkers Prev, 17, 2729-2736. 
 
Wang BX, Rahbar R, Fish EN. (2011) Interferon: current status and future prospect in  
cancer therapy. Journal of Interferon & Cytokine Research, DOI: 
10.1089/jir.2010.0158 
 
Wang S, Counterman LJ, Haslam SZ. (1990) Progesterone action in normal mammary  
gland. Endocrinology, 127 (5), 2183-2189. 
 
Weber LK, Keri RA. (2011) Bisphenol a increases mammary cancer risk in two distinct 
 mouse models of breast cancer. Biol Reprod., 85(3), 490-497. 
 
Weinstein EJ, Kitsberg DI, Leder P. (2000) A mouse model of breast cancer induced by 
amplification and overexpression of the neu promoter and transgene. Molecular 
Medicine, 6 (1), 4-46. 
 
Wellberg E, Metz RP, Parker C, Porter WW. (2010) The bHLH/PAS transcription factor 
singleminded 2s promotes mammary gland lactogenic differentiation. 
Development, 137, 945-952. 
 
Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G,  
Heukeshoven J, Pantel K. (2005) Changes in cytoskeletal protein composition 
indicative of an epithelial-mesenchymal transition in human micrometastatic and 
primary breast carcinoma cells. Clinical Cancer Research, 11 (22), 8006-8014. 
 
W       J, B    DS, P      N, M      LB, L’I       K, S    Y,        D, V        ,  
Augenlicht LH, Mariadason JM. (2006) Histone deacetylase 3 (HDAC3) and 
other class 1 HDACs regulate colon cell maturation and p21 expression and are 
deregulated in human colon cancer. Journal of Biological Chemistry, 281(19), 
13548-13558. 
 
Wilson VS, Blystone CR, Hotchkiss AK, Rider CV, Gray LE. (2008) Diverse  
mechanisms of anti-androgenic action: impact on male rat reproductive tract 
development. International Journal of Andrology, 31, 178-187. 
 
 184 
Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. (2004) Down-regulated  
expression of cytokeratin 18 promotes progression of human breast cancer. 
Clinical Cancer Research, 10, 2670-2674. 
 
Wolff MS, Toniolo PG, Lee EQ, Rivera M, Dubin N. (1993) Blood levels of  
organochlorine residues and risk of breast cancer. Journal of the National Cancer 
Institute, 85 (8) 648-652. 
 
Woo SU, Bae JW, Yang J-H, Kim JH, Nam SJ, Shin YK. (2007) Overexpression of 
interleukin-10 in sentinel lymph node with breast cancer. Annals of Surgical 
Oncology, 14 (11), 3268-3273. 
 
Wyde ME, Bartolucci E, Ueda A, Zhang H, Yan B, Negishi M, Youu L. (2003) The  
environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat 
hepatic cytochrome P450 2B and #A expression through the constitutive 
androstane receptor and pregnane X receptor. Mol Pharmacol, 64 (2), 474-81. 
 
Xu Y, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivee B, del Toro R, Suchting S,   
Medvinsky A, Silva J, Yang J, Thomas J, Kotch A, Aitalo K, Eichmann A, Bagri 
A. (2010) Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together 
with VEGRF3. J.Cell Biol., 188 (1), 115-130. 
 
Yamamoto KR. (1985) Steroid receptor regulated transcription of specific genes and gene  
networks. Annu. Rev. Genet, 19, 209-252. 
 
Yancy HF, Mason JA, Peters S, Phompson EC, Littleton GK, Jett M, Day AA. (2007)  
Metastatic progression and gene expression between breast cancer cell lines from 
African-American and Caucasian women. Journal of Carcinogenesis, 6:8. 
doi:10.1186/1477-3163-6-8. 
 
Yang L, Zha J, Zhang X, Li W, Li Z, Wang Z. (2010) Alterations in mRNA expression of  
steroid receptor and heat shock proteins in the liver of rare minnow (Grobiocypris 
rarus) exposed to atrazine and  ,   DDE. Aquat Toxicol, 98 (4), 381-387. 
 
Yap WN, Zaiden N, Tan YL, Ngoh CP, Zhang XW, Wong YC, Ling MT, Yap YL.  
(2010) Id1, inhibitor of differentiation, is a key protein mediating anti-tumor 
responses og gamma-tocotrienol in breast cancer cells. Cancer Letters, 291, 187-
199. 
 
You L, Sar M, Bartolucci E, Ploch S, Whitt M. (2001) Induction of hepatic aromatase by  







Yasuoka H, Kodama R, Tsujimoto M, Yoshidome K, Akamatsu H, Nakahara M, Inagaki  
M, Sanke T, Nakamura Y. (2009) Neruopilin-2 expression in breast cancer: 
correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 
expression. BMC Cancer, 9, 220. 
 
Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. (2000) Testosterone  
inhibits estrogen-induced mammary epithelial proliferation and suppresses 










































Real-     PCR                                 ΔΔC                        L         
Schmittgen (2001). The cycle threshold (Ct) value is the cycle at which the fluorescence 
                     ,                 1                                RFU   T   ΔCt for 
each sample is calculate by subtracting the average Ct value of the housekeeping gene, 
cyclophilin A (ppia),  from the average Ct value of the gene of interest/target gene. The 
ΔC                                                                 N   ,     ΔΔC     
                                      ΔC                                           ΔC  
of the control group. That number is then used to calculate the relative fold change in 
expression (2
-ΔΔC 




Figure 47.  Example of a small ΔCt. Real-time PCR data for krt18 analysis in mammary 
tissue. Dotted arrows are indicative of cycle threshold (Ct) values for ppia and krt18 gene 
            T   ΔC                            -              T   ΔC     ue for this 









Figure 48. Example of the logarithmic graph view of real-time PCR data from 
Figure 47. The fluorescence threshold value was set to 100 RFU for all experiments. The 
threshold is consistently above background fluorescence and within the linear phase of 




Figure 49. Example of a large ΔCt. Real-time PCR data for Ifi44 analysis in mammary 
tissue. Dotted arrows are indicative of cycle threshold (Ct) values for ppia and ifi44 gene 
            T   ΔC                            -              T   ΔC                 
example is 10.15. 
                                Cycle 





Ifi44 ΔC  
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Figure 50. Example of the logarithmic graph view of real-time PCR data from 
Figure 49. The fluorescence threshold value was set to 100 RFU for all experiments. The 
threshold is consistently above background fluorescence and within the linear phase of 





Figure 51. Example of real-time PCR melt curve analysis. Melt curve for krt18 
reactions illustrated in figures 47 and 48 . The presence of one peak at 85°C is indicative 










     
 
                                          
   
ΔCt = Avg. Ct (gene of interest) - Avg. Ct (housekeeping gene) 
 
C       ΔC  = 31 85 - 20.6 = 11.65 
 , ´ DDE  ΔC  = 26 95 – 19.8 = 7.15 
 
ΔΔCt = ΔCt (of treated group) – ΔCt (of control group) 
 




= Relative fold change 
 
2
-ΔΔC   
= 2
-(-4.5)
 = 22.6 
 
Figure 52.  Example calculation using the 2
-ΔΔCt  
method. Example of csn1s2a 
expression induced by  ,   DDE treatment.  The two raw Ct values are averaged by both 
genes and the housekeeping gene average is subtracted from it. For the ΔΔC , the ΔC  of 
the control group is subtracted from the treatment group. Lastly, in order to get the 
relative gene expression, 2







Control p,p´ DDE 
Gene Csn1s2a Cph2 Gene Csn1s2a Cph2 
Raw Ct 
value 





31.9 20.6 Raw Ct 
value 
26.9 19.8 
Average Ct 31.85 20.6 Average Ct 26.95 19.8 
Control p,p´ DDE  
                     Cycle                      Cycle 
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Real-Time RT-PCR Primer Sequences 
 
MMTV Promoter Investigation 
 
Gene Abbreviation Sequence 
Mouse neu neu F1 CATTCACCCTACCACCCTCT 
 
neu R1 GCTTCCTTAGCTCTGTCTCC 
Rat neu neu F1 TGGATGTACCTGTATGAGACG 
 




Gene Abbreviation Sequence 
Aldo-keto reductase fam1 memC18 akr1c18 F1 GTCACTCCATTCCTGTCCTG 
 akr1c18 R1 GCCTGGCCTATCTCTTCTTC 
Bcl2-like 11 bcl2l11  F1 GTCAACACAAACCCCAAGTC 
 bcl2l11  R1 GTTTCGTTGAACTCGTCTCC 
Brain expressed gene 1 bex1 F1 TGGAGTCCAAAGATCAAGGCGT 
 bex1 R1 TGGCTCCCTTCTGATGGTATCT 
Breast Cancer 1 brca1 F1 CAAGATAAAGCCGGAATTGA 
 brca1 R1 TATCCACTTTCCTCCTGCAA 
Casein beta csn2 F1 AAGGTGAATCTCATGGGACA 
 csn2 R1 ATCTGTTTGTGCTTGGGAAG 
CD52 antigen cd52 F1 AACAAAAACAGCACCTCCAC 
 cd52 R1 GCTGAGGTAGAAGAGGCACA 
CD81 antigen cd81 F1 GCCAGTCCTTCAGAAAGTGA 
 cd81 R1 ATATCACAGGCGAAGTCCAA 
Chemokine (C-C motif) ligand 19 ccl19 F1 AGCCTTCCGCTACCTTCTTA 
 ccl19 R1 CTTCAGTCTTCGGATGATGC 
Chemokine (C-C motif) ligand 21b ccl21b F1 GACTCTGAGCCTCCTTAGCC 
 ccl21b R1 AGGGTTTGCACATAGCTCAG 
Chemokine (C-C motif) ligand 5 ccl5 F1 GCCCACGTCAAGGAGTATTT 
 ccl5 R1 TGAACCCACTTCTTCTCTGG 
Chemokine (C-C motif) receptor 7 ccr7 F1 GATTTCTACAGCCCCCAGAG 
 ccr7 R1 CCACGAAGCAGATGACAGAA 
Glycosylation adhesion molecule glycam1 F1 AATGAAGACTCAGCCCACAG 
 glycam1 R1 CTCTTGATTCTCTGGCTTGG 
Histone deacetylase 3 hdac3 F1 GATCGATTAGGCTGCTTCAA 
 hdac3 R1 GGATGGAGTGTGAAATCTGG 
IL2-inducible T-cell kinase itk F1 TCCTGTATGTGTTTGCTCCA 
 itk R1 CATTCTTGGATGGGTCGTAG 
Inhibitor of DNA binding 1 id1 F1 GACATGAACGGCTGCTACTC 
 id1 R1 CTTCAGACTCCGAGTTCAGC 
Housekeeper Gene 
 
Gene Abbreviation Sequence 
Cyclophilin 
 
ppia F1 AGGTGAAAGAAGGCATGAAC 
ppia R1 ACAGTCGGAAATGGTGATCT 
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Microarray #1 (continued) 
 
Gene Abbreviation Sequence 
Interleukin 18 il18 F1 GCGTCAACTTCAAGGAAATG 
 Il18 R1 AGTCTGGTCTGGGGTTCACT 
Interleukin 2 receptor, gamma il2rg F1 CGGGCTCCAGAAAATCTAAC 
 il2rg R1 TACCGTTTCAGCTCATCCAC 
Interleukin 7 receptor il7r F1 TTGGTCATCTTAGCCCATGT 
 il7r R1 TCGGGATTGAAACTCACATT 
Keratin 18 krt18 F1 TTGCGAATTCTGTGGACAAT 
 krt18 R1 TTCCACAGTCAATCCAGAGC 
Lymphocyte protein tyrosine kinase lck F1 TCTAGTCCGCCATTACACCA 
 lck R1 AGTACCCCATCCACACTTCC 
Pou domain, class 2, associating factor 1 pou2af1 F1 TACCAGGGTGTTCGAGTCAA 
 pou2af1 R1 GGAAGCAGAAACCTCCATGT 
Schlafen 2 slfn2 F1 ACTGCTGTGGGTGTCTCAAG 
 Slfn2 R1 CGGTGATGTTCATTTTCCAG 
Selectin sell F1 CTGGACACTGCTCT TTGTG 
 Sell R1 ACCCCAGTTCTCTGCTTCTT 
Serum Amyloid A1 saa1 F1 CATTTGTTCACGAGGCTTTC 
 saa1 R1 CAATGGTGTCCTCATGTCCT 
Serum Amyloid A2 saa2 F1 TCATTTATTGGGGAGGCTTT 
 saa2 R1 AAGGCCTCTCTTCCATCACT 
Solute carrier organic anion transporter family, 
member 3a1 slco3a1 F1 GTGATGTGTGTGTGCAGCTT 
 slco3a1 R1 GTGCTCCAGAACAGACAGGT 
T-cell receptor alpha chain tcra F1 TGGAGTCAGTGTTCTGTGGGA 
 tcra R1 ACTTTGTCTCACCTGCTGCT 
Telomerase reverse transcriptase tert F1 TGACTTCTTCCTGCACTTCC 
 tert R1 TTCACCACTGTCTTCTGCAA 
Thioredoxin 2 txn2 F1 TGTTGTGGACTTTCATGCAC 
 txn2 R1 AATGGCAAGGTCTGTGTGAT 
Tropomyosin-2 F1 tpm2 F1 AGAGGACGAGGTGGAAAAGT 
 tpm2 R1 ATCTCCTGCAGCTCCATCTT 
Tumor necrosis factor receptor superfamily 
member 13c tnfrsf13c F1 GACATACAAGCAGCCTGGAG 
 tnfrsf13c R1 CTCTTGCTGGACTCCTTCTG 
Tumor necrosis factor super family, member 11 rankl F1 CTATGATGGAAGGCTCATGG 















Gene Abbreviation Sequence 
Acetoacetyl-CoA synthetase aacs TCCTTGGTCCTGTATGATGG 
 aacs TGTGGAGGTTGTGAGTTTCC 
ATP citrate lyase Acly F1 GCACAGAAACTCACATGACG 
 Acly R1 TCGGGACTCAGAAAAAGATG 
Casein gamma Csn1s2a F1 CAGAGCAGTGTGAACCAGTG 
 Csn1s2a R2 GGTATCTGGGGATGAAGAGC 
Early growth response 2 Egr2 F1 TTTGACCAGATGAACGGAGT 
 Egr2 R1 TTGCCCATGTAAGTGAAGGT 
Inhibitor of DNA binding 4 id4 F1 GTGAACAAGCAGGGTGACAG 
 Id4 R1 GGAATGACAAGACGAGACGA 
Insulin induced gene 1 insig1F1 GGCTGTTGTCGGTTTACTGT 
 insig1 R1 CCAAAGAGAGGGCTGCTAA 
Interferon-induced protein 44 Ifi44 F1 CCCTGCCATTTATTCTGTGT 
 Ifi44 R1 GCAGTGGGTCATGGGTATAG 
Keratin 18 Krt18 F1 TTGCGAATTCTGTGGACAAT 
 Krt18 R1 TTCCACAGTCAATCCAGAGC 
Prune homolog 2 prune2 F1 CTGGAGGACTACCTGCTTCA 
 prume2 R1 GGCAAGGGTTCTGACTTTCT 
Ribosomal protein S12 rps12 TGTATGTCAAGCTGGTGGAG 
 rps12 TAACCACTACGCAACTGCAA 
Secreted frizzled-related sequence protein 5 sfrp5 F1 ATGGCCTCATGGAACAGAT 
 sfrp5 R1 GTCCCCGTTGTCTATCTTGA 
Small proline-rich protein 1A sprr1a F1 CATCACCATACCAGCAGA AG 
 sprr1a R1 GATTGAAGGTCACAGCATTG 
Solute carrier member2 fam5 Slc2a5 F1 TTTGGCTCATCCTTCCAATA 
 Slc2a5 R1 TGCCCAGTTTATTCACCAAG 
Thrombospondin 1 Thbs1 F1 AAGGAACCTCCCAAAATGAC 
 Thbs1 R1 GACTGGTAGCCGAAAACAAA 
Thyroid hormone responsive SPOT14 
homologue  Thrsp F1 GGAGGAGCTGGACCTAGAAG 






















Gene Abbreviation Sequence 
Androgen Receptor ar F1 AATTTCGGAGGAAAAATTGC 
 ar R1 CAAAGGAATCTGGTTGGTTG 
Arylhydrocarbon receptor ahr F1 GCG GCG CCA ACATCA CCT AT 
 ahr R1 AGC CGGTCT CTG TGT CGCTT 
Cyclin D1 ccnd1 F1 CGTACCCTGACACCAATCTC 
 ccnd1 R1 AAGACCTCCTCTTCGCACTT 
Cyp19a1 cyp19a1 F1 GTTCCATGTCATGAAGCACA 
 cyp19a1 R1 AACTTCCACCATTCGAACAA 
Estrogen receptor 1 (alpha) esr1F1 TATCCGGCACATGAGTAACA 
 esr1 R1 CACACCAGCCACCACCTTCT 
G protein-coupled receptor 30 gpr30 F1 AGATCAGGACACCCAACAGA 
 gpr30 R1 TTAAGGGGAGCAGAGTCCTT 
Progesterone Receptor pgr F1 GGCAAATCCCACAGGAGTTTG 
 pgr R1 AGACATCATTTCCGGAAAATTC 
Progesterone Receptor (for PR-A) pgr F1 CAGTGGTGGATTTCATCCATG 
 pgr R1 CTTCCAGAGGGTAGGTG 
Progesterone Receptor (for PR-B) pgr F1 ATGACTGAGCTGCAGGCAAAG 





Gene Abbreviation Sequence 
Interleukin 10 il10 F1 AGCCTTATCGGAAATGATCC 
 il10 R1 ACTCTTCACCTGCTCCACTG 
Interleukin 12 il12 F1 CCCTCCTAAACCACCTCAGT 
 il12 R1 GTCTTCAGCAGTGCAGGAAT 
Interleukin 18  il18 F1 GCGTCAACTTCAAGGAAATG 
 il18 R1 AGTCTGGTCTGGGGTTCACT 
T            G      F      β1 tgfb1 F1 GCCAGATCCTGTCCAAACTA 
 tgfb1 R1 TTCCCGAATGTCTGACGTAT 
 
 
 
 
